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S U M M A R Y
A summary of the experimental chapters is included at the start 
of each of these chapters, however for the ease of the reader these 
are also compiled in this summary. The aim of this thesis is to 
explore the relationship between hepatic drug metabolism and liver 
disease and in particular to determine if the parameters of drug 
elimination provide useful information as liver function tests.
The value of kinetic data as a screening test for liver disease 
is explored in chapter 9, using patients at risk of developing 
methotrexate induced liver disease. Standard biochemical liver 
function tests and the clearances of antipyrine and indocyanine green 
have been compared in psoriatic patients taking methotrexate, 
psoriatic patients on topical treatment, patient controls and patients 
with hepatic cirrhosis. The methotrexate-treated patients showed 
significant elevations in alkaline phosphatase (p<0.025) and gamma 
glutamyl transpeptidase activities (p<0.05) compared to topically 
treated psoriatics and patient controls. The clearance of antipyrine 
was reduced in the methotrexate treated group but not significantly 
(0.1 > p > 0.05). In contradistinction, the weight-adjusted clearance 
of indocyanine green was significantly impaired in the methotrexate 
group in comparison with the topically treated psoriatics (p < 0.01). 
These data suggest that the serial measurement of alkaline phosphatase 
and indocyanine green clearance may provide a non-invasive indicator 
of the development and progression of methotrexate-related liver 
injury.
In chapter 11 the effect of betablockade on portal pressure is 
assessed. Antipyrine elimination was determined to assess the effect
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of nadolol therapy on hepatic drug oxidation. Indocyanine green 
elimination was measured to see if it accurately reflected changes in 
portal pressure, thus possibly providing a non-invasive monitor of 
changes in the portal circulation. The effect of Nadolol 160mg/day on 
antipyrine and indocyanine green kinetics and wedged hepatic vein 
pressure was assessed in 6 patients with hepatic cirrhosis and portal 
hypertension. There was a significant reduction in wedged hepatic 
vein pressure during treatment with nadolol (Nadolol = 13.1 + 3.6 
mmHg: Placebo = 19.9 + 5.6 mmHg). There were no significant
alterations in the standard liver function tests, antipyrine or 
indocyanine green kinetics. These data show that Nadolol leads to a 
fall in portal pressure similar to that produced by propranolol. 
Nadolol is excreted by the kidney so that its elimination should be 
predictable even in patients with severely compromised liver function, 
which suggests that it may be a more suitable drug for use in these 
patients.
Two experiments were performed to assess the value of antipyrine 
and indocyanine green elimination in predicting the metabolism of 
other compounds. In chapter 12 the kinetic and psychomotor function 
were studied after an intravenous dose of 0.075 mg/kg of body weight 
of Midazolam. A total of 7 patients with alcoholic cirrhosis and 8 
patient controls were studied. Pour of the 7 cirrhotics died of 
complications of their liver disease within 6 months of completion of 
the study. The bioavailability of midazolam was significantly 
increased in the cirrhotic patients (p< 0.025). These patients also 
had evidence of greater sedation than the control group for up to 6 
hours after the dose was administered (p<0.05). The clearance of 
midazolam did not correlate significantly with the serum albumin or
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bilirubin or with the kinetics of antipyrine or indocyanine green.
This study demonstrates significant delay in the elimination of 
midazolam and reduction in psychomotor function in patients with 
severe alcoholic liver disease. Caution should be exercised in using 
this drug for pre-medication in such patients prior to endoscopic 
examination.
In chapter 13 kinetic analysis was performed following single 
intravenous (25mg) and oral (200mg) doses of the novel partial opioid 
agonist meptazinol (Meptid) in patients with non-cirrhotic liver 
disease (NCLD) and biopsy-proven cirrhosis. Comparison was made with 
a group of patients with normal hepatic function. There was no 
significant alteration in the plasma clearance of the drug (cirrhotics 
= 33.5 + 8.7 L/hr; NCLD = 98.4 + 11 L/hr; control = 78.5 + 7.3 
L/hr). Fbllowing the oral dose, 7 out of 15 cirrhotic patients 
vomited but only 1 patient in each of the other groups was unable to 
tolerate the drug (p = 0.06). This may be explained by very much 
higher peak meptazinol concentrations in the cirrhotic (n=8; 184 + 
37ng/ml, p<0.01) and NCLD (n=8; 131 + 38ng/ml, p<0.05) patients than 
those of the controls (n=7; 53+ 12ng/ml) reflecting a mean four fold 
and two fold increase in oral bioavailability respectively 
(cirrhotics: n=8; 27.9 + 5.3%: p< 0.001; NCLD: n=7; 13.7+3.9%:
p<0.05; controls: n=7; 6.5 + 1.3%). There was no evidence of 
accunulation following chronic dosing with 200mg meptazinol four tines 
daily for 13 doses in 7 control, 7 NCLD and 6 cirrhotic patients as 
would be predicted by the lack of change in drug clearance. There was 
no correlation between the elimination of midazolam and the 
elimination of either antipyrine or indocyanine green. There were no 
detectable differences in psychomotor function measured objectively
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using the Leeds Psychomotor Tester or subjectively by linear analogue 
scoring between the groups in all three parts of the study. This 
study shows that the use of meptazinol in cirrhotic patients is likely, 
to be limited by gastrointestinal intolerance rather that excessive 
sedation. These two studies provide further evidence that there is 
little value in the use of probe drugs to predict the elimination of 
other molecules in a disease state.
In chapter 8 the kinetics of antipyrine elimination were measured 
in patients with porphyria in attack and remission and a control 
group. The clearance of antipyrine was significantly lower in 
patients with acute attacks of porphyria compared to the other two 
groups (In attack = 0.37 + 0.06 ml/min/kg: In remission = 0.55 + 0.17
ml/min/kg: controls = 0.63 + 0.18 ml/min/kg: P < 0.02). There were
no significant correlations between the indices of porphyria 
metabolism and the measurements of antipyrine kinetics. These data 
show that the elimination of Antipyrine is reduced in acute attacks of 
porphyria, indicating that there is a reduction in the functional 
capacity of cytochrome P450 in these patients. The total lack of any 
correlation between antipyrine kinetics and the markers of porphyrin 
metabolism suggest that these changes occur as a result of haem 
deficiency rather than a functional inhibition of the enzyme system.
The disposition of antipyrine and indocyanine green was studied 
in 11 patients with congestive cardiac failure (CCF) before and after 
treatment and 32 control patients (chapter 14). The antipyrine 
distribution was not significantly altered in patients with CCF. The 
indocyanine green half life was significantly prolonged in patients 
with CCF (CCF = 10.0 + 8.0 min; Control = 4.2 + 1.1 mins: p < 0.01).
The indocyanine green disposition was not significantly altered in a
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further 12 patients with valvular heart disease but without evidence 
of CCF. There was a close correlation between the 103 half life and 
the clinical assessment (r = 0.99; p < 0.001). In the 12 patients 
without CCF there was no correlation between cardiac pressure 
measurements and the disposition of antipyrine or indocyanine green. 
This study suggests that changes in liver blood flow may be an 
important determinant of the changes in drug metabolism seen in 
patients with CCF.
In chapter 10 the relative value of standard liver function 
tests, antipyrine and indocyanine green elimination in the assessment 
of the natural history of chronic liver disease. One hundred and 
sixteen patients with chronic liver disease were studied. When the 
patients were divided by diagnostic groups there were similar changes 
in the standard liver function tests and kinetic parameters in all the 
groups. The only exception was that patients with primary biliary 
cirrhosis had a marked reduction in the volume of distribution of 
antipyrine (controls = 36.3 + 13.7 1; PBC = 25.4 + 7.3 1 : p<0.005). 
This suggests that these patients have a reduced total body water, 
which may be a consequence of the hyperlipidaemia seen in this 
condition. The patients were divided into those with and without the 
major complications of liver disease - Encephalopathy, ascites and 
portal hypertension. A reduction in antipyrine clearance of 2, 16 and 
14% respectively was found in the patients with these complications. 
The reductions in indocyanine green clearance were much greater at 44, 
48 and 37% respectively. The antipyrine clearance was reduced by 26% 
in patients with biopsy proven active cirrhosis compared to a 
reduction of 50% in the indocyanine green clearance. The non­
survivors had a 3% reduction in antipyrine clearance, and a 75%
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redaction in indocyanine green clearance.
When these data was analysed by multiple regression and Cox's 
proportional hazard model, the most powerful 1 of the kinetic 
parameters was the indocyanine green half-life. When this was 
included with the patients age in the model all the other biochemical, 
histological and kinetic data became redundant. These data show that 
indocyanine green elimination provides important information regarding 
the severity of liver disease. The greater magnitude of change seen 
with indocyanine green compared to antipyrine suggests that an 
inportant determinant of the complications and survival in liver 
disease is the functional liver blood flow rather than the hepatic 
metabolic capacity.
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C H A P T E R  1
INTRODUCTION AND AIMS
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The liver is a highly complex organ which fulfils many different 
functions. One of these is the biotransformation and elimination of 
of lipid soluble molecules including many drugs. The relationship 
between the liver and drug metabolism is complex but is of major 
clinical importance.
Patients who have liver disease require medication either as 
treatment for their liver disease or for the treatment of unrelated 
symptoms and diseases. The response of patients with impaired liver 
function can be unpredictable. Some patients will be unduly sensitive 
to sedatives and may become consciousness or suffer from respiratory 
depression as a result of the administration of standard doses of 
these drugs. Sane patients may be unresponsive to some medications 
because they have lost the ability to transform these drugs into their 
active metabolites. It would be clinically useful to be able to 
detect the patients with liver disease who have an altered capacity to 
metabolise drugs so that appropriate drugs can be selected for them 
and the dose of these drugs tailored to the patients own capacity to 
metabolise them.
The altered drug metabolising capacity which occurs in liver 
disease may provide important diagnostic information. There are over 
50 primary diseases of the liver, and the liver can be secondarily 
involved in a number of other disease processes. In an attempt to 
differentiate these diseases hundreds of biochemical tests of varying 
complexity have been designed. A few of the diseases can be detected 
and characterised by simple non-invasive tests but for the majority 
dangerous and invasive liver biopsies are still required. The 
various forms of liver disease involve different cells and organelles 
within the liver. Similarly various drugs are primarily metabolised
32
and excreted by different hepatic structures. It is possible that 
specific patterns of altered drug metabol ism may occur in different 
liver diseases. So that be chosing specific probe drugs in may be 
possible to produce a profile of the liver function which may be of 
diagnostic importance.
Alterations in hepatic drug metabolism may also provide important 
prognostic information. There is no generally accepted measurement of 
the severity of liver disease. Advances in the treatment of liver 
disease has been limited by the lack of objective and repeatable 
measurements of the severity of liver disease. Alterations in 
mortality rates have been the major measurement of therapeutic 
efficacy (CONN & LINDENMUTH 1969, COOK et al 1971). One Of the 
problems in devising a standard liver function test is that there are 
so many different functions and pathological processes which occur in 
the liver. Many of these functions and processes impinge on the 
metabolism of drugs and it may be that measurements of the rate of 
elimination of some drugs may yield important prognostic information.
The principal aim of the thesis is to explore the relationship 
between liver disease and the metabolism of drugs. The specific aims 
are :
1. To review the literature pertaining to drug metabolism and liver 
function to -
a) Determine the current value of liver function tests.
b) To compile a database of information on the alterations in 
drug metabolism which occur in different disease states.
2. To determine the value in measuring the kinetic parameters of the 
metabolism of different drugs in -
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a) Detecting subclinical liver disease
b) Monitoring alterations in liver function
c) Predicting the natural history of liver disease
d) Predicting the metabolism of other compounds
e) Predicting hepatic histology
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C H A P T E R  2
NORMAL LIVER FUNCTION AND THE FUNCTIONAL EFFECTS OF LIVER DISEASE.
INTRODUCTION
Ihe liver has more functions than any other single organ in 
the human body, the major functions of the liver are shown in 
Table 2.1. The extent to which any of the functions becomes 
disturbed in liver disease depends on the nature of the disease 
and its severity. These functional variations are important for 
two reasons. Firstly, the majority of the signs and symptoms of 
liver disease result from these changes rather than the 
under lying disease process. Secondly, these changes can be used 
to produce important diagnostic and prognostic information.
Before assessing the value of drug disposition as a test of liver 
function, the current understanding of the functions of the liver 
and the functional effects of liver disease will be reviewed.
METABOLIC FUNCTIONS 
.1 Protein
Albumin
The average human body contains about 300 grams of albumin 
of which 40% is within the intravascular compartment. The normal 
liver produces 10-12 grams of albumin per day which constitutes 
about 25% of the total daily hepatic synthesis of protein. The 
turnover of albumin is slow with a serum half-life of 20 days.
Hypoproteinaemia is a common feature of chronic liver 
disease. Many factors contribute to its aetiology including
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TABLE 2.1 FUNCTIONS OF THE LIVER
1. METABOLIC FUNCTIONS
PROTEIN METABOLISM
- Albumin synthesis
- Globulin synthesis
- Coagulation factor synthesis (11,V,VII,IX,X)
- Amino Acid turnover
- Urea synthesis
- Ammonia synthesis and clearance
CARBOHYDRATE METABOLISM
- Glycogen storage
- Glycogenolysis
- Galactose metabolism
- Fructose metabolism
- Alcohol metabolism
- Gluconeogenesis
- Lactose clearance
LIPID METABOLISM
- Ketogenesis
- Fatty acid turnover
- Triglyceride metabolism
- Lipoprotein production
- Cholesterol synthesis
- Phospholipid metabolism
2. STORAGE FUNCTION
- Vitamin B 12, Iron, Fat, Glycogen
3. HORMONE METABOLISM
- Sex Hormone Metabolism
- - Inactivation of Adrenocortical hormones
- Inactivation of Antidiuretic hormone
- Conversion of T4 to T3
- Catabolism of insulin
- Catabolism of growth hormone
- Catabolism of glucagon
3. EXCRETORY FUNCTION
- Bilirubin/Nitrogenous waste products
4. DIGESTIVE FUNCTION
- Bile acid production
5. IMMUNOLOGICAL FUNCTION
- Kupffer cell function/Complement metabolism
6. HAEMATOLOGICAL FUNCTION
- Haemopoesis in the neonate
7. BIOTRANSFORMATION OF DRUGS
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decreased synthesis, portosystemic shunting (ZIMMON et al 1969), 
nutritional deficiency and alterations in the intravascular/ 
extravascular distribution. Not all these mechanisms may operate 
in an individual patient and in alcoholic cirrhotics with 
hypoalbuminaemia the rate of albumin synthesis may even be normal 
(ROTHSCHILD et al 1969, ROTHSCHILD et al 1970). There is 
evidence of a compensatory prolongation of the half life of 
albumin in liver disease (DYKES 1968, STERLING 1951, WILKINSON 
and MENDENHALL 1963). The serum albumin levels can be increased 
in chronic liver by the administration of corticosteroids (CAIN 
et al 1970) suggesting that the depression of albumin may be due, 
at least partly, to a change in the regulation of production 
rather than finite changes in the hepatic synthetic capacity.
Globulins
The liver is the site of synthesis of the alpha 1 globulins 
of which alpha 1 antitrypsin is quantitatively the most 
important. Deficiency of this protease results in the early 
occurrence of pulmonary emphysema and is associated with chronic 
liver disease (SHARP 1976).
Caeruloplasmin is another alpha 1 globulin which is 
associated with a specific form of liver disease. It is reduced 
in patients with Wilson’s disease, which allows copper to 
accumulate in the tissues, resulting in damage to the liver and 
the central nervous system..
Beta globulins synthesised in the liver include transferrin,
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haemopexin, some components of complement, plasminogen and 
fibrinogen. The liver is the only site of fibrinogen production. 
In mild liver disease the serum level is either normal or 
slightly elevated (WARDLE 1974). However in severe 
hepatocellular disease the serum level may fall as low as 1.5 
umol/1 (RA1NOFF 1982). Changes in the Beta globulins are seen in 
liver disease with increases in viral hepatitis, extrahepatic 
biliary obstruction and Primary Biliary Cirrhosis (HOBBS 1967).
The alpha lipoproteins are also synthesised in the liver and 
have a short half life of four days, and reductions in serum 
levels have been demonstrated in acute viral hepatitis (McINTYRE 
and HEATHCOTE 1974).
Coagulation factors
All the coagulation factors except for factor VIII are 
synthesised within the liver. They have short half lives varying 
from four days for fibrinogen to 2 hours for factor VII.
Following absorption from the gut vitamin K is utilised in 
the liver in the synthesis of Prothrombin (factor II), factor 
VII, Stuart factor (IX) and Christmas factor (X). Deficiencies 
of these factors lead to abnormalities in the intrinsic and 
extrinsic pathways of coagulation, resulting in prolongations of 
prothrombin time and the cephalin or partial thromboplastin time. 
In obstructive jaundice there are reduced levels of these factors 
because reduction in the delivery of bile salts to the gut 
results in the malabsorption of vitamin K. The resulting 
bleeding tendency is responsive to the parenteral administration
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of vitamin K. In parenchymal liver disease deficiency of these 
factors may result from reduced hepatic protein synthesis.
Factor VIII is probably not produced within the liver and 
elevated levels have been found in acute viral hepatitis (GAZZARD 
et al 1975), alcoholic cirrhosis (GREEN and RA1N0FF 1974) and non 
alcoholic cirrhosis (OCJTRYVE et al 1973). Factor V is 
synthesised within the liver but it is not dependent on vitamin K 
and reduced factor V levels are unusual in uncomplicated 
obstructive jaundice (CEDERBLAD et al 1976) and so theoretically 
it should be of value in differentiating clotting abnormalities 
due to hepatocellular failure from those due to vitamin K 
deficiency. Factor XIII is reduced in hepatocellular disease but 
not in obstructive jaundice (WALLS and LOSOWSKY 1971).
Abnormal platelet function also occurs in acute liver 
failure (RUBIN et al 1977) and cirrhosis (THOMAS et al 1967).
Aminoacids
The liver is the major site of amino acid metabolism. Amino 
acids are broken down within the liver to form components of the 
carbohydrate and lipid metabolic pathways. Both transamination 
and deamination lead to the formation of ketoacids and ammonia, 
glutamate, or glutamine. The ketoacids are metabolised by the 
Krebs citric acid cycle and ammonia is converted to urea by the 
Krebs urea cycle. About 85% of human nitrogen excretion is in 
the form of urea excretion through the kidney. Removal of about 
90% of the functioning hepatic mass is required before there are
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significant alterations in amino acid metabolism. In both acute 
and chronic liver disease there is a failure of urea synthesis 
(SHAMBAUGH 1978). The maximal rate of urea synthesis is reduced 
in cirrhotic patients from 4.46 mmol (65mg) urea N/hr/kg to 
1.93mmol (27mg) urea N/hr/kg. There is a resulting fall in serum 
urea and a concomitant increase in serum ammonia levels (ROSOFF 
and ROSOFF 1977). Liver failure is also associated with an 
accumulation of the straight chain aminoacids with a decrease in 
the branch chain amino acids (Leucine, Isoleucine, and Valine).
.2.2 Carbohydrates
One of the major roles of the liver is the maintenance of 
glucose homeostasis. The liver is responsible for disposing of 
ingested carbohydrate particularly glucose and fructose. It has 
the capacity to store glucose as glycogen and lipid, and to 
create new glucose from glycogen, lipid, aminoacids and glycerol. 
The normal liver can store 80-1 OOg of glycogen.
Glucose intolerance is common in chronic liver disease 
(ALBERTI & JOHNSON 1986) although the mechanisms by which it 
occurs are not well understood. Some of the possible mechanisms 
are shown in Table 2.2. Inpaired insulin production can occur in 
some forms of liver disease e.g. chronic active hepatitis 
(ALBERTI et al 1972) and haemochromatosis, but hyperinsulinaemia 
is more common in most forms of liver disease (OONN and DAUGHADAY
 1970; SESTOFT and REHFIELD 1970; FELIG et al 1970). The hyper­
insulinaemia is due to defective hepatic clearance of insulin 
(JOHNSON et al 1977) which results either from parenchymal liver
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cell failure or portosystemic shunting (JOHNSON et al 1978).
The direct shunting of glucose from the portal circulation into 
the systemic circulation occurs in liver disease but is probably 
not quantitatively important because under normal circumstances 
only about 8% of glucose is extracted on the first pass through 
the liver (RADZIUK et al 1978).
TABLE 2.2
THE POSSIBLE MECHANISMS OF GLUCOSE INTOLERANCE IN LIVER DISEASE
1. GENERAL FACTORS
Nutritional deficiency 
Potassium deficiency
2. HEPATIC FACTORS
Decreased parenchymal mass 
Portosystemic shunting 
Decreased glycogen synthetic capacity 
Impaired action of insulin 
Increased glucagon secretion 
Increased cortisol secretion 
Increased growth hormone secretion 
Haemosiderosis 
Hypoinsulinaemia
3. EXTRAHEPATIC FACTORS
Peripheral insulin resistance 
Increased non esterified fatty acids 
Circulating antagonists
(After ALBERTI and JOHNSTON 1986)
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The inpaired ability to synthesise and store glycogen 
remains a likely cause of carbohydrate intolerance. This 
may be related to to reduced insulin sensitivity due to either 
damaged insulin receptors or increased levels of hormones which 
antagonise insulin (COLLINS et al 1970). Peripheral insulin 
resistance occurs in alcoholic cirrhotics (HED et al 1977). It 
is possible that other defects of the action of insulin exist at 
the receptor and post receptor level.
A number of hormones antagonise the action of insulin by 
driving gluconeogenesis. These include glucagon, gluco­
corticoids, and growth hormone. Circulating glucagon levels are 
elevated in cirrhosis, despite this the production of glucose by 
the liver in cirrhotics is normal. If the high glucagon levels 
are suppressed by the infusion of somatostatin the insulin 
resistance remains (GRECD et al 1974) suggesting that the high 
glucagon levels are not primarily responsible for the insulin 
resistance of cirrhosis. Growth hormone levels are elevated in 
some cirrhotics but this is a very variable finding and elevated 
levels do not correlate with the finding of insulin resistance, 
and suppression of elevated levels with somatostatin does not 
correct the resistance (GRECD et al 1974). Levels of the other 
insulin inhibitory hormones such as cortisol are usually normal 
in cirrhosis.
Another possible mechanism of glucose intolerance is the 
presence of a circulating non-hormonal antagonist (DZURIKOVA et 
al 1974) or the lack of some "glucose tolerance factor" normally 
produced by the liver. There is no clear evidence for such a
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factor.
The inpaired clearance of galactose in liver disease has 
been demonstrated (SHAy et al 1931, ZIEVE and HILL 1955, TYGSTRUP 
1964). The liver removes galactose from the circulation and 
converts it to glucose by phosphorylation and epimerization.
This is discussed further in Chapter 3.
Normally about 70% of fructose is rapidly converted to 
lactate within the liver. This lactate is then rapidly 
metabolised but this does not occur in the diseased liver and 
results in hyperlactataemia and there have been reports of fatal 
lactic acidosis occuring in patients with severe liver disease 
given fructose infusions. Sorbitol is also potentially hazardous 
as it follows the same metabolic pathway.
2.2.3. Lipids
Lipids reach the liver in the form of lynph and as fatty 
acids in the portal blood. Within the liver the fatty acids are 
converted by B-oxidation in the mitochondria into acetyl-Goa, 
which is one of the key molecules in the production of 
cholesterol, triglyceride, phospholipid and lipoprotein. Under 
normal circumstances fat makes up about 5% of the liver's weight 
but in disease this can increase to 40-50% which is mostly in the 
form of triglyceride. The liver will normally synthesise 1.5 - 
2g of cholesterol per day (OLSON 1965). A fall in the liver's 
ability to synthesise apolipoproteins is thought to predispose to 
the development of fatty liver.
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The first abnormality in lipids noted in liver disease was 
the elevation in free cholesterol which particularly occurs in 
obstructive jaundice (EPSTEIN 1932). Decreased levels of 
Lecethin: Cholesterol Acyltransferase (LCAT) have been 
demonstrated in human liver disease and the levels have 
correlated with the percentage of cholesterol present in the 
ester if ied form (SABESIN et al 1977, MONROE et al 1983). LCAT 
catalyses the invitro ester if ication of cholesterol (GLOMSET 
1968). Reduced LCAT activity can result from either a reduced 
synthesis of the enzyme by the liver or inpairment of release 
from the hepatocytes. In acute viral hepatitis the alpha and 
pre-beta lipoprotein bands disappear and reappear on recovery 
(GJCNE et al 1971). These abnormalities are also probably due to 
LCAT deficiency (DAY et al 1978).
Hypertriglyceridaemia may occur in acute or chronic 
hepatitis and cholestasis (McINTYRE et al 1975). Normally 
triglycerides are cleared from the blood by peripheral and 
hepatic lipases, in liver disease the peripheral lipases are 
normal but there can be a marked reduction in the hepatic lipase 
activity (BOLOZANO et al 1975, MULLER et al 1974).
Increases in the beta^globulin fraction of the lipoproteins 
have been shown in primary biliary cirrhosis (KUNKEL and ARHENS 
1949). These changes in the lipoprotein pattern were shown to be 
due to the appearance of an abnormal lipoprotein (EDER et al 
1955). By removing the ’normal1 low density lipoproteins it was 
found that a lipoprotein remained which was rich in phospholipid 
and free cholesterol (SWITZER 1967), this has been called 
Lipoprotein-X (LP-X) (SEIDEL et al 1970). The accumulation of
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this lipoprotein does not appear to be related to LCAT 
deficiency, and LP-X appears to be virtually specific for 
cholestasis (SEIDEL et al 1973). It has been claimed that LP-X 
gives a better differentiation of "medical" from "surgical" 
jaundice than the other biochemical tests of liver function 
(MAQ3ANI and ALAUPOVIC 1976). This has however, been disputed 
(MILLER and JOHNSON 1976, RITLAND et al 1973) and it has been 
superceded as a diagnostic test by ultrasound.
The clinical repercussions of these changes are few. In 
longstanding obstructive jaundice xanthelasma and xanthomas may 
form, and the high levels of cholesterol may also produce a 
peripheral neuropathy. The alteration in the lipid content of 
the red blood cells result in deformity of the red cells 
producing the characteristic "Target cells" of hepatobiliary 
disease.
2.3 STORAGE FUNCTIONS
The liver has large stores of iron, vitamin B12, copper, 
lipid and glycogen. The liver can be damaged by disorders of the 
storage but with the possible exception of glycogen the 
measurement of the storage capacities has little relevance to the 
quantification of liver disease but may be of value in the 
diagnostic differentiation of the storage disorders.
2.4 HORMONE METABOLISM
The liver is involved in the activation, action and 
' deactivation of a number of hormones. The polypeptide hormones 
are degraded by interaction with specific cell surface receptors.
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2.4.1 Glucagon
Glucagon levels are high in cirrhotic patients, and there is 
a significant correlation between the level of glucagon and the 
plasma ammonia (KABADI et al 1985). The increased levels of 
glucagon may be a physiological response to reduced glycogen 
stores in chronic liver disease. Glucagon stimulates 
gluconeogenesis and results in the maintenance of blood glucose 
levels in these patients.
2.4.2 Testosterone and Oestrogen
The relationship of sex hormones to liver disease has 
recently been reviewed (JOHNSON 1984). The typical alcoholic 
cirrhotic has low levels of circulating androgens and high levels 
of oestrogens. Several mechanisms are responsible for these 
alterations including malnutrition, vitamin deficiency, liver 
disease, direct gonadal toxicity of alcohol and inhibition of 
gonadotrophin production. Gonadal failure can occur in 
alcoholics before there is evidence of liver dysfunction.
The major androgen in men is Testosterone which is produced 
by the Leydig cells of the testis and then converted to the more 
biologically active dihydrotestosterone. Testosterone is 
degraded, mainly in the liver, by conjugation with sulphuric and 
glucuronic acid before being excreted in the bile. In alcoholic 
liver disease the circulating levels of testosterone are reduced 
(BAKER et al 1976). This is probably due to a combination of the 
testicular toxicity of alcohol (GDBB et al 1978) and an 
inhibition of gonadotrophin production.
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Oestrogens are also metabolised with the liver by 
conjugation with sulphuric or glucuronic acid. Oestradiol is the 
most biologically active of the oestrogens and it has been shown 
to be normal (GALVAZHTELES et al 1973), slightly increased (BAKER 
et al 1976) or markedly elevated (CHOPRA 1976) in chronic liver 
disease. Levels of circulating oestrone are elevated in liver 
disease, however this has only a weak oestrogenic effect being 
only a fifth as potent as oestradiol. The feminisation of the 
chronic alcoholic appears to be out of proportion to the 
elevation of weakly active oestrone. The hypothesis (EDMONSTON 
et al 1939) that feminisation in chronic liver disease occurred 
because of a failure of oestrogen degradation is now untenable.
It seems more likely that the feminisation occurs because of 
an imbalance in the oestrogen/androgen ratio rather an absolute 
excess of either. However, the oestrogen receptors in the liver 
are high affinity/low capacity receptors and it appears that 
even elevations in androgen levels of a factor of 1000 will not 
lead to displacement of oestradiol from these receptors. It is 
now suggested that there are altered numbers of oestrogen 
receptors in the livers of alcoholic men which is probably a 
result of gonadal failure.
2.4.3 Parathormone
The liver appears to be inportant in the metabolism of 
parathormone (FANG & TASHIGIAN 1972). However, the bone 
thinning and spontaneous fractures which occur in chronic liver 
disease are multifactorial, with dietary deficiency,
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malabsorption, alterations in vitamin D metabolism playing a 
part.
2.4.4 Adrenocortical hormone
Obrtisol is mainly degraded within the liver to tetra- 
hydrocortisone and subsequently conjugated with glucuronic acid. 
Plasma levels of cortisol tend to be normal or reduced in liver 
disease although the significance of these results is difficult 
to interpret because of the marked reductions in plasma albumin 
and cortisol binding protein (PETERSON I960, SHOLITON et al 
1961).
2.4.5 Antidiuretic hormone
Delayed degradation of antidiuretic hormone is believed to 
be partly responsible for the hypervolaemia in chronic liver 
disease.
2.4.6 Thyroid Hormone
The liver has a major role in thyroid hormone metabolism 
being involved in the conjugation, biliary excretion and 
deamination of thyroxine and in the deiodination of thyroxine to 
the highly active tri-iodothyronine.
The majority of patients with chronic liver disease appear 
to be clinically euthyroid although the biochemical assessment of 
thyroid status can be confusing.
2.4.7 Insulin - See Carbohydrates 2.1.2
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2.4.8 Growth Hormone
The half life of growth hormone is extremely short at about 
19 minutes (CWENS et al 1973). The liver and kidneys are the 
major sites of degradation of growth hormone. Basal growth 
hormone levels are elevated particularly in cirrhosis and this 
has been attributed to a reduction in the clearance (GRECD et al 
1974). However, the liver is responsible for about 90% of the 
clearance of growth hormone and normal levels have been found in 
liver disease (TA^IOR et al 1972).
2.4.9 Other Hormones
Aldosterone is inactivated in the liver and failure of this 
inactivation is one of the factors that results in the retention 
of fluid in liver disease.
Prolactin levels are variable in liver disease, 12% of 
patients have a level above the reference range but there is a 
poor correlation with gynaecomastia (MORGAN et al 1978).
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2.5 EXCRETORY FUNCTION
The principal excretion product of the liver is bilirubin.
It is a tetrapyrole pigment mainly derived in the reticulo­
endothelial system by the degradation of haem from aging red 
blood cells and to a lesser extent from catalase, myoglobin, and 
the cytochromes. Bilirubin is virtually insoluble in water and 
it is transported in the plasma bound to albumin. The bilirubin 
is then taken up by the hepatocytes and conjugated with 
glucuronic acid to the mono- and diglucuronide. These reactions 
are catalysed by the microsomal enzyme Glucuronyl transferase.
The diglycuronide is highly water soluble and is excreted in the 
bile with little enterohepatic circulation. The hepatic handling 
of bilirubin has recently been reviewed (SCHMID 1975).
In liver disease changes in the metabolism of bilirubin can 
occur at five main sites, and all can result in an elevation in 
the total serum bilirubin concent rat ion:-
1. Increased load of bilirubin presented to the liver 
cell.
2. Reduced uptake and intracellular transport of
bilirubin.
3. Reduced conjugating capacity.
4. Reduced excretion at the cannilicular surface.
5. Reduced biliary flow.
The level of the serum bilirubin is not a particularly 
sensitive marker of the severity of liver disease with 
disproportionate elevations occurring in cholestasis.
The liver is responsible for the clearance of a number of 
other substances which accumulate in liver disease. These
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include the weak neural transmitters such as octopamine, and beta 
phenylethanolamine. Increases in urine and serum octopamine 
levels have been found in patients with hepatic encephalopathy 
(FISCHER and BALDESSARINI 1971; MANGHANI et al 1975).
2.6 DIGESTIVE FUNCTION
The liver plays an important part in the digestive processes 
by the production of bile acids. Bile acids are important 
because they are involved in four major pathophysiological 
processes
1. The production of bile acids from cholesterol provides the 
major metabolic pathway in the elimination of cholesterol.
2. The bile acid pool is largely stored in the gall bladder 
where they enhance solubilisation of cholesterol.
3. Bile acids stimulate hepatic bile production, and they are 
important determinants of the liver's capacity to eliminate 
various other endogenous and exogenous metabolites.
4. In the duodenum bile acids act as detergents and emulsify 
triglycerides and facilitate the absorption of fatty acids, 
monoglycerides, and lipid soluble vitamins.
The normal human liver converts 0.78-1.29 (300 - 500mg) of 
cholesterol into bile acids per day. At normal body Ph the bile 
acids are in the form of salts with sodium as the main cation.
The bile salts are large asymmetrical molecules with both 
hydrophobic and hydrophilic regions this allows them to aggregate 
as large polymolecular structures (micelles). Following 
synthesis in the liver the bile salts are conjugated within the
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liver with Glycine and Taurine. About 95% of the bile salts 
secreted by the liver are absorbed in the small bowel and 
recirculated to the liver. The hepatic uptake of bile acids from 
the portal vein is highly efficient with a first pass extraction 
of 62% for Chenodeoxychorate 70% for Cholic acid (GILMORE and 
THOMSON 1978) and 89% for the unconjugated bile acids (GILMORE 
and THOMSON 1981).
2.7 IMMUNOLOGICAL FUNCTION
A major part of the bodies reticuloendothelial system lies 
within the liver. The Kupffer cells clear bacteria and 
endotoxins from the portal vein by phagocytosis and pinocytosis. 
The natural portosystemic shunts which occur in liver disease 
bypass the Kupffer cell and may in part be responsible for the 
high incidence of infection and endotoxaemia in these patients.
Abnormalities in grannulocyte function, humoral immunity, 
and lymphocyte function are described in alcoholic liver disease 
(ZETTERMAN & SORRELL 1981)
The liver also takes up and secretes IgA. The bile contains 
no IgG or IgM but IgA accounts for 40% of its protein content.
2.8 HAEMATOLOGICAL FUNCTION
The liver is the primary site of erythrocyte production in 
the foetus from the ninth to the twenty-fourth week when the bone 
marrow takes over. The potential for haemopoesis remains into 
adult life and in some circumstances of marrow failure the liver 
may again become a major haemopoetic organ.
C H A P T E R  3
A REVIEW OF THE STANDARD TESTS OF LIVER FUNCTION
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3.1 INTRODUCTION
Uiere are a wide variety of tests available for the 
investigation of patients with or suspected of having liver 
disease. These tests are often referred to as "liver function 
tests", although it is quite clear that many have little or 
nothing to do with either a liver function or the severity of 
liver disease. In normal clinical practice these tests are 
generally considered as having three basic uses.
Firstly, as screening tests they are of value in detecting 
liver disease. These tests need to be sensitive to changes in 
liver function but do not necessarily have to be specific for a 
particular liver disease, as they indicate that further 
investigation is required.
Secondly, as diagnostic tests they allow the differentiation 
of the types of liver disease so that appropriate advice and 
therapy can be given. They must be specific for the individual 
types of liver disease but their sensitivity is less important.
A full description of these tests is outwith the scope of this 
review but a summary of the major diagnostic tests of liver 
disease is included in Table 3.1.
Thirdly, as tests of the severity of liver disease they can 
fulfil four functions:
1) Assessment of Prognosis: An accurate assessment of the
prognosis of a patient with liver disease has become more 
important over the last few years as the therapeutic options 
have increased. For patients with fulminant hepatic failure 
various techniques of liver support have been developed, and
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for patients with end stage chronic liver disease hepatic 
transplantation can be considered. The rational use of 
these expensive and potentially dangerous techniques 
requires the identification of patients with a very limited 
prognosis.
However, the use of quantitative liver function tests 
in the assessment of prognosis makes three assumptions 
(TYGSTRUP & VILSTRUP 1983). It is unlikely that any of the 
current liver function tests fulfils these criteria.
a) The function decreases in a predictable way with the 
progression of the disease.
b) Death is inevitable when the function has deteriorated 
to a certain degree.
c) The test has a predictable relationship to the function. 
It is uncertain whether any liver function test fulfils any 
or all of these criteria.
2) Drug dosage adjustment: Patients with liver disease may 
have an altered capacity to metabolise drugs. The extent of 
these changes depends on the drug involved and the severity 
of the liver disease. There is no standard method of 
adjusting the dose of hepatically metabolised drugs to take 
into account this impairment of metabolic capacity. A 
simple adjustment would be of value particularly in the 
prescription of analgesics and sedatives to these patients.
3) Monitoring: Tests of the severity of liver disease should
allow the monitoring of the progress of the liver disease 
and also its response to specific therapies. If accurate
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tests of the severity of liver disease were available these 
tests would presumably reflect the progression of the liver 
disease towards terminal liver failure, and would then be of 
value in the assessing whether new therapies altered the 
progression of liver disease.
4) Detection of complications: Some of the complications of
chronic liver disease, for example portosystemic 
encephalopathy, are notoriously difficult to detect 
clinically. Ihey lead to a subtle but significant 
deterioration in the patients performance which could be 
corrected if detected. The testing of all patients for 
these complications is difficult and it would be of great 
value if a subgroup of patients with liver disease who were 
likely to have these complications could be identified.
The purpose of this chapter will be to review the currently 
available liver function tests and in particular to try to 
indentify which tests are of most value in assessing the severity 
of liver disease.
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TABLE 3.1 THE MAJOR DIAGNOSTIC TESTS OF LIVER DISEASE
TEST
Ferritin
Hepatitis Bs antigen 
Hepatitis A immunoglobulin 
Alpha 1 fetoprotein 
Alpha 1 antitrypsin
Antimitochondrial antibody 
Smooth muscle antibody 
Caeruloplasmin 
Leptospira titres 
Liver ultrasound 
Isotope liver scanning 
Computerised axial tomography 
Bile duct imaging
- iv cholangiogram
- E.R.C.P.
Nicotinic acid test 
Liver biopsy
HEPATIC DIAGNOSIS
- Haemochromatosis
- Hepatitis B
- Hepatitis A
- Hepatocellular carcinoma
- Alpha 1 antitrypsin 
associated liver disease
- Primary biliary cirrhosis
- Chronic active hepatitis
- Wilsons disease
- Leptospirosis
- Extrahepatic obstruction
- Liver tumours
- Liver tumours
- Gallstones 
-Sclerosing cholangitis
- Bile duct malignancy
- Gilbert’s syndrome
- Parenchymal liver disease
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Liver function tests can best be divided into the following 
categories:
1) Tests of a liver function
2) Tests of hepatocellular destruction
3) Tests of bile duct patency
4) Tests of hepatic fibrosis
3.2 TESTS OF A LIVER FUNCTION
All these tests reflect one of the functions of the liver 
outlined in Chapter 2.
3.2.1 Serum Albumin
Hie use of serum proteins to assess liver disease assumes 
that changes in the serum level of a protein are due to 
alterations in the capacity of the liver to produce that protein. 
There are however, two major problems with this interpretation.
Firstly, alterations in the serum proteins may result from 
changes in the anabolism, distribution, catabolism or loss of 
protein from the body. Therefore, a reduction in serum protein 
levels may not represent a true reduction in the capacity of the 
liver to produce that protein.
Secondly, true reduction in the rate of synthesis of a 
protein may result from either a reduction in the capacity of the 
synthetic mechanism or an alteration in the regulation of the 
synthetic mechanism. Which in turn may result from some 
extrahepatic manifestation of liver disease.
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The relatively long half life of albumin (20 days) make it 
an insensitive test of acute liver disease (McINTYRE and 
HEATHCOTE 1974). The daily synthesis of albumin is 
approximately 3% of the total albumin pool. If albumin 
production ceased totally for a week then the serum albumin would 
only fall by 25%. Albumin is the major site of protein binding 
for acidic drugs (LCJNDE et al 1970) and the doses of these drugs 
may need to be altered in patients with hypoalbuminaemia.
The insensitivity and lack of specificity for liver disease 
result in albumin having a limited role as a liver function test. 
However the estimation of serum albumin has the great advantage 
of simplicity and provides a rough guide to the severity of 
chronic liver disease provided that other causes of 
hypo-albuminaemia e.g. nutritional deficiency, nephrotic 
syndrome, protein losing enteropathy and catabolic states are 
excluded.
3.2.2 Globulin
Many of the globulins have short half lives and may be 
abnormal in liver disease when the serum albumin is still within 
the reference range (SKREDE et al 1973). The estimation of the 
individual globulins was difficult but a group of liver 
function tests was available which depended on abnormalities in 
the ratio of the various globulins to albumin. These tests have 
been superceded by protein electrothoresis and the immunological 
measurement of specific protein factors but included:
a) Cephalin-Cholesterol flocculation test. This test reflects 
an increase in the serum globulins and a decrease in the
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serum albumin (BREEN and SCHENKER 1971). The test is more 
often positive in parenchymal liver disease than in 
obstruction (HILL and ZIEVE 1957) but it lacks specificity 
and adds little to the measurement of serum albumin.
b) Thymol tubidity and flocculation tests. These tests are 
similarly affected by an increase in the globulin 
concentration and a fall in albumin but are also affected in 
a major fashion by changes in the lipoprotein and beta 
globulin fractions. The tests may be positive in
hyperlipaemic state.
c) Zinc Sulphate turbidity test is more influenced by 
isolated changes in globulins than the other two tests.
Alpha feto protein is usually only produced by foetal liver 
cells, but it has proven to be a sensitive screening test in the 
detection of hepatocellular carcinoma (ALPERT et al 1971). The 
serum level of alpha fetoprotein is also elevated in the presence 
of active hepatic regeneration (WEPSIC & KIRKPATRICK 1979).
Fibrinogen is reduced in liver disease and is associated 
with a poor prognosis (FINKBINER et al 1959). Fibrinogen 
deficiency can result either from reduced synthesis or from 
excessive consumption in disseminated intravascular coagulation.
The acute phase reactants are a group of proteins which 
either rise or fall in association with tissue necrosis (WEST et 
al 1964). The changes which occur in liver disease are generally 
difficult to interpret and they are not of diagnostic or 
prognostic help.
The concentration of beta 2 microglobulin is elevated in the
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majority of patients with chronic active or persistent hepatitis 
and in alcoholic cirrhotics but is normal in alcoholic fatty 
liver (HALLGREN 1979).
3.2.3 Pseudocholinester ase
Pseudocholinesterase is an enzyme whose serum level falls 
when there is protein catabolism and rises during anabolic 
phases. It has been used in prediction of liver function 
following portocaval shunting (HUNT and LEHMANN 1960).
3.2.4 Coagulation Factors
Ihe prothrombin time is the most useful test of coagulation 
in patients with liver disease. It measures the rate at which 
prothrombin is converted into thrombin in the presence of 
thromboplastin, calcium ions. It is influenced by factors I, II, 
V, VII and X. In the absence of a deficiency of vitamin K the 
prothromin time is only prolonged in severe hepatocellular injury 
(GREEN et al 1976) and has prognostic value in fulminant hepatic 
failure. A progressive prolongation of the prothrombin time has 
particularly ominous significance in acute viral hepatitis or in 
hepatic damage due to an overdose of paracetamol. Some of the 
individual clotting factors also have prognostic value. A factor 
VII of less than 8% of the normal mean value indicates a poor 
prognosis in acute liver failure (DYMOCK et al 1975).
3.2.5 Urea Synthesis
Ihe rate of urea synthesis in response to an aminoacid load 
is impaired in patients with cirrhosis (RYPINS et al 1980). A
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serum urea approaching zero then this is a sign of a poor 
prognosis (SHERLOCK 1985).
3.2.6 Minoacids
In chronic liver disease the pattern of aminoacids in the 
peripheral blood shows an elevation of the aromatic aminoacids 
phenylalanine, tyrosine, tryptophan, methionine, glutamate, and 
aspartate with a reduction in the branch chain aminoacids valine, 
leucine, isoleucine. No correlation has been found between 
these changes in aminoacids in chronic liver disease and the 
severity of the disease as reflected by elevations in the serum 
transaminases (ROSEN et al 1977) and the presence of portocaval 
shunts (ZOLI et al 1981). In acute liver disease there is an 
elevation in all the the aminoacids except the branch chain 
aminoacids and especially methionine which may increase as much 
as 27 fold (RECORD et al 1982). There is some correlation 
between the severity and prognosis of fulminant liver failure and 
changes in the aminoacid concentration (ZOLI et al 1981). The 
rise and fall of the serum aminoacids was thought to correlate 
well with the level of encephalopathy, particularly the ratio of 
the branch chain aminoacids to the aromatic aminoacids was 
considered to be inportant but this measurement is now considered 
to be of little value (ZEIVE 1979).
3.2.7 Glucose Tolerance
This is often abnormal in liver disease but lacks 
specificity and does not appear to be of diagnostic value. The 
coincidence of a high blood sugar and high circulating insulin 
levels strongly suggests parenchymal liver disease.
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3.2.8 Glycogen Reserve
Ihe hepatic reserves of glycogen can be tested by 
administering lmg of glucagon intramuscularly or intravenously. 
The consequent rise in blood glucose then gives an indication of 
the hepatic glucagon content (FELIG et al 1970). Ihis test 
lacks specificity and is very dependent on the nutritional 
status.
3.2.9 Tests of Gluconeogenesis
Alterations in gluconeogenesis can be inferred from 
alterations in the concentrations of the precursors of gluco­
neogenesis in the peripheral blood. Blood lactate in particular 
correlates well with other tests of liver function with the most 
marked changes occurring in cirrhotic patients. Ihe value of the 
measurement of lactate is reduced by the stringent requirements 
for its sampling (no muscle movement and the immediate removal of 
protein). The measurement of lactate may be of particular value 
in patients with fulminant liver failure who require parenteral 
nutrition, these patients are particularly prone to develop 
lactic acidosis because of the liver’s impaired capacity to 
remove lactate.
3.2.10 Galactose Tolerance
The elimination of galactose by the liver is dependent on 
liver blood flow and the hepatic metabolic capacity. When 
galactose is administered in a dose of 30 grams intravenously the 
metabolic pathway is saturated and the elimination follows zero
64
order kinetics. Used in this fashion the elimination of 
galactose is only dependent on liver function. At lower plasma 
concentrations the metabolic pathway is not saturated and the 
elimination becomes a first order process with an exponential 
decline in plasma concentrations. The elimination in these 
circumstances is dependent on the liver blood flow and the 
elimination capacity. The application of this test would be as a 
measurement of liver blood flow but it has not been widely used 
use of the lack of a sensitive assay for galactose, although one 
has recently been described (HENDERSON et al 1982).
The standard galactose tolerance test consists of the 
administration of an intravenous load of 350 - 500 mg/kg body 
weight of galactose, and utilises zero order kinetics. A marked 
prolongation of the half life of galactose has been demonstrated 
in cirrhotic patients with results prolonged by 250-2500% 
conpared to control subject (ZIEVE & HILL 1955, TYGSTRUP 1964, 
TENGSTRQM 1969). The galactose tolerance test discriminates 
better between cirrhotic patients and normal subjects than serum 
albumin, alkaline phosphatase, thymol turbidity, or ALT 
(TENGSTRQM 1969) but was not of value in the differentiation of 
fatty liver from cirrhosis (LINDSKOV 1982). In comparison 
to the BSP retention test a modified galactose retention test has 
proved to be less sensitive in the discrimination of cirrhotic 
patients from healthy controls (ZIEVE & HILL 1955; BIRCHER et al 
1973). In cirrhotic patients it correlated with most of the 
standard biochemical tests of liver function and correlated only 
poorly with the clinical signs of and the histological severity
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of liver disease (LINDSKOV 1982). In rats the elimination 
of galactose is independent of enzyme inducing agents (KEIDING et 
al 1973).
In fulminant liver failure the galactose tolerance test has 
some prognostic value being significantly lower in a group of 
non-survivors, and it is superior to the standard biochemical 
tests of liver function (RANEK et al 1976). However, some 
patients with normal galactose clearances and fulminant hepatic 
failure die (RAMSOE et al 1980). A marked reduction in the test 
has also been found in patients who develop encephalopathy after 
portosystemic shunting (KARDEL et al 1975).
The test has been sinplified by validating the use of an 
oral dose of galactose and by changing the sampling to a breath 
test. In this test the patient ingests a dose of 14C or 13C 
labelled galactose and the elimination of labelled carbon dioxide 
in the breath is measured (SHREEVE et al 1976). Hie 
descrimination between cirrhotics and normal subjects was better 
with the galactose breath test than the serum bilirubin, alkaline 
phosphatase, and serum albumin.
The major assunption in the use of the galactose elimination 
capacity is that there is negligible extrahepatic metabolism or 
excretion. This assumption is now challenged (LINDSKOV et al 
1983).
3.2.11 Storage Function
The measurement of serum ferritin and serum iron/total iron 
binding capacity, caeruloplasmin have some relevance in the 
diagnosis of haemochromatosis and Wilson's disease but are not a
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value in assessing the severity of liver disease.
Ihe only storage function which has been explored as a liver 
function test is that of glycogen storage which is discussed 
above under carbohydrate metabolism.
3.2.12 Bilirubin
Ihe handling of bilirubin in the liver involves several 
different hepatic functions including uptake across the 
hepatocyte membrane, intracellular transport, conjugation by the 
microsomal enzymes and excretion into the biliary canaliculus. 
Bilirubin is measured by the Van den Bergh diazo reaction which 
splits the bilirubin molecule into two dipyrole azopigments. 
Unconjugated bilirubin requires to be dissolved in alcohol prior 
to this reaction and therefore gives an indirect Van den Bergh 
result. This test is cumbersome and not particularly sensitive.
A normal range for serum bilirubin is difficult to define because 
the distribution curve for control subjects tends to be skewed to 
the right because of the inclusion of some patients with minor 
abnormalities the the handling of the pigment. Elevations in the 
serum bilirubin has significance as a diagnostic test as well as 
indicating the severity of liver damage.
The total serum bilirubin is generally not a sensitive test 
of liver dysfunction (GITNICK 1981) as elevations tend to occur 
late in the natural history of most liver diseases and 
disproportionate elevations occur in cholestatic liver disease.
A major value of the measurement of bilirubin is its specificity 
for liver disease. Elevated serum bilirubin levels have been 
found to be of prognostic value in primary biliary cirrhosis,
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with a level of >34 micromols indicating a three to six year 
survival and a level >170 micromols being associated with a 
survival of <1.5 years (SHAPIRO et al 1979). In alcoholic 
hepatitis bilirubin levels in excess of 100 umol/1 tend to be 
associated with a poor prognosis (HARDISON & LEE 1966).
The fractionation of the total serum bilirubin into its 
conjugated and unconjugated coirponents is of diagnostic value 
especially in the diagnosis of Gilbert's disease, when there are 
unconjugated hyperbilirubinaemia with less than 20% of the total 
serum bilirubin in the conjugated form.
3.2.13 Bromosulphthalein
Bromosulphthalein (BSP) is a brominated phthalein dye, 
sodium phenoltetrabronphthalein disulphonate, which is handled by 
the liver in a similar fashion to bilirubin. Following 
intravenous injection BSP is carried in the blood bound to 
albumin and alpha-1-1 ipoprotein. BSP is taken up by the liver 
cells and is conjugated to glutathione. The conjugated BSP is 
then actively excreted across the canalicular membrane (GITNICK 
1981). Retention of BSP is generally considered to be a reliable 
and sensitive indicator of hepatic dysfunction (SCHOENFIELD 
1965), but it is affected by other factors such as fasting 
(BRADLEY et al 1969).
BSP has been used as a sensitive indicator of hepatic 
dysfunction in investigations of the mechanisms of intrahepatic 
cholestasis of pregnancy (REYES et al 1981). In patients with a 
previous history of this condition there was an exaggerated 
slowing in the biliary phase of the removal of BSP.
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The elimination of BSP has a biexponential pattern. By 
repeatedly sanpling for up to 60 minutes it is possible to 
calculate the rate of uptake of BSP into the liver cells, of 
reflux back into the plasma, and of its transfer into bile 
(BARBER-RILEY et al 1961).
Dibromosulphthalein is a dibromo analogue of BSP, it has a 
high hepatic extraction of 80-100% but unlike BSP it is not 
conjugated, it has a major disadvantage as a test of liver 
function in that there is active renal tubular excretion (MEIJER 
et al 1983).
3.2.14 Nitrogenous Waste Products
Several of the waste products of nitrogen metabolism have 
been shown to be altered in hepatic disease. Mercaptans 
(methanethiol, ethanethiol, dimethylsufide) accumulate in severe 
disease (McCLAIN et al 1980).
Gamma aminobutyric acid (GABA) is a potent inhibitory 
neurotransmitter which is generated in the gastrointestinal tract 
by the action of bacteria and is degraded in the liver by GABA 
transaminase. The accumulation of GABA in chronic liver disease 
has been inplicated in the genesis of portosystemic 
encephalopathy (SCHAFER and JONES 1982). There are as yet no 
data available in human subjects as to the value of GABA in the 
prediction of prognosis or in the detection of encephalopathy.
3.2.15 Ammonia
The level of ammonia is raised in cirrhosis particularly in 
patients with a marked degree of portosystemic shunting (ROSOFF & 
ROSOFF 1977). The role of ammonia in the genesis of
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portosystemic encephalopathy remains obscure. The ammonia 
levels are affected by changes in diet, and colonic production of 
ammonia and portosystemic shunting. Serum ammonia estimations 
have been of some discriminating value in patients with fulminant 
hepatic failure (DEMEDTS et al 1974).
Ammonium Chloride Test: The capacity for ammonia metabolism 
can be tested by the ammonium chloride test. The patient is 
given three grams of ammonium chloride with a blood test for 
ammonia prior to administration and at plus 45 minutes. Normal 
tolerance is indicated by a return to baseline ammonia levels 
within 45 minutes of administration. The test is now little used 
because of improvements in the understanding of the mechanisms of 
encephalopathy (KORMAN et al 1974).
3.2.16 Bile acids
Bile acids are both produced and metabolised within the 
liver. Marked elevations in bile acids seen in liver disease are 
entirely analagous to the changes in serum concentration seen 
with many highly extracted drugs. Porto-shunting of blood round 
the liver play an important part in the production of elevated 
serum levels (OHKUBO et al 1984). There are four main methods of 
assessing changes in the serum bile acids
a) Ehsting bile acids. The measurement of fasting conjugated 
bile acids is a less sensitive test in the detection of 
hepatic dysfunction than the transaminases (BERRARIS et al 
1983). This test has been modified as a breath test using 
15N-labelled ammonium chloride (JUNG et al 1985). There is 
a poor correlation with hepatic histology (MILSTEIN et al
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1976, RICKERS et al 1982, LINNET et al 1982, LINNET & RYE 
ANDERSON 1983). This test is however more sensitive than 
the serum bilirubin (van BLANKENSTEIN et al 1983). The 
correlation to serum albumin, bilirubin and BSP retention is 
poor (HIRAYAMA et al 1979).
b) Post prandial bile acids. The measurement of post prandial 
bile acids can be considered as an endogenous bile acid 
tolerance test, in which the patient ingests his own bile 
acids following a meal. It was suggested that the post 
prandial measurement is a more sensitive indicator of 
hepatic dysfunction than the fasting bile acids (KAPLOWITZ 
et al 1973, BARNES et al 1975, FADSA 1976). The test has 
also been found to be more sensitive than indocyanine green 
and bromosulphthalein clearances in the detection of minimal 
liver disease (JAVITT 1977) although this is disputed (van 
BLANKENSTEIN 1981). Initially the results were expressed as 
a ratio of the trihydroxy to dihydroxy bile acids, however 
the value of this ratio has been challanged because of its 
failure to separate patients with liver disease from control 
subjects. The test has been modified and the results are 
now expressed as the ratio of cholic to chenodeoxycholic 
acid. In this form the test is more sensitive for the 
detection of liver disease than the fasting bile acids or 
the standard liver function tests (ANGELICD et al 1977). 
Although in alcoholics the postprandial bile acids were less 
sensitive than the serum aspartate transaminase in the 
detection of minimal liver disease (GALIZZI et al 1978).
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The test has been used to discriminate between cirrhotic 
patients, normal subjects and patients with extrahepatic 
obstruction (PENNINGTON et al 1977).
Hie first pass metabolism of bile acids is probably not 
altered in liver disease so that the test no longer has a 
firm theoretical basis. If it is truely a more sensitive 
test than the fasting levels then it may be because of 
changes in extrahepatic factors such as gall bladder storage 
and portal blood flow (GILMORE & HOFMAN 1980).
c) Bile acid tolerance test. In this test the tolerance to 
exogenous bile acids is assessed. An intravenous test using 
cholylglycine (LARUSSO et al 1975) has proved to be 
insensitive in detecting mild liver disease (THJODLEIFSSON 
et al 1977, GILMORE & THOMSON 1978), but an oral test has 
proved to more sensitive (GILMORE & HOFMANN 1980). A test 
measuring the capacity of the liver to conjugate cholic acid 
is significantly lower in nonsurvivors with viral hepatitis 
but there was considerable overlap and a survival limit 
could not not be defined. Glycine conjugation correlated 
with the prothrombin time and galactose elimination 
capacity but not with the serum albumin or the antipyrine 
clearance (BREMMELGAARD et al 1983).
d) Breath test. The bile acid tolerance test has been 
modified to a breath test to avoid the need for repeated4 
blood samples. In this test 14C glycocholic acid is 
administered and the excretion of C14 is measured in the 
breath, the rate of appearance being proportional to the 
rate of elimination of the 14C glychocholic acid by the
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liver. This test is however less sensitive than the 
measurement of total serum bile acids (GILMORE & THOMSON 
1978, THJODLEIFSSON et al 1977).
Potentially the most useful measurement would be the 
hepatic extraction of bile acids. This measurement requires 
catheter is at ion of the hepatic veins and is therefore not 
readily available (THOMSON & GILMORE 1981).
3.3 HEPATOCELLULAR DESTRUCTION
The majority of tests which reflect the active destruction 
of hepatocytes consist of the measurement of hepatic enzymes in 
the peripheral blood. Why these enzymes appear in the blood in 
liver disease is not clear. When they do appear they behave like 
serum proteins being distributed in the plasma and interstitial 
fluid. The half-lives of elimination are usually measured in 
days. The mechanism by which these enzymes are cleared is not 
fully understood but there is some evidence of clearance by the 
reticuloendothelial system (WATKIN & FLEISCHER 1963).
Fbur factors are of inportance in determining the level of 
the enzymes in the serum.
a) The concentration of the enzyme in the hepatocytes.
b) The amount of leakage from the hepatocyte.
c) The rate at which the circulating enzyme is cleared 
from the blood.
d) The number of liver cells damaged.
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3.3.1 Aminotransferases
The roost commonly measured liver enzymes are the aspartate 
(AST) and alanine (ALT) aminotransferase, previously known as 
serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic 
pyruvate transaminase (SGPT). These enzymes catalyse the 
conversion of alpha amino acids to alpha-keto acids by the 
transfer of an amino group. They have negligible and are present 
in high concentration in the liver cells with AST in the 
cytoplasm and mitochondria while ALT is found only in the 
cytoplasm (BOYDE & LATNER 1961). ALT is considered to be a more 
sensitive and specific test of acute hepatocellular damage, 
whereas changes in AST occur in chronic damage to the hepatocyte 
(CDODLEY 1971). The half life of AST is 17 hours which is 
considerably shorter than ALT at 47 hours, they have negligible 
renal and biliary secretion (DUNN et al 1958).
The total activity of AST consists of different isoenzymes 
which originate either in the mitochondria or the cytoplasm. In 
parenchymal liver disease with a raised total AST activity the 
cytoplasmic isoenzyme is always elevated and the mitochondrial 
enzymes is high in approximately 50% of cases. The mitochondrial 
isoenzyme is particularly elevated in patients with metastatic 
liver disease (SKRHA et al 1978). The ratio of mitochondrial AST 
to total AST is significantly elevated in alcoholics with and 
without evidence of liver disease compared to nonalcoholic 
controls and patients with viral hepatitis (NALPAS et al 1984).
In acute liver disease the ALT and AST are usually markedly 
elevated and a fall in the enzyme level usually precedes a 
clinical improvement. A persistent elevation of the amino­
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transferase for six or more months following an attack of acute 
hepatitis is suggestive of progression to chronicity and is an 
indication for a liver biopsy. The correlation between the 
transaminases and the histological findings is poor so that 
attenpts to tailor the dose of steroids to the transaminases has 
not proved to be useful.
The estimation of AST has been found to be a more sensitive 
measure of minimal liver disease in alcoholics than either 
postprandial bile acids or the aminopyrine breath test (GALIZZI 
et al 1978).
3.3.2 Ornithine carbamyl transferase
This measurement of this enzyme is not widely available 
because of the conplicated methodology involved. It is a 
mitochondrial enzyme and elevated levels are found only in liver 
disease and are particularly associated with active 
hepatocellular damage (REICHARD 1961). Measurement of ornithine 
carbamyl tranferase has been found to be a more sensitive 
indicator of liver disease than AST and ALT (SKREDE et al 1973).
3.3.3 Lactate dehydrogenase
Many different tissues contain lactate dehydrogenase and 
elevated levels therefore lack diagnostic specificity. There are 
five major isoenzymes of which LD1 is predominantly found in 
liver tissue and the serum activity enzyme is elevated in 
conditions of hepatocellular damage (MASSEY et al 1971).
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3.3.4 Isocitrate dehydrogenase
This enzyme is found in the hepatic cytoplasm as well as in 
skeletal muscle, the heart and the kidney. Elevated levels are 
usually indicative of liver disease but the measurement does not 
appear to have and particular benefit over the measurement of the 
other enzymes (OKUMURA & SPELLBERG 1950).
3.3.5 Sorbitol dehydrogenase
This enzyme is almost exclusively found in the liver and 
elevated levels are found inpatients with hepatocellular damage 
but its use is limited by its instability in blood (DeRITIS et al 
1965).
3.3.6 Glutamate dehydrogenase
This is a mitochondrial enzyme which is found in the liver, 
heart, kidney and skeletal muscle. A comparison of glutamate 
dehydrogenase and AST in alcoholics suggested that the former was 
the more sensitive indicator of hepatocellular damage (VAN WAES & 
LIEBER 1977). However a recent study found that elevated levels 
of glutamte dehydrogenase reflected recent alcohol intake rather 
than hepatic histology (JENKINS et al 1982).
3.3.7 Guanase
Guanase activities are high in the brain, liver and kidney 
but are low in the myocardium, pancreas and skeletal muscle. 
Serum guanase activity is elevated in acute and chronic liver 
disease and there is a suggestion that it is a more sensitive 
predictor of liver dysfunction than gammaglutamyl transpeptidase,
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ALT, AST (ITO et al 1982).
3.3.8 Aldolase
Fructose 1,6 diphosphate aldolase occurs as three 
isoenzymes. The A isoenzyme occurs in muscle, aldolase B in the 
liver and aldolase C in the brain. Elevated levels of aldolase B 
have been demonstrated in patients with acute and chronic liver 
disease and hepatic neoplasia. Levels corelated closely with ALT 
levels but B aldolase has the advantage that it is liver 
specific (ASAKA et al 1984).
3.4 BILE DUCT PATENCY
In most forms of liver disease there is some degree of 
hepatocellular destruction and some obstuction to the flow of 
bile. The relative pr(portion of each conponent varies in each 
type of liver disease. It is of great therapeutic importance to 
be able to distinguish patients with predominantly biliary 
obstruction, particularly those with an extrahepatic lesion.
3.4.1 Alkaline phosphatase
The most commonly utilised measurement which is used as an 
indicator of biliary obstruction is the serum alkaline 
phosphatase (AP). The term alkaline phosphatase is used for a 
group of enzymes which catalyse the hydrolysis of a number of 
organic phosphate esters with the liberation of inorganic 
phosphate and an organic radical. Different isoenzymes are found 
in the liver, kidney, bone and intestine. The liver enzyme is 
found in the microvilli of the bile canaliculus and it may
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participate in transport mechanisms but its basic functions 
remain unknown.
Elevation of alkaline phosphatase are seen in biliary 
obstruction, metabolic bone disease and diffuse infiltration of 
the liver with the highest levels being recorded in complete 
extrahepatic biliary obstruction. The activity in the serum of a 
patient with obstructive jaundice comprises two components. One 
derived from the liver cells is identical to the liver isoenzyme 
and the other only appears in biliary obstruction and is derived 
from bile (PRICE & SAMMCNS 1974). Elevated levels of the enzyme 
are due to an overspill from the hepatocyte, whose content of the 
enzyme is increased in biliary obstruction (KAPLAN 1972). 
Quantitation of the biliary isoenzyme has been suggested as a 
method of improving the sensitivity of alkaline phosphatase in 
differentiating total biliary obstruction from partial 
obstruction (PRICE & SAMMCNS 1976), although this is disputed 
(SORENSEN et al 1981). Intrahepatic cholestasis can not be 
clearly distinguished from extrahepatic cholestasis on the basis 
of alkaline phosphatase estimations (GUTMAN 1959). The 
intestinal isoenzyme may provide a better guide to this 
differentiation (WARNES et al 1977). The basis for this approach 
is that the presence of bile in the bowel is necessary for the 
release of the intestinal isoenzyme, and in biliary obstruction 
the levels of this isoenzyme will be either reduced or absent.
A further isoenzyme alpha-1 has been claimed to be specific 
for hepatic metastasis (VIOT et al 1979).
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3.4.2 5 Nucleotidase
5-nucleotidase is a phosphomonoesterase that hydrolyses the 
nucleotide attached to the 5 position of a pentose chain. It is 
widely distributed in the body and in the liver it is located in 
the sinusoidal and canalicular membranes. Elevations in the 
serum occur in patients with liver disease and in women in the 
third trimester of pregnancy (KATER & MISTILIS 1972). It is not 
elevated in bone diseases (KAPLAN 1972). Elevated levels are 
found in all types of liver disease but the most marked changes 
are found in cholestasis. The changes in 5-nucleotidase activity 
tend to parallel those seen in the alkaline phosphatase but tend 
to fall more rapidly on the relief of the obstruction. The 
alkaline phoshatase tends to be more sensitive, and for this 
reason it is irrational to use the estimation of 5-nucleotidase 
as a method of confirmation of liver disease in patients with an 
elevated alkaline phosphatase (CONNELL & DINWDODIE 1970). The 
main clinical application of 5-nucleotidase estimations is the 
confirmation of liver disease in children.
3.4.3 Leucine aminopeptidase
Leucine aminopeptidase is a proteolytic enzyme which 
hydrolyses amino acids. Elevations of leucine aminopeptidase are 
found only in patients with diseases of the hepatobiliary system 
and pancreas (NACHLAS et al 1957). The levels are particularly 
high in patients with obstructive jaundice due to a carcinoma of 
the head of the pancreas (RUTENBERG et al 1958). It is also 
elevated in pregnancy (BRESSLER & FORSYTH 1959), but it is not
79
increased in patients with bone disease (RUTENBERG et al 1958).
It shows a similar sensitivity as alkaline phosphatase and 5 
Nucleotidase.
3.4.4 Gamma glutamyl transpeptidase
The serum levels of gamma glutamyl transferase (GGT) are 
elevated in all forms of liver disease and particularly high 
levels are found inpatients with obstructive jaundice (LUM & 
GAMBINO 1972). Five isoenzymes have been demonstrated only two 
of which occur in normal individuals (WENHAM et al 1979). The 
enzyme is not confined to the liver and high levels are found in 
some non-hepatic conditions including renal neoplasia, nephrotic 
syndrome (ORLOWSKI 1963), renal transplant rejection, acute and 
chronic pancreatitis, congestive cardiac failure (RUTENBERG et al 
1963), diabetes mellitus (GOLDBARG et al 1963) and angina 
pectoris (HEEfrroRTH-vmiTTY et al 1967), but it is not elevated in 
pregnancy. Elevated levels are also found in patients taking 
drugs which induce tha hepatic monoxygenase enzymes (RDSALKI et 
al 1971). It has therefore been suggested that it may be of 
value in monitoring the abstinence of alcoholics (HORNER et al 
1979).
The high serum levels seen in extrahepatic obstruction are 
not sufficent to confidently differentiate 'medical1 from 
'surgical' jaundice (KEANE and GARCIA 1973). The levels seen in 
cirrhotic patients are very variable and an elevation in the 
enzyme may be the only biochemical abnormality. The serum levels 
do not correlate closely with the levels in the hepatocyte, 
suggesting that increased concentrations in the hepatocyte may
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not be an inportant mechanism in the production of high serum 
levels (SELINGER et al 1982). There is a tendency for the serum 
levels of the enzyme to fall in the terminal phases of liver 
disease presumably because of a failure in its synthesis (NOSSLIN 
et al 1966). The conplete absence of the enzyme from bone 
together with its greater sensitivity in cholestasis (WHITFIELD 
et al 1972) and its ease of estimation have resulted in the 
widespread use of the enzyme as a means of confirming that an 
elevated alkaline phosphatase is of hepatic origin (LUM & GAMBINO 
1972).
There is no information available on the prognostic value of 
GGT but its greater sensitivity for liver disease compared to 
bilirubin, aminotransferases, and alkaline phosphatase make it a 
useful screening test.
3.5 HEPATIC FIBROSIS
The normal architecture of the liver is supported by a 
framework of connective tissue. This consists of collagen which 
is a heterogeneous class of extracellular proteins with a unique 
aminoacid conposition. Three distinct forms of collagen have 
been isolated and are designated as collagen I,II,III. In 
chronic liver disease this framework becomes thickened and 
distorted. Increased deposition of type III collagen occurs in 
early fibrosis (PROCKOP et al 1979) and type I collagen is 
produced in the later stages of fibrosis (ROJKIND 1981).
Gollagen is formed by the activation of amino acids in the 
ribosomes. Specific enzymes including prolyl hydrolase, lysyl 
hydrolase and glycosyltransferase act on the procollagen which is
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then secreted into the extracellular space where the procollagen 
peptidases remove the peptide extensions from the amino and 
carboxy terminals (PROCKOP et al 1979, FESSLER & FESSLER 1978). 
The collagen fibrils and possibly procollagen are later degraded 
by collagenase.
A noninvasive measure of hepatic fibrosis might be of 
clinical value in distinguishing patients with active cirrhosis 
and also patients with the committed precursors stages of 
cirrhosis from those with inactive disease. In cirrhosis the 
liver content of collagen increases five fold. The mechanism by 
which collagen accumulates is unknown but four process can be 
involved (GARTER et al 1982)
1. An increased rate of collagen synthesis
2. An increased production of type IV collagen which is 
resistant to degradation by collagenase
3. An increase in the number of collagen cross links, 
which also render collagen more resistant to collagenase
4. An alteration in the activity of collagenase
The noninvasive measurements which are used in the
assessment of intrahepatic f ibrogenic activity are based on three 
basic principles
a) Analysis of metabolic products which are either needed 
in the synthesis of collagen or are released during its 
degradation. These include proline, hydroxyproline and 
the analysis of the amino-terminal peptide for type III 
collagen.
b) Measurement of serum metabolites which induce or 
stimulate collagen formation in vitro.
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c) Measurement of enzymes involved in the modification of 
collagen including prolylhydroxylase and galactosyl- 
hydroxysyl glucosyltransferase.
The concentration of hydroxyprol ine is increased in patients 
developing chronic liver disease. Elevated levels of prolyl 
hydrolase have also been demonstrated in the early stages of 
cirrhosis (MANN-et'al 1979).
An alternative approach to the non-invasive detection of 
hepatic fibrosis is the determination of the aminoterminal 
propeptide type III. This is elevated in patients with alcoholic 
cirrhosis compared to controls (ROHDE et al 1979). In another 
study type III procollagen peptide levels could not be used to 
differentiate alcoholic cirrhosis from alcohol associated fatty 
liver, although grossly elevated levels were suggestive of 
alcoholic hepatitis (NIEMELA et al 1983). There remain 
considerable methodological problems in the measurement of this 
peptide (ROJKIND 1984).
3.6 COMBINATION TESTS OF LIVER FUNCTION
The liver has many different functions, it is possibly that 
the assessment of a combination of functions may yeild more 
information than the measurent of a single function.
3.6.1 Child's classification
The best known of the combination indices of liver function 
is the Childs' classification (Table 3.3) which was later 
modified by PUGH (PUGH et al 1973). This index provides a
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scoring system for clinical and biochemical features of liver 
disease (TABLE 3.4). Those patients who have a total score of 5 
or 6 have well preserved liver function and are classified as 
Child's grade A. Moderate liver function is a score of 7,8,9 
(grade B) and severe liver disease is a total score of > 9 (grade 
C). The original application of this grading was in the 
selection of patients with bleeding oesophageal varices for 
portocaval shunts. The two main problems of this grading are 
that the assessment of ascites and encephalopathy are highly 
subjective and that the biochemical measurements can be very 
unstable following an acute gastointestinal bleed, with the 
bilirubin in particular being disproportionately elevated. 
Discriminant functional analysis of the Child's classification 
show that in the prediction of survival there is a high degree of 
correlation between the individual components, and therefore the 
index contains redundant information (BARBARE et al 1985). The 
childs classification has less prognostic value than an index 
derived by multi variant analysis (CHRISTENSEN et al 1984).
Despite these problems the Child's classification remains the 
standard method for differentiating the severity of liver 
disease.
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TABLE 3.3 CHILD'S CLASSIFICATION OF THE SEVERITY OF LIVER DISEASE
Grade A Grade B Grade C
Serum Bilirubin 
(umol/1)
< 40 40-50 > 75
Serum Albumin
(g/i)
> 35 30-35 < 30 •
Ascites None Easily
controlled
Poorly
controlled
Neurological Disorder None Minimal Advanced
coma
Nutrition Excellent Good Poor
(from CHILD 1964)
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TABLE 3.4 PUGH'S MODIFICATION OF CHILD'S CLASSIFICATION OF THE 
SEVERITY OF LIVER DISEASE.
POINTS SCORE 
1
FOR INCREASING ABNORMALIY 
2 3
Encephalopathy (Grade) None 1 or 2 3 or 4
Ascites Absent Slight Moderate
Bilirubin (mg/lOOml) 1-2 2-3 > 3
Albumin (g/1) >35 28 - 35 < 28
Prothrombin time (sec ) 1-4 4-6 > 6
Bilirubin in Primary 
Biliary Cirrhosis 1-4 4-10 > 10
(From PUGH et al 1973)
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3.6.2 Simple ratio procedures
Since biochemical tests of liver function were introduced 
attempts have been made to combine two or more of these tests in 
a simple ratio to provide a third more sensitive or specific 
test. Initially it was suggested that an AST/ALT ratio of >1 
was suggestive of cirrhosis, hepatocellular carcinoma, metastasis 
or lymphoma, and a ratio of <1 suggested extrahepatic 
obstruction, viral hepatitis, or drug induced hepatotoxixity 
(WROBLEWSKI 1958). More recently interest in the AST to ALT 
ratio has been revived by the suggestion that a ratio of greater 
than 2 is highly suggestive of alcoholic hepatitis and cirrhosis 
(COHEN & KAPLAN 1975). A ratio >2 was found in 70% of patients 
with alcoholic cirrhosis or hepatitis compared to only 8% of 
patients with chronic active hepatitis, 4% with viral hepatitis, 
and no patient with obstructive jaundice. However a ratio of >2 
was found in 26% of patients with cryptogenic cirrhosis. AST is 
predominantly a cytoplasmic enzyme where as ALT originates 
predominantly from a mitochondria so that an explanation of these 
findings is that a low AST/ALT suggests some impairment of the 
cellular membrane and a high ratio suggest mitochondrial damage, 
as in alcoholic liver disease (SKREDE et al 1973). This 
explaination is unlikely to be correct because the finding of a 
high ratio does not correlate with elevated levels of the 
mitochondrial enzyme ornithine carbamyl transferase. The change 
in the ratio has been shown to be due to a reduction of the 
concentration of ALT in the hepatocyte rather than to a 
differential pattern of release (MATLOFF et al 1980). These
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changes may to some extent be due to deficiency of pyridoxal 5- 
phosphate (DIEHL et al 1984), the biologically active form of 
vitamin B6. This vitamin is necessary for the activation of the 
aminotransferases.
6.3 Correlation matrices
Correlation matrices have been used to suggest that the 
standard liver function tests are themselves dependent on four 
underlying hepatic functions (MILOSZEWSKI et al 1970). These 
functions were :
1. Disturbance or modification of the hepatocyte 
membrane. This was most reflected by changes in the 
zinc sulphate and thymol turbidities and the ALT.
2. Protein synthesis. This is shown by changes in the 
serum albumin and prothrombin time.
3. Hepatic excretory function. Ihis is best reflected by 
the alkaline phosphatase and serum bilirubin.
4. Imrnunological function. This function is reflected in 
the standard liver function tests by the serum 
globulins.
,6.4 Discriminant function analysis
In discriminant function analysis a set of weighting factors 
are added to the individuals test results. The sum of the 
weighted test profile is then termed the 'discriminant1
d = wltl + w2t2 +w3t3 ........wntn
where d is the discriminant , wl wn are the weighting
factors for test results tl tn. The analysis depends on
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the definition of prearranged groups in the data for example non­
survivor and survivors or diagnostic groups. The weightings are 
the calculated to minimise any within group variation and to 
maximise betwen group variation.
Initial studies of this technique produced results for the 
differention of six forms of liver disease which were not better 
than random guessing (BARON 1970). This analysis has now been 
applied to the diagnostic value of standard liver function tests 
in large groups of patients with liver disease. It was found 
that the optimum group of tests for the differentiation of liver 
diseases was very dependent on which liver diseases were to be 
separated. On a standard battery of six tests about two thirds 
of the patients were allocated to the correct disease group. The 
most significant information was derived from the alkaline 
phosphatase and either the AST or ALT.
Another application of these methods is a computer based 
index for the diagnosis of parenchymal liver disease. The system 
considers 14 pieces of information of which it found 9 to be of 
value in differentating the diagnosis in an individual case. The 
system produced the correct diagnosis in 53% of the cases and 
included the correct diagnosis in a list of two likely diagnoses 
in 73% of cases. The nine components in order of their 
effectiveness in producing a diagnosis were
1. Plasma disappearance rate of indocyanine green
2. Alanine transaminase
3. Zinc turbidity test
4. Alkaline phosphatase
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5. Age
6. Hepatitis Bs Ag
7. Rheumatoid factor
8. AST/ALT ratio
9. AST
Five tests were found to have no discriminant diagnostic 
value and they included the serum cholesterol, total proteins, 
total bilirubin, albumin to globulin ratio and the gamma globulin 
fraction (ITOSHIMA et al 1983). This type of analysis has also 
been applied to various parameters of BSP elimination to allow 
the separation of normal subjects from obstructive jaundice from 
a group with cirrhosis (MOLINO et al 1978).
This analysis has also been used to assess the prognosis in 
liver disease. In a group of 129 patients with cirrhosis nine 
prognostic variables were evaluated. These variables included 
age, ascites, encephalopathy, gastrointestinal bleeding, serum 
bilirubin, serum albumin, GGT,AST, and prothrombin time. It was 
found that the serum bilirubin and GGT were of particular 
prognostic value and a bilrubin/GGT ratio of > 1 was associated 
with a 12 month survival of only 12% (POYNARD et al 1984).
In a group of 72 patients with mixed liver disease multiple 
regression analysis showed that the best predictors of 
histological and clinical severity were Lecithin - cholesterol 
acyl transferase (LCAT), total plasma cholesterol, alkaline 
phosphatase, and serum bile acids (SIMKO et al 1985).
Discriminant analysis has also been used to construct a simple 
nomogram for the assessment of the severity of liver disease 
(HAMILTON 1977). This was based on the total bilirubin, alkaline
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phosphatase, Zinc turbidity, and alanine aminotransferase. This 
nomogram has not been widely applied, probably due to loss in the 
zinc turbidity test being superceded by other liver function 
tests.
Multiple regression analysis has been used to evaluate 
prognostic features in a group of 248 patients with primary 
biliary cirrhosis. Five variables were found to have independent 
prognostic significance; serum albumin, serum bilirubin, 
cirrhosis, age and central cholestasis. These factors were 
combined as a prognostic index which was validated against 
independent data (CHRISTENSEN et al 1985(a)). The same group 
applied similar methods to patients with cirrhosis to predict 
patients who would benefit from therapy with prednisolone. Fbur 
variables had therapeutic value. Antinuclear factor and large 
piecemeal necrosis were associated with a beneficial effect of 
prednisolone and ascites and large regenerative nodules were 
associated with a deleterious effect of prednisolone (CHRISTENSEN 
et al 1985(b)).
3.6.5 Canonical analysis
Canonical anlysis is a type of descriminant analysis in 
which there is a transformation applied to the initial vectors to 
reduce the within sanple ellipsoids of scatter to spheres. This 
technique allows the weighting of the individual liver function 
tests so that the resulting sums of the liver function test for 
patients with a specific diagnosis is similar and different from 
patients with other diagnoses (BARON 1970).
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3.6.6 Artificial Intelligence
An system for the functional assessment of liver disease has 
been constructed based on Artificial Intelligence methodology. 
The system gives an assessment of four aspects of liver function 
- biosynthesis, cholestasis, reactivity, cellular destruction.
The data used includes albumin, pseudocholinesterase, 
prothrombin time, bromosulphthalein clearance, bromsulphthalein 
retention at 45 minutes, ALT, AST, isocitrate dehydrogenase, 
bilirubin, GGT, rheumatoid factor, immunoglobulin A, 
immunoglobulin G and immunoglobulin M (LESMO et al 1984).
3.6.7 Numerical Taxonomy and cluster analysis
At any given time a patient has a given set of of liver 
function test results. These results can be considered as the 
coordinates of a point in some multidimensional space. As 
further patients are added to this space so the space becomes 
crowded and it is likely that certain groups or 'clusters' will 
appear. The basic problem in this method is the desciption of a 
cluster. The distance between two patients is called the 
Mahalanobis D2. A small D2 signifies the close proximity of the 
patients. The formation of clusters then occurs as follows.
First the D2 is calculated for all possible patient pairs.
Second the pair with the smallest D2 are clustered. Third the D2 
for each nonclustered pair with the cluster is calculated.
Fourth the D2s obtained are compared to the D2s obtained in stage 
1. The lowest D2 is taken and results in a patient either being 
added to the- original cluster or forming a second cluster with 
another patient. The process is then repeated from stage three
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until the D2s obtain fail to reach some preset level of 
statistical significance.
The use of cluster analysis has been extensively 
investigated in the diagnosis of liver disease with disapointing 
results (BARON & FRASER 1965, FRASER & BARON 1966). One of the 
early computer models for the diagnosis of liver disease utilised 
two and three dimensional plotting to allow the recognition of 
characteristic profiles in specific forms of liver disease 
(STRANDJORD et al 1973).
3.6.8 Bayes theorem
A medical diagnosis can be considered as an analysis of 
symptoms. The physician has an almost unconcious awareness of 
the relative frequencies of any symptom in any disease state, and 
a diagnosis involves the eliciting of symptoms and an awareness 
of the relative probabilities of those symptoms. If Sp denotes 
the patients symptom profile, and D represents one particular 
disease then the 'conditional probability1 is denoted as p(D/Sp). 
This probability is dependent on two main factors. Firstly the 
overall statistical chance that a patient has a particular 
disease for example in alcoholic liver disease has a prevelance 
of 1 in 10,000 then before the patient divulges any symptom there 
is a probability of 0.0001 that he has alcoholic liver disease. 
This is termed the 'population factor' and is denoted as P(D).
The second factor determining the conditional probability is the 
probability that any patient with disease D will have the symptom 
profile of the presenting patient this is denoted as p(D/sp).
Ihe relationship between these factors is described by the
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equation
p (D/sp) = 1 * P (D) *P (sp/D) 
k
k is a constant relating to the experience and practice of 
the physician involved.
Usually the equation will be used to calculate the 
conditional probabilities of at least two diseases. The 
equations are then
p(D2/sp)=l/k * P(D2)*P(sp/D2) 
p(Dl/sp)=l/k * P (Dl) *P (sp/Dl)
Hie relative probability of the two diseases can then be
expressed by cancelling k out of the equations as
p (Dl/sp) =1A * P(D1)*P (sp/Dl) 
p (D2/sp) =l/k * P(D2) *P(sp/D2)
This equation can then be expanded to consider the relative 
probabilities of a any number of diseases. This technique makes 
two major assumptions, firstly that each disease state is 
mutually exclusive of the others and secondly that there is no 
correlation between the individual components of of the symptom 
profile.
Discriminant analysis was used by TENGSTROM to evaluate 
serum bilirubin, thymol turbidity, alkaline phosphatase, ALT and 
the galactose tolerence test in the differentiation of cirrhosis 
from viral hepatitis, biliary obstruction and patients with 
normal liver biopsies (TENGSTROM 1969).
An evaluation of this type of analysis has been applied in a 
computer based system has been applied to the differential 
diagnosis of jaundice. This system takes account of 72 pieces of 
information taken from the history, physical examination,
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biochemistry and haematological reports. The accuracy in 
diagnoses between 11 causes of jaundice was 77% and in the 
differentiation of surgical from medical jaundice the system was 
accurate in 95% of cases (STERN et al 1975).
C H A P T E R  4
PHARMACOKINETICS AND PHARMACODYNAMICS
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4.1 INTRODUCTION
All therapeutic agents which are absorbed into the body 
require to be excreted. Some drugs are water soluble and can be 
directly excreted from the human body in urine, bile, sweat or 
other body secretions. However the majority of drugs are lipid 
soluble and require to undergo biotransformation within the body 
to render them more water soluble. This improves their excretion 
in two ways. Firstly, the metabolites can be filtered out of the 
circulation by the renal glomeruli and secondly because they are 
less able to penetrate lipid membranes therefore they are less 
likely to be reabsorbed from the renal tubules. The rate at 
which these transformations to aqueous solubility occur largely 
dictates the rate of elimination of these drugs from the body. 
Most of these transformations occur in the liver and are mediated 
by mitochondrial enzymes.
These transformations are considered to be of two types 
(WILLIAMS 1971). The Phase 1 reactions involve the hydrolysis, 
oxidation or reduction of the molecule by the monooxygenase 
enzymes in the smooth endoplasmic reticulum. This system 
comprises a large number of enzymes the best studied of which are 
cytochrome P-450 and cytochrome P-448. The function of the system 
is to supply oxygen in the form of high energy complexes. These 
reactions generally decrease the pharmacological activity of the 
molecule but occasionally a more active molecule is created 
(azathioprine to 6-mercatopurine and prednisone to prednisolone). 
These reactions may also result in the production of a more toxic 
metabolite than the parent compound for exanple paracetamol.
The second group of transformations (Phase 2) involve the
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conjugation of the parent molecule or its metabolites with a 
small endogenous molecule to render them more water soluble. 
Conjugation to a variety of molecules including glucuronic acid, 
sulphates, aminoacids, acetic acid or glutathione may occur. A 
list of some of the drug metabolising reactions and the enzymes 
involved is included in TABLE 4.1. It has become clear that many 
of these enzymes exist in multiple forms whose activity may be 
affected differently by external agents. For example 
chlordiazepoxide and diazepam are both primarily metabolised in 
the liver by N-demethylation but the elimination of 
chlordiazepoxide is profoundly reduced in the elderly whereas the 
elimination of diazepam is less affected.
The purpose of this chapter is firstly to examine the 
factors which determine the elimination of drugs from the body. 
Secondly, to review the drugs which have been used as indicators 
of liver disease.
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TABLE 4.1 HEPATIC DRUG METABOLISING REACTIONS IN MAN
Reaction Enzyme Substrate
Oxidation
alkyl hydroxylation
aromatic hydroxylation
epoxidation
N,S,0-dealkylation
deamination
N-hydroxylation 
N-oxidation 
S-oxidation 
desulphuration 
alcohol oxidation 
aldehyde oxidation
cytochrome P-450 
cytochrome P-450 
cytochrome P-450 
cytochrome P-450 
cytochrome P-450 
monoamine oxidase 
cytochrome P-450 
cytochrome P-450 
cytochrome P-450 
cytochrome P-450 
ale: dehydrogenase 
aide:dehydrogenase
pentobarbi tone
phenytoin
dieldrin
aminopyr ine,antipyr ine
amphetamine
tyr amine
aniline
sparteine, car bamazepine
chlorpromaz ine
thiopentone
ethanol
acetaldehyde
Reduction
azo reduction 
nitro reduction 
dehalogenation 
ketone reduction
Hydrolysis
deesterification 
deamination 
epoxide hydrolysis
azo-reductase
nitro-reductase
ketone reductase
esterase
amidase
epoxide hydratase
prontosil
chloramphenicol
halothane
warfarin
pethidine 
procainamide 
styrene oxide
isoniazid
propranolol
ethinyloestradiol
paracetamol
acetylsalicylic acid 
catecholeamines
Conjugation
acylation
glucuronidation
sulphation 
mercaptopurine acid
formation 
amino acid conjugation
N ,S,O-methylation
acetyltransferase 
glucuronyl
transferase
sulphotransferase
glutathione
transferase 
amino acid
transferase 
methyltransferase
From PARK 1982
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4.2 DEFINITION OF PHARMACOKINETIC PRINCIPLES
Pharmacokinetics involves the study of the distribution and 
elimination of drugs. Examination of the various pharmacokinetic 
parameters can be of value in two ways. Firstly it allows the 
description of a profile of a drug and this information is then 
of use in determining size and frequency of drug doses. Secondly 
in the diseased state information can be gained regarding the 
functional capacity of the elimination mechanisms.
4.2.1 Absorption
When drugs are given by mouth they are mostly absorbed from 
the small bowel into the portal circulation. Tne speed of 
absorption depends on the rate of gastric emptying, small bowel 
motility, the surface area of the small bowel, the capacity and 
rate of the transport mechanisms and the intestinal blood flow. 
When drugs are given intramuscularly they are directly absorbed 
into the systemic circulation and the rate at which this occurs 
is dependent on the molecular weight of the drug, its solubility 
and. the blood flow at the site of injection.
4.2.2 Systemic availability
Bioavailability or systemic availability is the fraction of 
an orally administered dose which reaches the systemic 
circulation. When a drug is given intravenously it is given 
directly into the systemic circulation and the whole dose is 
therefore available to the systemic circulation i.e. it is 100% 
bioavailable. When a drug is administered orally some of the 
administered dose may not reach the systemic circulation either 
because it is not absorbed or because it is metabolised in the
100
gut wall or liver. This effect is called the presystemic 
elimination or the "first pass metabolism" of the drug. The 
systemic availability of a drug can determined by measuring the 
area under the drug concentration/time curve following 
intravenous and oral administration. Drugs which are undergoing 
a major degree of presystemic elimination are listed in TABLE 
4.2. Alterations in the presystemic elimination of drugs can 
lead to large changes in the amount of orally administered drugs 
which reach the systemic circulation.
TABLE 4.2 DRUGS THAT UNDERGO SUBSTANTIAL FIRST PASS ELIMINATION.
Acetylsalicylic acid Methyltestosterone
Alprenolol Metoprolol
Aminosalicylic acid Morphine
Amitriptyline Nalorphine
Chlormethiazole Nortriptyline
Chlorpromazine Oral contraceptives
Dextropropoxyphene Oxprenolol
Doxepin Paracetamol
Glyceryl trinitrate Pentazocine
Hydralazine Pethidine
Imipramine Prazosin
Indoramin Propranolol
Isoprenaline Propoxyphene
Isosorbide dinitrate Quinidine
Labetalol Salbutamol
Levodopa Terbutaline
Lignocaine Triazolam
Lorcainide Verapamil
From BRODIE 1983 
In man the factors affecting the presystemic elimination of 
drugs are the size and frequency of the dose, the metabolic 
capacity of the liver and the degree of portal-systemic shunting.
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4.2.3 Distribution
The relationship between the amount of drug in the body to 
the concentration in the plasma is expressed as the apparent 
Volume of distribution (Vd). This is influenced by many factors 
including the affinity of the drug for different tissues and the 
degree of binding of the drug to protein.
The apparent volume of distribution can be calculated from 
the equation .
Vd = D
Co (1)
where D is the administered dose and Co is the blood 
concentration back extrapolated on the concentration/time curve 
to the time of administration (time zero).
4.2.4 Half-life
Ihe half life is defined as the time taken for the 
concentration of the drug to decrease by 50% following absorption
and distribution. It can be expressed by the equation
t 1/2 = ( 0.693 Vd )
cl (2)
It can be seen from this equation that the half-life is 
dependent both on the volume of distribution and on the clearance 
of the drug. Either of these variables may alter in liver 
disease and it is therefore invalid to assume that alterations in 
half life reflect alterations in the elimination of the drug 
unless the volume of distribution is known.
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4.2.5 Clearance
The clearance of a substance is defined as the volume of
blood from which the substance is irreversibly removed in unit
time. Ebr drugs which follow single conpartment kinetics the
clearance (cl) is calculated by the equation :
cl = 0.693.Vd
tl/2 (3)
where tl/2 is the plasma half life.
If the drug shows multiconpartment kinetics then the
clearance should be calculated according to the equation :
cl = DOSE
NJC (4)
where ALJC is the area under the concentration/time curve.
The total clearance of a drug can also be considered as the 
sum of the clearances of the drug by individual organs. Ebr some 
drugs the equation would be :
cl = renal cl + hepatic cl (5)
Ebr many lipid soluble drugs the plasma clearance is
effectively the same as their hepatic clearance because they 
cannot be filtered through the glomerulus. Ebr an individual 
organ the clearance can be calculated from the concentration of 
drug entering (ca) and leaving (cv) the organ and the organ blood 
flow (Q).
cl = Q [ ca - cv ]
ca (6)
The arteriovenous difference is refered to as the extraction
ratio (E).
E = [ ca - cv ]
ca (7)
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Therefore the clearance can also be expressed as
cl = Q . E (8)
As the extraction ratio approaches unity then the clearance 
becomes dependent on the blood flow. Conversely when E is small 
then the clearance is dependent on the hepatic extraction and 
independent on the blood flow. This relationship can be used to 
divided into two groups
1. Flow-limited drugs have a high hepatic extraction ratio 
(>.7) and their clearance is then dependent on the rate of 
delivery of the drug to the liver i.e. liver blood flow. 
These drugs have a large presystemic elimination and can be 
recognised because they are either not recommended for oral 
use or the recommended oral dose is much larger than the 
intravenous dose to make allowance for the large presystemic
elimination. They can be used to monitor changes in the
/
liver blood flow but this technique assumes that the 
hepatic extraction ratio remains constant.
2. Capacity limited drugs have a low hepatic extraction ratio 
(<.3) and their clearance is primarily dependent on the rate 
at which the liver can extract them from the portal blood. 
Examples of this type of drug include phenytoin, diazepam, 
tolbutamide, warfarin , quinidine , digitoxin , and 
clindamycin. These drugs are particularly suitable as 
models for the demonstration of alterations in the hepatic 
metabolic capacity. This technique assumes that the rate 
limiting step in their extraction is hepatic metabolism and 
not the uptake across the hepatocyte membrane.
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4.2.6 Intrinsic clearance
Hie intrinsic clearance of a drug is the clearance of the 
drug if the organ blood flow was not a limiting factor. Hie 
intrinsic clearance is therefore dependent only on the protein 
binding and the activity of the eliminating mechanism.
Hie intrinsic clearance can be deduced if one assumes that 
the concentration of the free drug in the hepatic vein (fbcv) is 
equal to the concentration in the hepatic water. Where fb is the 
fraction of the drug unbound to plasma protein. The rate of 
removal of free drug from liver water will then be
cl(int).fbcv
But this is also given by Q(ca-cv)
Thus cl(int).fbcv = Q(ca-cv)
cl(int) = Q(ca-cv) 
fbcv (9)
since E = ca-cv 
ca
then cl(int) = QE
fb(l-E) (10)
then QE = cl(int).fb - cl(int).fb.E (11)
then QE + cl(int).fb.E = cl(int).fb
and E = fb.cl(int) 
Q+fbcl (int) (12)
therefore cl = Q . fb.cl(int)
Q+fbcl (int) (13)
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This proof is derived from ROBERTS et al 1979
The intrinsic clearance can also be considered in terms of
Michaelis-Menton enzyme kinetics.
cl(int) = Vmax
Rn + C (14)
where C is the drug concentration, Vmax the maximal rate of
metabolism, and Km is the Michaelis-Menton dissociation constant.
4.2.7 Protein binding
Drugs exist in the circulation either as the free unbound 
form or bound to a constituent of the blood, the majority of the 
binding occurs with albumin. A reduction in the degree of 
binding results in an increase in the concentration of the free 
pharmacologically active drug and this results in an enhanced 
effect but also may lead to an increased rate of excretion.
The elimination of drugs may be influenced by the drug 
binding and drugs can be subdivided on ability of the liver to 
extract the drug from the binding sites. Drugs are then 
subclassified as :
a) Restrictive drugs where only the free unbound fraction 
is available for extraction .
b) Nonrestrictive drugs where both the bound and unbound drug 
are available for extraction.
Drugs can be classified into groups, from which it may be 
possible to predict how their systemic availability would alter 
in disease states (TABLE 4.3).
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TABLE 4.3 CLASSIFICATION OF DRUGS ACCORDING TO INTRINSIC CLEARANCE AND
PROTEIN BINDING.
GROUP FREE INTRINSIC CLEARANCE PROTEIN BINDING
I HIGH HIGH
II LOW LOW
III LOW HIGH
(Drugs with a hepatic extraction ratio of >30% are classified as 
having a high intrinsic clearance, and a protein binding >85% is 
considered to be a high value)
From HOYUMPA et al 1978
Group I drugs have a high presystemic elimination, and if 
there is a significant degree of portal-systemic shunting then 
there may dramatic changes in the availability of these drugs. 
Changes in protein binding have little effect on the clearance of 
these drugs.
Group II drugs are independent of liver blood flow and the 
major determinant of their elimination should be a change in the 
intrinsic clearance.
Group III drugs have a high protein binding and if this is 
high enough then the hepatic clearance becomes proportional to 
the degree of drug binding.
4.2.8 Portal-systemic shunts
In chronic liver disease a proportion of the blood in the 
portal vein does not come into contact with the hepatocytes but 
instead is shunted directly into the systemic circulation. This 
shunting occurs both extrahepatically through oesophageal varices
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and intrahepatically as a result of the disturbed liver 
architecture. In alcoholic liver disease the degree of shunting 
varies between 60 - 80 % of the total liver blood flow (GKOSZMANN 
et al 1972). This shunting has important pharmacokinetic 
consequences particularly for drugs with a high hepatic 
extraction ratio.
It is possible to calculate the degree of shunting which 
occurs in liver disease. The "intact hypothesis theory" assumes 
that the true hepatic extraction [E(true)] is normal in liver 
disease. The hepatic extraction has now to be expressed as:-
E(actual) = E(true).fm (15)
where fm is the proportion of the portal blood flowing through 
the functioning hepatic tissue (WOOD et al 1978).
From equation (8)
cl (h) = Q.E = Q.fm.E(true)
But neither fm or E(true) can be directly measured.
Therefore substituting the intrinsic the equation becomes
cl(h) = Q.E = fm.Q.cl(int*)
Q + cl (int*)
then
fm _ cl (h) + cl (h)
cl(int*) Q
This equation now allows the calculation of the apparent 
intrahepatic shunt, but in order to do this hepatic vein 
catheterisation is required to calculate the liver blood flow.
If it assumed that fm will be the same for two different drugs A
(17)
(18)
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and B then
cl (h)A + cl (h) A = cl (h)B + cl(h)B 
cl(int*)A Q cl(int*)B Q (19)
and rearranging gives a value for Q
cl (h)A cl (h)B
Q = [ cl (h)B
[cl (int*)B
cl (h) A ]
cl(int*)A ] (20)
this value of Q can then be substituted into equation (16) and 
a value for fm obtained (MCLEAN et al 1979). The value of such 
calculations has yet to be established.
It is important to consider the route of drug administration 
when using drugs as tests of liver function. The oral route 
usually provides a more sensitive test. Orally administered are 
affected proportionately more by changes in hepatic extraction 
than a drug given intravenously. So that a reduction of hepatic 
extraction from 90 to 80% will decrease the intravenous clearance 
by 10% but the oral clearance by 100% (GILMORE & HOFMANN 1980).
4.2.10 Breath tests
There are two major problems with the measurement of these 
pharmacokinetic parameters. Firstly there is a need for frequent 
blood sampling in order to define accurate kinetic parameters and 
secondly there may be technical difficulties in measuring the 
very low concentrations of the drugs which occur in the plasma. 
Breath tests have been developed in an attempt to overcome these
4.2.9 Route of administration
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problems. The basis of these tests is that a test drug is 
labelled with a small dose of radioactivity, usually in the form 
of a 14C atom which is placed in the drug at the site where 
metabolism occurs. Following the initial metabolism of the drug 
the 14C forms 14Go2 which is then measured in the exhaled breath.
There are two limitations to this approach. Firstly the 
kinetic parameter which is measured is the plasma disappearance 
rate which is dependent on both the clearance and the volume of 
distribution. Secondly the metabolism of the drug is not 
necessarily the rate limiting step in the appearance of the 
radioactivity in the breath.
4.2.11 Conventional and distributed models
Various theoretical models have been used to describe the 
hepatic handling of drugs. In the conventional model the 
hepatocytes are all "lumped" together within the liver (FIGURE 
4.1) and the liver is considered as a "well stirred" bag of 
hepatocytes. This model predicts that after an instantaneous 
injection of a drug into compartment P, the plasma concentration 
will decline as defined by the sum of two exponentials whose 
slopes and intercepts are simple functions of the rate constant 
for hepatic uptake (kl) and the rate constant for the return of 
material from the hepatocytes to the plasma (k2). The drug is 
then irreversible removed from the liver cells (k3) (RICHARDS et 
al 1959). This model assumes that the plasma volume is a well 
stirred compartment and that all the hepatocytes are perfused 
with the same concentration of drug rather than the range of 
concentrations found down a sinusoid.
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The "parallel tube" model assumes that the liver is 
composed of a number of parallel tubes with the enzymes evenly 
distibuted. As the perfusing fluid travels down the tubes so the 
drug is extracted and the concentration of the drug in the fluid 
declines (FIGURE 4.2) (FORKER & LUXTON 1978). In this model a 
small central compartment P receives the bolus of drug. The 
volume of this compartment is Vp and it represents the volume 
into which the drug is instantaneously mixed. A compartment R 
contains a portion of the plasma volume, exchange occurs between 
P and R at a rate H which is equivalent to the cardiac output 
minus the hepatic plama flow (F). The splanchnic part of the 
model contains a parrallel array of sinusoids with a mixing 
compartment C and a simple delay represented by compartment D.
The sinusoidal array consists of a number (m) of identical units 
(FIGURE 4.3).
Mathematical analysis of these models suggests that the 
"lumped" model systematically underestimates the rate constants 
for hepatic uptake and reflux in to the plasma. These errors are 
most marked in the initial extraction phase. The estimates of 
the excretion rate constant and the steady state plasma clearance 
were accurate to within 3% (FORKER & LUXTON 1978). A full 
appreciation of the two basic models is outwith the scope of this 
thesis but the can be found in a review by PANG and ROWLAND 1977.
FIGURE 4.1 THE CONVENTIONAL OR "LUMPED’1 MODEL OF HEPATIC 
PHARMACOKINETICS
Plasma Liver Cells
ki
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FIGURE 4.2 TOE DISTRIBUTED MODEL OF HEPATIC PHARMACOKINETICS
SINUSOIDAL ARRAY
SPLANCHNIC MIXMG
HEART & LUNGS
SPLANCHNIC DELAY
PERPHERAL MXNG
FIGURE 4.3 SINUSOIDAL UNIT OF TOE DISTRIBUTED MODEL
X = 0  X=VU /m
Uj (x,t) SINUSOD, Vol.=Vu/m
z j  (x .t) LIVER CELLS, Vol =V, / m
v j (x .t) DISSE SPACE , Vol =V U /m
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4.3 THE INFLUENCE OF LIVER DISEASE ON THE MECHANISMS OF DRUG 
ELIMINATION
There are three major mechanisms by which liver disease may 
result in an alteration in the elimination of drugs and each of 
these mechanisms could theoretically be expected to be 
particularly relevant to a particular group of drugs. The 
mechanisms are
1. Liver blood flow. There are three factors which it is 
important to consider in relationship to the liver blood 
flow.
a) Total organ flow. This is primarily dependent on the 
cardiac output and intrahepatic resistance.
b) Intrahepatic shunts. These are of two types, the large 
'anatomical shunts' which allow the passage of 15 
micron spheres and red blood cells, and the functional 
shunts which are vessels perfusion nonfunctioning 
hepatic tissue (GROSS & PERRIER 1975).
c) Extrahepatic shunts. These are the major shunts which 
mainly occur round the oesophagus, retro-peritoneal 
tissues, umbilicus and scars.
As previously described alterations in the hepatic blood 
flow by any of these mechanisms should particularly affect 
drugs given orally which have a large presystemic 
elimination.
2. Activity of the microsomal enzymes. A reduction in 
microsomal enzyme activity may result from a reduced number 
of viable hepatocytes and possible a reduced functional 
capacity of the remaining hepatocytes. This mechanism
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particularly affects the clearance of drugs with a low 
hepatic extraction ratio.
3. Plasma Protein. Generally the levels of plasma proteins
are reduced in liver disease. Because there are reduced 
numbers of binding sites in the plasma this will have the 
effect of increasing the free concentration of the drugs 
which are highly protein bound. Ihe free drug has a greater 
degree of access to the elimination mechanisms. So that tine 
major effect of a reduction in plasma proteins will be to 
increase the plasma clearance of drugs which are highly and 
restrictively bound to tine serum proteins.
Two major theories of the alteration of drug elimination in 
cirrhosis have arisen. The first termed the "sick cell" theory 
suggests that the alterations are due to reduced functional 
activity of the microsomal enzymes within the hepatocytes (BRANCH 
and SHAND 1976). The second is the "intact hepatocyte" theory 
which states that the alterations in drug elimination are due to 
some areas of the liver with normal perfusion and normally 
functioning enzymes and some areas with large portal-systemic 
shunts (WOOD et al 1979(b)).
Recent experimental work has cast doubt on the validity of 
these theoretical considerations. In cirrhotic patients there is 
an inconsistent alteration in the total liver blood flow but on 
average there is a modest reduction of 15% (BRANCH & SHAND 1976). 
Ihis is much less than the changes in clearance which occur in 
cirrhosis for many of the highly extracted drugs (Appendix 2). It 
would appear that the critical factors producing the reduction in
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clearance is a reduction in the hepatic extraction (HCJET and 
VILLENEUVE 1983). There is however a reasonably good correlation 
between the clearance of high and low extraction ratio drugs in 
liver disease (BRANCH & SHAND 1976). From equation (9) for a drug 
like antipyrine with a low hepatic extraction a twofold reduction 
in the intrinsic clearance will result in a halving of the total 
clearance.
ie total cl = Q. int cl
Q + int cl
total cl = 1500.50 = 48 ml/min
1500 +50
with a reduction of the intrinsic clearance of 50%
total cl = 1500.25 = 25 ml/min
1500 + 25
Whereas for a drug like indocyanine green with a high
extraction ratio a similar reduction in the intrinsic clearance
will only reduce the total clearance by 25%.
ie total cl = 1500.3000 = 1000 ml/min
1500 + 3000
with a reduction of intrinsic clearance of 50%
total cl = 1500.1500 = 750 ml/min
1500 + 1500
This is surprising result because it suggests that the 
extraction mechanism for drugs with a high hepatic extraction 
ratio is more sensitive to the effects of liver disease than the 
mechanism low extraction ratio drugs. This may be so but an 
alternative explanation has been suggested based on the presence 
of functional intrahepatic shunts. From equation (13) any change
116
in the true hepatic extraction ratio produces a smaller than 
expected change if the actual hepatic extaction ratio because of 
the presence of shunting. This shunting will have a greater 
effect on drugs with a high hepatic extraction ratio, 
ie low extraction ratio drug
E (actual) = .1 * 100 ( if the shunt is lOOml/min)
= 10 ml/min
and for a high extraction ratio drug 
E(actual) = .7 * 100 
= 70 ml/min
Thus the greater effect of shunting offsets the smaller 
effect of changes in the hepatic extraction ratio resulting in a 
good correlation between the clearances of high and low 
extraction drugs.
4.4 THE EFFECT OF LIVER DISEASE ON THE DISPOSITION OF DRUGS
Appendix 2 contains a list of drugs on which data exists 
regarding their disposition in various types of liver disease.
The list includes a calculation of the percentage difference in 
the parameters from normal subjects. As expected it can be seen 
from this list that the elimination of most drugs is impaired to 
some extent in most forms of liver disease.
There is no standard measure of the severity of liver 
disease and there is a tendency in the literature to describe the 
severity of liver disease in histological terms which is clearly 
invalid. It assumes that patients with cirrhotic liver disease
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have a very much poorer prognosis than patients with non­
cirrhotic liver disease. However, these generalisations are not 
valid in clinical practice because many patients with acute 
hepatitis or alcoholic hepatitis have a much poorer prognosis 
than patients with inactive cirrhosis. It is therefore not 
possible to make firm conclusions as to the relative suitability 
of the various drugs by direct comparison of the results in this 
list. The list is intended to serve as a data base of the 
current knowledge of the effects of liver disease on drug 
metabolism in man.
4.5 THE USE OF DRUGS AS INDICATORS OF HEPATIC DISEASE
Ihere are several drugs which have been evaluated as tests 
of liver function. Antipyrine and indocyanine green are two of 
the most extensively studied coirpounds in this context and their 
use is reviewed in the appropriate chapters. The other drugs 
which have been used are reviewed below.
4.5.1 Any lobar bi tone
Amylobarbitone has been used as a probe of drug oxidation in 
man. It elimination depends almost exclusively on hepatic 
hydroxylation with less than 1% of the administered dose being 
unchanged in the urine. It is 50-60% protein bound and the 
salivary concentrations of the drug correlate well with the 
plasma concentration. The clearance does not correlate well with 
the clearance of antipyrine suggesting that there may be at least 
two drug hydroxylating systems in the liver (INABA et al 1976).
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4.5.2 Aminopyrine
Dimethylaminoantipyrine (aminopyrine), is rapidly absorbed, 
evenly distributed in the body water and metabolised by N- 
demethylation in the liver. A 14C aminopyrine breath test has 
therefore suggested as an appropriate method for the non-invasive 
assessment of hepatic demethylation capacity (HEFNER et al 1974). 
However, there are problems with this technique. Firstly, the 
rate limiting step of this method remains unclear (PLATZER et al 
1978). Secondly, there are various different methods of 
expressing the results, a 2 hour cumulative excretion (HEFNER & 
VESSEL 1975; GALIZZI et al 1978(a)) has been used but requires an 
assumption of the endogenous production of C02. Others use 
repeated measurements to derive a constant for the elimination of 
14 C02 (BIRCHER et al 1977; SCHOELLER et al 1982). Finally, a 
modified 2 hour breath test calculated from the area under the 
breath specific activity curve has been used and found to be more 
sensitive in detecting enzyme induction by glutethemide than the 
standard tests (HENRY et al 1979).
Qualitatively, the initial studies suggested that the 
elimination of aminopyrine was most impaired in parenchymal liver 
disease rather than cholestasis (HEPNER et al 1977 (a)). This 
allows the test to distinguish between primary biliary cirrhosis 
and chronic active heptatitis (BURNSTEIN and GALAMBOS 1981).
There is a good correlation with serum albumin, BSP clearance 
(HEPNER & VESELL 1975) the galactose elimination capacity 
(BIRCHER et al 1973), fasting bile acids, bilirubin, and AST 
(MORELLI et al 1981). However, the correlation with antipyrine
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clearance is poor, and aminopyrine proved to be more sensitive in 
the detection of minimal liver disease (HEPNER & VESELL 1975). A 
good correlation has been found between the plasma disapearance 
rate for the breath test and for direct plasma measurements 
(BIRCHER et al 1976, HEPNER & VESELL 1976). The breath test 
responds to the administration of enzyme inducers in normal 
controls (HEPNER & VESELL 1974) and in patients with cirrhosis 
(PIKEN & HEPNER 1979). Aminopyrine breath tests have been used 
to demonstrate intrahepatic enzyme defects in porphyria 
(OSTRCWSKI et al 1983), and as a sensitive indicator of hepatic 
dysfunction in patients undergoing jejunoileal bypass for obesity 
(BAKER et al 1983).
When used as a quantitative liver function test there is a 
good correlation with clinical gradings of the severity of liver 
disease including the Childs classification (MORELLI et al 1981). 
The test has prognostic value in alcoholic hepatitis (SCHNEIDER 
et al 1980) and in patients with liver disease undergoing surgery 
(GILL et al 1983). In conjunction with thyroid function tests 
and prothrombin time the aminopyrine breath test is of some value 
in separating survivors from non-survivors with mixed liver 
disease (HEPNER & CHOPRA 1979). In a small group of cirrhotic • 
patients the aminopyrine breath test was a poorer predictor of 
survival than the serum albumin (HENRY et al 1985).
Aminopyrine has two major advantages over antipyrine, 
firstly it is a conpletely non-invasive test, and secondly the 
small doses of aminopyrine involved are unlikely to produce 
significant microsomal enzyme induction or inhibition, although
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induction of gammaglutamyl transpeptidase has been demonstrated 
in rats (SAITOH et al 1982). It also has two major disadvantages, 
firstly as a breath test it measures the plasma appearance of 14C 
and this reflects the plasma disapearance rate of aminopyrine 
which is a variable dependent both on the elimination of 
aminopyrine and its volume of distribution. Secondly there is 
doubt about the mechanism of elimination of aminopyrine with a 
suggestion that only 50-60% of the administered dose is 
demethylated in the liver (BIRCHER et al 1977).
4.5.3 Cyclobarbital
Qrclobarbital has been evaluated as a suitable probe drug in 
liver disease. It had a similar ability to descriminate between 
patients with normal and abnormal liver function test as the 
aminopyrine breath test (BREYER-PFAFF et al 1984).
4.5.4 Phenacetin
Phenacetin is a drug with a high hepatic extraction ratio 
whose metabolism is dependent deethylation by cytochrome P448.
Its used as a probe drug in liver disease has been suggested and 
a breath test designed which allowed the clear separation of 
cirrhotic patients from patients without liver disease (BREEN et 
al 1984).
4.5.5 HIDA
Technetium-99m n(2,6-dimethylphenylcarbamoylmethyl) 
iminodiacetic acid (Tc-HIDA) is a radiopharmaceutical which has 
been extensively investigated as an agent for biliary imaging.
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It is eliminated by the liver through its anionic pathway. It 
has been used as an indicator of liver function but has the 
disadvantage that its clearance is competitively inhibited by 
bilirubin (HARVEY et al 1979).
4.6 PHARMACODYNAMIC RESPONSES
This chapter has considered the ways in which liver disease 
can alter the mechanisms by which drugs are distributed, 
metabolised and excreted from the body. It is important to 
remember the effect that these changes may have on the clinical 
effect of these drugs. Patients with cirrhosis are particularly 
sensitive to the sedative effects of morphine (LAIDLM et al 
1969), and chlorpromazine (MAXWELL et al 1972, READ et al 1969), 
tranylcypromine (MORGAN and REID 1972) and diazepam (BRANCH et al 
1976(c)). This sensitivity is most pronounced in patients with 
hypoalbuminaemia or a past history of portosystemic 
encephalopathy.
The mechanisms of this sensitivity are unknown but may 
include :
1. Alterations in the cerebral receptors.
2. Increased penetration of the unbound drug into the 
central nervous system.
3. An accumulation of toxic substances within the 
central nervous system with the sedatives acting as 
an extra insult.
The ideal sedative for patients should have a large 
therapeutic/toxic ratio, it effect should be rapid and easily
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titratable, it should have a low degree of protein binding and it 
should not cause increased cerebral sensitivity. Oxazepam has 
many of them but it has not been formulated for parenteral use. 
Lorazepam is metabolised in a similar fashion but its pharmacodynamic 
response tends to be slow and prolonged. There remains no ideal 
sedative for patients with severe liver disease.
4.7 CONCLUSION
In conclusion it is possible to identify a number of 
features which a drug should possess to make it suitable for use 
as a probe of liver function.
1. It should be non toxic.
2. It should be eliminated solely by the liver.
3. The hepatic elimination mechanism should be altered in liver 
disease.
4. The drug should be administered orally and should undergo 
rapid and complete absorption.
5. The drug should have a high hepatic extraction ratio
6. It should be easy to measure in the plasma.
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C H A P T E R  5
ANTIPYRINE METABOLISM IN THE ASSESSMENT OF HEPATIC FUNCTION
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5.1 INTRODUCTION
Antipyrine was first synthesised in 1884 in the laboratory 
of Emil Fisher. Initially it was used as an antipyretic but its 
analgesic properties were soon discovered. It was a popular pain 
killer until the 1930's when new more effective analgesics such 
as asprin became available. It was then marketed in combination 
with chloral hydrate (WELLDORM) and was again widely 
prescribed.
In 1949 a method for the measurement of antipyrine in plasma 
was described (BRODIE et al 1949). The observations that it was 
rapidly and evenly distributed in the body water with a 
negligible degree of protein binding led to the use of 
antipyrine as a measurement of the total body water (SOBERMAN et 
al 1949).
In the 1960's antipyrine was used extensively to investigate 
the inter-individual variations hepatic drug metabolism and 
results suggested that these were genetically controlled (VESELL 
and PAGE 1968). It was also used to measure induction and 
inhibition of the hepatic monooxygenase enzymes (VESELL and PAGE
1969). The widespread use of antipyrine kinetics as a non- 
invasive measure of hepatic oxidation was validated by the 
demonstration of a correlation between antipyrine half life and 
the cytochrome P-450 content of liver biopsy material taken from 
patients with liver disease (SOTANIEMI et al 1977a, SOTANIEMI et 
al 1977b). A close correlation also exists between the 
antipyrine clearance and the activities of the individual drug 
metabolising enzymes (VUITTON et al 1981).
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In the WTO's antipyrine kinetics was first used to 
investigate liver disease (BRANCH et al 1973).
Antipyrine has therefore had five major roles in 
pharmacology
1. Therapeutically as Analgesic/Antipyretic.
2. Measurement of total body water.
3. Qiantification of interindividual variations in drug 
metabolism.
4. Measurement of enzyme induction/inhibition.
5. Measurement of liver function.
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FIGURE 5.1 THE CHEMICAL STRUCTURE OF ANTIPYRINE
c h 3 
c h 3
5.2 ANTIPYRINE METABOLISM
5.2.1 Metabolic pathways
The chemical structure of antipyrine is shown in Figure 5.1. 
Following the oral administration of antipyrine there is rapid 
absorption from the gastrointestinal tract and the bio­
availability is close to 100%. The drug is evenly distributed in 
the body water with a negligible degree of protein binding. The 
hepatic extraction is low at 2% (BRANCH et al 1974) but it is 
almost coupletely oxidised by cytochrome P-450 dependent liver 
microsomal enzymes. Its clearance is therefore relatively 
independent of liver blood flow. Negligible amounts appearing 
unchanged in the urine (VESELL 1979(b)) and 65% appears as
HC C —
0  =  C
N
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oxidised metabolites (DANHOF, V M  ZUILEN et al 1982).
There are at least four major phase 1 metabolites of 
antipyrine: 4-hydroxy-antipyrine, 3-hydroxymethylantipyrinef 
norantipyrine and p (41) -hydroxy-antipyrine (BRODIE and AXELROD 
1950, YOSHIMURA et al 1968, BATY and PRICE EVANS 1973). It is 
likely that different enzymes are involved in the production of 
these different metbolites (DANHOF, et al 1979). These compounds 
may be further metabolised to 3-carboxy-antipyrine and 4,4 
dihydroxy-antipyrine. These metabolites are excreted in the 
urine as the conjugated glucuronide or sulphated forms. The 
pathways of antipyrine metabolism are shown in Figure 5.2. The 
demonstration of a close correlation between the disappearance of 
antipyrine from the plasma and the appearance of 4-hydroxy- 
antipyrine in the urine validates the measurement of antipyrine 
half-life as a measure of antipyrine metabolism (HUFFMAN et al 
1974). Antipyrine is also poorly excreted in the bile (ELESTROM 
and LINDGREN 1974).
Traditionally its kinetics have been considered to follow a 
one conpartment model (PERRIER and GIBALDI 1974), although there 
is a biphasic shape to the concentation-time curve suggesting 
that its kinetics should be evaluated according to a two 
conpartment model. The use of a one conpartment model has been 
justified by a close degree of agreement between the results of 
data analysed according to the two models (DANHOF, VAN ZUILEN et 
al 1982). The initial disposition constant and the rates of 
distribution of antipyrine between the central and peripheral 
compartments are unaltered in liver disease (GREISEN & ANDRE AS EN
1976).
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FIGURE 5.2 METABOLIC PATHWAYS OF ANTIPYRINE
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The initial analysis for antipyrine was by a spectro- 
photometric assay (BRODIE et al 1949). This method has now been 
replaced by more sensitive and specific methods based on gas 
liguid chromatography (PRESCOTT et al 1973, LINDGREN et al 1974), 
radioimmunoassay (CHANG et al 1976) and high pressure liguid 
chromatography (DANHOF, De GRQOT et al 1979, SHARGEL et al 1979). 
The methodology for the HPLC method is described in Chapter 7.
The measurement of antipyrine elimination has been 
sinplified by the observation that there if a close correlation 
between the concentrations in the plasma and saliva (VESELL, 
PASSANANTI et al 1975(b), WELCH et al 1975, FRASER et al 1976, 
CHANG et al 1976). Salivary levels of antipyrine are unaffected
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by salivary flow rates (VAN BOXTEL et al 1976). Using salivary 
data the volume of distribution and clearance are slightly 
elevated conpared to data from plasma studies (DANHOF, VAN ZUILEN 
et al 1982). The use of salivary clearances have validated the 
use of salivary measurements in in normal subjects and in 
patients with liver disease (MEFFIN et al 1977, LUOMA and 
SOTANIEMI 1981). The method can be further simplified by using 
only a single sanple taken at 18 hours after ingestion of 
antipyrine. A good correlation has been found between this 
method and multiple plasma sampling (DOSSING et al 1982).
An alternative method of assessing antipyrine metabolism 
is the measurement of the 4-Hydroxy metabolites in the urine. A 
good correlation (r = +0.95, P< 0.001) has been shown between 
the plasma clearance of antipyrine and the urinary excretion of 
4-Hydroxy Phenazone (ANDREASEN & GREISEN 1976).
5.2.3 Antipyrine kinetics in healthy volunteers
Several authors have described normal ranges for the 
elimination of antipyrine in healthy volunteers (TABLE 5.1) From 
the result it is clear that there is a very wide inter individual 
variation in the metabolism of antipyrine.
TABLE 5.1 ANTIPYRINE HALF LIFE IN HEALTHY VOLUNTEERS.
AUTHOR PLACE NO RANGE MEAN
VESELL & PAGE 1968 PENNSYLVANIA 36 6.9-16.7 10.9
KOLMODIN et al 1969 STOCKHOLM 33 5.2-35.0 13.1
O'MALLEY et al 1971 DUNDEE 61 6.1-23.0 12.0
VESTAL et al 1975 MARYLAND 307 4.8-41.7 13.8
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5.2,4 Reproducibility of antipyrine kinetics ,
The reproducibility of antipyrine half-lives has been 
studied in healthy volunteers. The subjects had antipyrine 
estimations at weekly intervals with a mean variance of 5.1% 
(VESELL 1979(b)). The reproducibility of antipyrine kinetics in 
control populations has been demonstrated by other authors 
(BRANCH et al 1973). In repeated estimations over a periods in 
excess of a year the half life remains constant (DAVIES et al
1973).
5.3 FACTORS INFLUENCING ANTIPYRINE METABOLISM
The metabolism of antipyrine has been extensively 
studied in man and a large number of drugs, disease states and 
patho-physiological states have been identified which influence 
its metabolism.
5.3.1 Drugs
A list of the percentage changes in antipyrine clearance 
induced by drugs is included as Appendix One. A large number of 
drugs exert relatively small changes in the elimination of 
antipyrine. There are a several drugs which have a major effect 
in enhancing the elimination of antipyrine (TABLE 5.2). There are 
only five identified drugs which exert a major inhibiting effect 
on its elimination (TABLE 5.3). For the purposes of this thesis a 
major effect on drug metabolism is defined as a mean change in 
the half life of greater than 30% of the mean baseline.
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TABLE 5.2 DRUGS MARKEDLY ENHANCING THE ELIMINATION OF ANTIPYRINE
DRUG PERCENTAGE CHANGE
IN HALF LIFE
Phenytoin 59%
(hrbamazepine 55%
Cannabis 55%
Rifanpicin 52%
Phenobarbitone 48%
Sulphinpyrazone 42%
Chlorinated Hydrocarbons 41%
Flupenthixol 39%
Spironolactone 38%
Amylobarbitone 36%
Pentobarbitone 35%
Antipyrine 32%
Glutethimide 31%
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TABLE 5.3 DRUGS MARKEDLY INHIBITING THE ELIMINATION OF ANTIPYRINE
DRUG PERCENTAGE CHANGE
IN HALF LIFE
Allopurinol 202%
Disulfiram 74%
Combined oral contraceptive 73%
Propranolol 65%
Aminopyrine 60%
Cimetidine 38%
5.3.2 Pathophysiological state
Ihe pathophysiological states in which antipyrine kinetics 
have been studied are summarised in TABLE 5.4. The changes which 
occur in the states are generally small.
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TABLE 5.4 PATHOPHYSIOLOGICAL STATES AND ANTIPYRINE METABOLISM.
STATE % CHANGE AUTHOR
IN CLEARANCE
Age (increasing)
Young men/old men 
Young women/old women 
Young men/young women 
Old men/old women 
Malnutrition
As ian Vegetar ians
High carbohydrate/low 
protein diet
High carbohydrate
High fat diet
Low calorie diet
Anorexia nervosa
52.2
18.5 
Inhibited
34.5
21.4
37.5
24.5 
Inhibited
32.8
Inhibited
Inhibited
18.6 
15.7
Inhibited
19.6
Extensive/poor debrisoquine <5 
metabolisers
White vegeterians <5
Cola nut chewing <5
Exercise <5
BACH et al 1981 
VESTAL et al 1975 
O'MALLEY et al 1971 
GREENBLATT et al 1981 
GREENBLATT et al 1981 
GREENBLATT et al 1981 
GREENBLATT et al 1981 
KRISHNASWAMY et al 1977 
NARANG et al 1977 
FRASER et al 1977 
KAPPAS et al 1976
ANDERSON et al 1979 
ANDERSON et al 1979 
KRISHNASWAMY et al 1984 
BAKKE et al 1978
DANHOF et al 1981
BRODIE et al 1980 
VESELL 1979(b)
THEILADE et al 1979
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STATE % CHANGE 
IN CLEARANCE
AUTHOR
Easting <5 REIDENEERG et al 1975
High protein <5 ANDERSON et al 1979
Menstrual cycle <5 RIESTER et al 1980
Noon/midnight <5 VESELL,SHIVELY et al 1977
Piperonyl butoxide <5 CDNNEY et al 1982
Summer/winter <5 PAIGEN et al 1982
Males/female <5 MUCKLCW et al 1980
Bed rest (3 days) -12.4 ELESTRQM et al 1978
Sprouts/cabbage diet -11.3 PANTOCK et al 1978
Charcoal broiled beef Induced KAPPAS et al 1978
Low carbohydrate/high 
protein diet
Induced KAPPAS et al 1976
High protein diet Induced KRISHNASWAMY et al 1984
Ethanol Induced VESELL,PAGE et al 1970
Smoking Induced WOOD et al 1979(a)
Induced HART et al 1976
-30.1 MUCKLOW et al 1980
Fluid deprivation -17.2 SWARTZ et al 1974
Exercise -40.0 SWARTZ et al 1974
Heat -31.6 SWARTZ et al 1974
Parenteral nutrition -24.0 PANTUCK et al 1984
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5.3.3 Acute liver disease
In acute viral hepatitis the half life of antipyrine can be 
prolonged by 100% compared to the results on recovery (BURNETT et 
al 1976). The elimination of antipyrine and galactose indicate 
correlated with the severity of an attack of acute hepatitis. 
Patients who died with fulminant liver failure had an almost 100% 
loss of functioning hepatic cell mass (RAMSOE et al 1980).
5.3.4 Chronic liver disease
Ohe use of antipyrine as a test of liver function was
first made popular in 1973 (BRANCH et al 1973). Ihey suggested 
that the changes in antipyrine kinetics were greater in patients 
with chronic liver disease than in those with acute reversible 
liver disease. The antipyrine half life was most prolonged in 
patients with hypoalbuminaemia and a prolonged prothrombin time 
suggesting there was a failure of microsomal protein synthesis.
Histology Tnere is a correlation between the 
severity of the histological damage and the antipyrine half life 
and this was particularly marked in patients with ballooning 
degeneration of the hepatocytes (PARREL et al 1978).
Encepha 1 opathy The antipyrine clearance has been shown 
to be significantly reduced during episodes of hepatic 
encephalopathy (4.6 ml/min) compared to measurements when taken 
there was no clinical evidence of encephalopathy (9.6 ml/min) 
(ANDREASEN and RANEK 1975). It is suggested that an antipyrine 
clearance of less than 6 ml/min was usually associated with 
clinical evidence of encephalopathy.
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Severity of liver disease s- The clearance of antipyrine is 
lower in patients with "incapacitating" liver disease. These 
"incapacitated" patients had significantly depressed serum 
albumin but no significant alterations in galactose elimination 
capacity or the prothrombin time (ANDREASEN et al 1974). The 
antipyrine half life is prolonged in decompensated chronic liver 
disease and chronic active hepatitis (FARREL et al 1979). In 
this study there was a high degree of correlation between the 
antipyrine half life, prothrombin time, ascites and 
encephalopathy. Hepatic resection for liver tumours produces a 
transient reduction in the serum albumin and the clearance of 
antipyrine (KAIRALOOMA et al 1982).
Enzyme inhibition Cimetidine produces no further 
inhibition of antipyrine metabolism in alcoholic cirrhotics 
(STAIGER et al 1981). However it is likely that the inhibitory 
effect of cimetidine was masked by an overall improvement in 
liver function due to the withdrawal of alcohol. In a similar 
study the expected inhibition of antipyrine clearance by 
propranolol was found not to occur in cirrhotics (LARREY et al
1983). This observation may again be due to a concomittant 
improvement in liver function. However, Propranolol is 
metabolised within the liver to an active metabolite which 
inhibits cytochrome P-450 (SCHNECK and PRITCHARD 1981). In 
cirrhotics the production of this active metabolite may be 
reduced and therefore the inactivation of cytochrome P-450 may 
less.
Enzyme induction s- The use of enzyme inducing drugs as
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a therapy for patients with liver disease has been explored by 
observing the effect on standard liver function tests and 
antipyrine kinetics (RAUTIO et al 1979). Antipyrine has also 
been used to observe the enzyme inducing effects of 
spironolactone (MIGUET et al 1980) and glutethimide (FARRELL et 
al 1979) in liver disease.
Fatty liver Non insulin dependent diabetics with fatty 
livers show a modest reduction in the clearance of antipyrine 
(PIRTTIAHO et al 1984).
Cholestasis The clearance of antipyrine is significantly 
reduced in patients with intrahepatic cholestasis but not in 
extrahepatic cholestasis (MIGUET et al 1981).
Screening for liver disease Antipyrine kinetics have been 
used as a screening test for liver disease in a group of workers 
exposed to various industrial solvents. The induction of 
antipyrine metabolism was found to be a more sensitive indicator 
of abnormal liver histology than standard liver function tests 
(SOTANIEMI et al 1982).
Polycystic liver In a family with polycystic liver 
disease the antipyrine half life was significantly longer in the 
affected members compared to those with normal livers (LUOMA et 
al 1980).
Liver volume There is a good correlation between liver 
volume, measured ultrasonically or isotqpically, and the 
clearance of antipyrine has been demonstrated in normal controls
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(PIRTTIAHO et al 1978), patients on anticonvulsants (PIRTTIAHO et 
al 1982) and patients with liver disease (HOMEIDA et al 1979). 
These results suggest that changes in antipyrine kinetics may 
reflect changes in hepatic mass but further studies show that in 
the elderly (BACH et al 1981) and in patients on antiepileptic 
therapy (ROBERTS et al 1976) there may also be changes in 
metabolising capacity per unit of hepatic mass. Correction of 
the antipyrine clearance for the liver volume only marginally 
improves the seperation of normal subjects from those with 
cirrhosis (TEUNISSEN et al 1984).
Metabolite production The effect of liver disease on 
antipyrine clearance is complex. In general the production of 
norantipyrine is reduced more than the rates of formation of 
hydroxyantipyrine and hydyoxymethylantipyrine (TEUNISSEN et al
1984).
5.3.5 Other disease states
Numerous disease states other than liver disease have been 
shown to influence the clearance of antipyrine, the effect of 
these states is summarised in TABLE 5.5. The extent of some of 
the changes in antipyrine kinetics are marked. For example the 
antipyrine clearance was reduced 46% in children while they were 
febrile (FORSYTH et al 1982).
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TABLE 5.5 DISEASE STATES AND ANTIPYRINE KINETICS.
Disease state 
Etiocholanolone Fever 
Pyrexia 
Hypothyroidism
Lead poisoning
Clearance Reference
Inhibited ELIN et al 1975
Inhibited FORSYTH et al 1982
Inhibited CROOKS et al 1973
EICHELBAUM et al 1974 
VESELL,SHAPIRO et al 1974 
SAENGER et al 1976
Inhibited MEREDITH et al 1977
Idiopathic hypoalbuminaemia Nil PIROLI et al 1981
Uraemia
Osteomalacea
Hyperthyroidism
Induced MADDOCKS et al 1975
No Change HARMAN et al 1977
Induced FRASER et al 1976
Induced CROOKS et al 1973
EICHELAUM et al 1974 
VESELL,SHAPIRO et al 1974 
SAENGER et al 1976
5.4 ANTIPYRINE METABOLISM IN THE PREDICTION OF ALTERED DRUG 
METABOLISM.
Antipyrine has been used in several studies to predict the 
metabolism of other drugs. In a small group of cirrhotic 
patients antipyrine kinetics had seme predictive value in 
determining the livers capacity to metabolise lorcainide (KIOTZ 
et al 1979) but the correlation just failed to reach statistical 
significance. Antipyrine kinetics have been used to predict age 
related changes in the metabolism of benzodiazepines, a 
correlation was found between antipyrine clearance and those
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benzodiazepines which undergo hepatic oxidation (diazepam, 
prazepam, clorazepam and flurazepam) but not with those which are 
conjugated (lorazepam, oxazepam and temazepam) (GREENBLATT et al 
1981). In another study a significant correlation was found 
between the clearances of oxazepam and antipyrine (KELLERMAN et 
al 1979). However the clearance of triazoloam, an hepatically 
oxidised benzodiazepine, correlated poorly with the clearance of 
antipyrine (GREENBLATT et al 1983).
The clearance of antipyrine has also been significantly 
correlated with the clearance of lignocaine (PERRUCA et al 
1980), phenylbutazone (DAVIES and THORGEIRSSON 1971a), and 
oxyphenylbutazone (DAVIES and THORGEIRSSON 1971b).
5.5 CORRELATION OF ANTIPYRINE KINETICS AND STANDARD LIVER FUNCTION 
TESTS
Most studies show a significant correlation between the 
serum albumin and prothrombin time and the elimination of 
antipyrine. Some studies show a weak relationship with the serum 
bilirubin as well (Table 5.6)
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TABLE 5.6 CORRELATION OF ANTIPYRINE KINETICS WITH STANDARD LIVER
FUNCTION TESTS.
n ALB.
ERANCH el al 1973 38 ***
ANDREASEN et al 1974 13 ***
BURNETT et al 1976 6 NS
FORREST et al 1977 17 **
FARRELL et al 1978 62 *
KRAUSZ et al 1980 25 NS
TAKASHI et al 1981 69 *
*** p<0.001 
** p<0.01
* p<0.05
NS p>0.05 
NA not available
P.T. BILI ALK.
PHOS
SGOT SGI
*** NS NS NS NS
*** NA NA NA NA
NS NS NA NS NA
** NS NS NA NS
*** * NA NA NS
NS NS NS NS NS
* * NS NS NS
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C H A P T E R  6
INDOCYANINE GREEN IN THE ASSESSMENT OF HEPATIC FUNCTION
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6.1 INTRODUCTION
Indocyanine green (ICG) was originally synthesised for use 
as a dye. It has tricarbocyanine structure (Figure 6.1) with a 
characteristic absorption spectrum at 800nm. During the 1950's 
it was extensively used in dye dilution studies to measure 
cardiac output (FOX et al 1957). In the early 1960's its use as 
a non-invasive measurement of liver blood flow was described 
(CAESAR et al 1961, LEEVY et al 1962). A good correlation exists 
between liver blood flow measured by a bolus injection of 
indocyanine green and direct measurement by electro-magnetic flow 
meters (NXUMALO et al 1978). The use of ICG clearance as a liver 
function test was first suggested in the early 1960's (CHERRICK 
et al 1960).
The use of a drug with a high hepatic extraction ratio is 
not a new concept in hepatology. For many years the retention of 
Bromosulphthalein (BSP) has been used as a sensitive indication 
of hepatic dysfunction. It can be expected that ICG should 
produce similar results but it has several important advantages 
compared to BSP :
1. Reduced toxicity: One of the reasons that BSP has not 
been more extensively use is the occurence of occasional 
anaphylactic reaction. These are less common with ICG (FRICK et 
al 1979).
2. No hepatic metabolism: ICG is excreted unaltered by the 
liver, so that its elimination reflects the its rate of delivery 
to the liver and the liver's ability to extract it from the 
blood.
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3. No enterohepatic circulation: There is evidence for an
enterohepatic circulation of BSP, but this has not been found 
with ICG.
4. No extrahepatic extraction: There is some extrahepatic
degradation and elimination of BSP which does not occur with ICG.
FIGURE 6.1 THE CHEMICAL STRUCTURE OF INDOCYANINE GREEN
CH3
i
HC -CH
N
i
C*CH-CH*CH-CH«CH-CH=CH- C
N
i
CH
CH2
i
c h2
c h2
SOijNa
CH
i
c h2
I
c h2
I
c h 2
so3
145
6.2 INDOCYANINE GREEN DISPOSITION
Following intravenous administration ICG is rapidly bound to 
albumin (95 %) with some binding to serum globulins (KAMISAKA et 
al 1974). It is not excreted by the kidney and there is 
negligible uptake in the peripheral tissues (CHERRICK et al 
1960). It is extracted from the blood by the liver but does not 
undergo biotransformation within the liver (WHEELER et al 1958, 
RAPAPORT et al 1959, CHERRICK et al 1960). It is excreted in 
the bile and there is no enterohepatic circulation (HUNTCN et al
1960). The use of a constant infusion of ICG at two or three
different doses allows the storage capacity of ICG within the 
liver to be calculated (BRODY & LEICHTER 1979).
The hepatic extraction of ICG can be saturated and at doses
of SmgAg the plasma disappearance reflects first order kinetics
and allows the use of Michaelis-Menton analysis to calculate the
maximal rate of removal (Vmax) from the plasma (PAUMGAR1NER et al
1970) by the equation:
R =Vtoax * (ICG)
Kn + (ICG)
Where R = the disappearance rate of ICG 
(ICG) = the dose of ICG
Km = the Michaelis-Menton constant
The estimation of indocyanine green clearance has been 
simplified by the use of a dichromatic ear piece densitometer for 
the plasma detection (HOWARD et al 1965). Estimation of the 
half life and the percentage disappearance rate per minute by 
this technique shows a close correlation with those determined by
146
direct plasma measurements (LEEVY et al 1967).
6.3. FACTORS INFLUENCING INDOCYANINE GREEN KINETICS.
6.3.1 Drugs
The elimination of ICG has been shown to be enhanced by 
phenobarbitone (GOGL et al 1971), which reduced the elimination 
half life by 64% compared to normal subjects. Similar results 
were found in a group of patients taking other enzyme inducing 
drugs including opiates and anticonvulsants (MELIKIAN et al 
1972). Further studies failed to find any change in indocyanine 
green clearance with anticonvulsants (HEPNER et al 1977(b)), 
phenobarbitone (ROBERTS et al 1979), rifampicin (BREIMER et al
1977) or glutethimide (JACKSON et al 1978). It was postulated 
that this enhanced elimination may be the result of either 
increased synthesis of hepatic carrier proteins or increased bile 
flow, both of these have been demonstrated in animals following 
drug administration (REYES et al 1971, CONKLIN and WAGNER 1971).
The effect of enzyme inhibition on ICG clearances has also 
been studied. Single doses of cimetidine reduce the clearance of 
ICG (FEELY et al 1981), although this is disputed (NELSON et al
1985) and it does not occur with chronic administration 
(DANESHMEND 1984). Ranitidine has no effect on ICG clearance 
(MASHFORD et al 1983) or its hepatic extraction (DUNK et al 
1983). Propranolol and labetalol produce significant reductions 
in ICG clearance (DANESHMEND et al 1981) presumably as a result 
of reduced liver blood flow. Alpha blockade with
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Phenoxybenzamine produced no consistent effect on ICG clearance 
(DANESHMEND 1981 et al). Nifedepine produces an increase in ICG 
clearance but glyceryltrinitrate reduces it (FEELY 1984).
6.3.2. Pathophysiological states
Genetic: A selective genetic defect in the clearance of ICG 
is described (OKUDA et al 1976, OHKUBO et al 1981, NAMIHISA 
et al 1981). It is suggested that there are two separate 
disorders, one inherited as an autosomal recessive and the 
other as an autosomal dominant trait (OHKUBO et al 1981).
Ihe patients with this defect have a normal or near normal 
BSP retention.
Smoking: There is no effect of moderate cigarette smoking
on ICG clearance (fOOD et al 1979).
Age: Ihe clearance of ICG consistently falls with age (WOOD
et al 1979).
Fasting: Ihe effect of calorie restriction on ICG kinetics
has been studied in man and in rats (OHKUBO et al 1978). 
Ihere is an increase in the elimination of ICG in the 
fasting state and it is suggested that this is the result of
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enhanced biliary excretion rather than inproved hepatic 
uptake. This in contrast to the reduced elimination of 
bilirubin (BARRET 1971) and bromosulphthalein (BRADLEY et al 
1969) seen in the fasted state. There is no change in 103 
clearance following the intragastric administration of 500ml 
milk (DANESHMEND et al 1981). Other workers have shown a 
small increase in ICG clearance following the ingestion of 
200 and 400 gram carbohydrate meals (SVENSSON et al 1984).
Pyloric stenosis: An unconjugated hyperbilirubinaemia can
coirplicate pyloric stenosis in infants and has been termed
the icteropyloric syndrome. The mechanism of this syndrome
is unknown. The clearance of ICG is reduced in children 
with pyloric stenosis who are not jaundiced but returns to 
normal levels following surgery to correct the pyloric 
stenosis (ROTH et al 1981). These results indicate either a
reduced liver blood flow or a reduced extraction of ICG in
pyloric stenosis. The latter is more likely and may be a 
result of fasting, this syndrome is not seen in adults with 
gastric outlet obstruction.
Multisystem injury: The plasma disappearance rate (PDR) of
103 is significantly lower in non-survivors with critical 
injuries. No patient with a PDR of < 6%/min survived 
(POLLACK et al 1979). This finding has been confirmed using
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the IOG clearance (ICG clearance non-survivors = 4.8ml/min; 
survivors = ll.lml/min) (KHOLOUSSY et al 1984). Following 
major injury the elimination of ICG is reduced and becomes 
biphasic. Ihe second slower phase of elimination becomes 
most marked about four days after the injury, at this time 
the liver blood flow has returned to normal but there is 
evidence of a marked reduction in the hepatic extraction of 
ICG (GOTTLIEB et al 1984). The second slower phase of 
elimination is thought to be due to the removal of the dye 
across the cannilicular membrane, although it may be due to 
a failure of intrahepatocyte transport or localisation of 
the dye within the hepatocyte.
Posture: Ihe erect posture and exercise significantly
reduce the clearance of ICG (DANESHMEND et al 1981).
6.3.3. Acute liver disease.
Ihe clearance of ICG is reduced in acute viral 
hepatitis without any change in the volume of distribution 
(WILLIAMS et al 1976).
6.3.4. Chronic liver disease.
Gilbert's Syndrome: Studies in Gilbert's syndrome show that
some patients have abnormal excretion patterns of ICG.
These studies suggest that there is two sub-populations of 
Gilbert's Syndrome who have abnormalities in the hepatic
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transport of organic ions other than bilirubin. There are 
similarities in Gilbert's Syndrome between the excretion of 
BSP and ICG suggesting that these two drugs have a common 
hepatic uptake mechanism (MARTIN et al 1976).
Rotor's syndrome: There is a marked reduction in the
clearance of ICG, bromosulphthalein and unconjugated 
bilirubin in patients with Rotor's syndrome (KAWASAKI et al 
1979).
Other liver-disease: ICG has been found to be a sensitive
test in the detection of liver disease. This sensitivity 
may be enhanced by increasing the dose from 0.5mg/kg to 
5mg/kg (LEEVY et al 1967). 103 clearance is particularly
reduced in patients with surgical portocaval shunts, hypo- 
albuminaemia (BRANCH et al 1976 (b)), alcoholic cirrhosis 
and primary biliary cirrhosis (GILMORE et al 1982). The 
estimation of Vmax has been suggested as a measurement of 
the functional reserve of the human liver (MOODY et al
1974). Improvements in the Vmax have correlated with 
improvements in the hepatic histology (BRODY & LEICHTER 
1979). But in chronic active hepatitis no consistent 
inprovement in Vmax is found during treatment with 
azathioprine (RIKKERS & SHERLOCK 1975). In patients 
undergoing partial hepatectomies for hepatocellular 
carcinoma a good correlation has been found between the 
extent of the hepatectomy and the ICG retention at 15 
minutes relative to the patients' outcome (OKAMOTO et al
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1984).
In chronic liver disease there is a poor correlation 
between the estimated liver blood flow measured by 103 and 
that estimated by 1131 labelled albumin. The discrepancy 
arose because of the reduced hepatic extraction of 103 in 
chronic liver disease (COHN et al 1972). In a group of 
cirrhotics ICG clearance was found not to be limited by 
liver blood flow but by changes in the intrinsic hepatic 
clearance (HUET & VILLENEUVE 1983).
Using discriminant functional analysis ICG clearance 
has been found to be one of the most useful differential 
diagnostic tests of liver disease (ITOSHIMA et al 1983).
6.4 INDOCYANINE GREEN KINETICS IN THE PREDICTION OF ALTERED DRUG 
METABOLISM.
The clearance of ICG does not predict the clearance of 
propranolol, and the simultaneous administration of propranolol 
produces an increase in the hepatic extraction of 103 (GRAINGER 
et al 1983(a)). In acute viral hepatitis there is no correlation 
between the clearance of lignocaine and any of the standard liver 
function test or any parameter of 103 disposition (WILLIAMS et al 
1976). In patients with congestive cardiac failure and in patient 
controls there is a good correlation between ICG clearance and 
Lignocaine clearance (ZITO and REID 1978, HUET & LELORIER 1980) 
although this is disputed (BAX et al 1980). A good correlation 
has been demonstrated between estimations of liver blood flow 
using ICG and Diethyl-Ida. In a group of patients with liver
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disease the hepatic extraction of Diethyl-Ida was approximately 
twice that of 103 suggesting that in these patients with severe 
liver disease an estimation of liver blood flow by Diethyl-Ida 
may be more appropriate than that with ICE (MUNOZ et al 1982).
The clearance of ICG correlates poorly with the clearances of 
Diazepam, aminopyrine and antipyrine (HEPNER et al 1977(b)).
6.5 OTHER USES OF INDOCYANINE GREEN IN HEPATOLOGY
The kinetics of ICG and colloidal gold isotope scans have 
been used as non-invasive monitors of portal hypertension. A 
significant negative correlation has been demonstrated between 
the elimination constant of ICG and the portohepatic gradient (r 
= -0.612 : p < 0.005) (MILLETTE et al 1973). In a similar study, 
however, there was no relationship between the severity of portal 
hypertension as measured by the corrected hepatic vein pressure 
neither ICG or Lignocaine clearance (HUET & VILLENEUVE 1983).
The relationship between abnormalities in hepatic colloid 
scans and liver blood flow has been investigated using ICG
(HORISAWA et al 1976). In this study it was suggested that the
abnormalities in colloid scans resulted from intrahepatic 
shunting of blood rather than from a reduction in total liver 
blood flow.
Recently the intravenous injection of ICG has been combined 
with peritoneoscopy. This technique allows the demonstration of 
the distribution of hepatocytes and has also been used to 
investigate the effect of liver disease on regional liver blood
flow (ITO et al 1983; SATO et al 1983).
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6.6 CORRELATION WITH STANDARD LIVER FUNCTION TESTS
Hie ICG clearance has been correlated with serum albumin (r 
= -0.63 : p <0.001), serum bilirubin (r = 0.63 : p <0.001), and 
prothrombin time (r = 0.59 : p <0.001). No correlation was 
found with AST, serum globulin, alkaline phosphatase, age or 
weight (BRANCH et al 1976).
ICG clearance correlates with serum antipyrine clearance (r 
= 0.94 : p <0.001) (BRANCH et al 1976).
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C H A P T E R  7
METHODOLOGY
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In this chapter the basic methodology that was used is described.
Where a protocol was used in only one study it is described in the
appropriate chapter.
7.1 CLINICAL ASSESSMENT
7.1.1 Diagnosis
The patients with liver disease were admitted either for 
diagnostic assessment of liver dysfunction or for the 
investigation and treatment of the complications of liver 
disease. The aetiology of liver disease has been diagnosed on 
conventional grounds, based on the clinical history, biochemical 
liver function tests, specific diagnostic tests and histology.
7.1.2 Clinical Features
The patients were assessed clinically and the size of the 
liver and spleen recorded in centimetres below the costal margin, 
ihe presence or absence of ascites and portosystemic 
encephalopathy was documented. Patients were graded for portal 
hypertension (PHT) as follows; a score of 0 = No PHT, 1 = Varices 
present, 2 = Previous bleeding from varices, 3 = Surgical 
portocaval shunt.
The serum alanine transaminase (ALT), aspartate transaminase 
(AST), alkaline phosphatase, gamma glutamyl transpeptidase (GGT) 
activities and bilirubin and albumin concentrates were measured 
using standard autoanalyser techniques (Technicon). The clinical 
and biochemical information were combined to grade the patients 
using Pugh's modification (PUGH et al 1973) of Child's
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classification of the severity of liver disease (See Chapter 3 
for details).
7.1.3 Histology
A liver biopsy was performed on 85 patients who had a 
clinical indication for this technique. The biopsy was performed 
in the standard intercostal fashion using either a Menghini or 
Tru-cut needle. The liver sections were stained with the 
following stains:- haematoxylin and eosin, periodic acid Schiff 
(PAS) before and after diastase, Masson's Trichrome, Van Giesson, 
Gordon and Sweets reticulum, Perl's Prussian blue for iron and 
Shikata's orcein. They were examined by an experienced hepatic 
histopathologist (Professor R.N.M. MacSween) without reference to 
the patient's clinical details. The biopsies were graded 
according to the scheme described by Farrell in 1978 for the 
following characteristics:
1) Architecture: Graded as:- normal,
dissarray, 
active cirrhosis, 
or inactive cirrhosis.
2) Necrosis: Graded as:- absent,
focal, 
diffuse, 
piecemeal, 
or confluent.
3) Degree of hepatocellular abnormality: (Graded 1-4 according
to the percentage of morphologically abnormal hepatocytes.)
Grade 1 = less than 25% abnormal 
Grade 2 = 25-50%
Grade 3 = 50-70%
Grade 4 = > 75%.
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4) The presence of specific histological features such as fatty 
change, parenchymal iron and ballooning degeneration of 
hepatocytes was also recorded.
7.2 ANTIPYRINE
7.2.1 Protocol
Following an overnight fast 600mg of antipyrine were 
administered orally at 9.00am and 10ml blood samples collected 
immediately prior to ingestion over 0,3,5,8,12,24 and 32 hours 
later. Samples were placed in lithium heparin tubes which were 
spun in a centrifuge at 2500 revolutions/min for 3 to 5 minutes 
and the plasma was extracted and stored at minus 20 degree 
centigrade.
7.2.2 Analytical methods
Antipyrine analysis was performed using a modification 
(MacPHEE et al 1984) of a high pressure liquid chromatography 
method (SHARGEL et al 1979). Standard solutions containing . 
20,15,10,5, and 2 microlitres/ml of antipyrine in methanol were 
produced. Twelve standard solutions were included in each 
analytical run. These were three 20's, two 15's, three 10's, two 
5’s, and two 2's. An internal standard was made using 10 mg of 
antipyrine in 100ml of methanol.
The test sanples were prepared by pipetting one ml of the 
plasma into each test tube, 100 ul of the internal standard, 250 
ml of 0.5 sodium hydroxide and 5 mis of dichloromethane was added 
to all tubes. The tubes were then centrifuged at 2500 
revolutions per minute for 5 to 10 minutes. The supernatant was
1
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removed and placed in a 30 degree centigrade water bath, blown 
dry and stored at minus 20 degrees centigrade until analysis. 
Before analysis the samples were reconstituted with 200-400 ul of 
methanol. The standard samples were used to produce a standard 
curve. The test samples were then analysed with a further 
standard included as every sixth sample.
The samples were injected onto a Waters C18V Bondabak 
column. Antipyrine was detected using a Cecil variable wave 
length ultraviolet detector. A typical HPLC tracing is shown in 
Fig. 7.1.
7.2.3 Reproducibility
The laboratory error for the HPLC method was assessed by 
repeating the analysis on 5 standard solutions. The coefficient 
of variation varied from 411% for the 20ng/ml samples to 8.2% for 
the 2ng/ml samples (Table 7.1).
The clinical reproducibility of antipyrine kinetics was 
assessed in fifteen patients with liver disease. Samples were 
taken on two separate occasions within 2 months with the patients 
remaining in a stable clinical condition. The mean variance was 
7.3% for the half life, 11.7% for volume of distribution and 3.6% 
for the plasma clearance (Table 7.2).
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Figure 7.1 A TYPICAL HIGH PRESSURE LIQUID CHROMATOGRAPHY TRACE 
SHOWING A PEAK FOR ANTIPYRINE AND THE ANTIPYRINE 
INTERNAL STANDARD.
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TABLE 7.1
MEAN, STANDARD DEVIATION AND COEFFICIENT OF VARIATION OF REPEATED HIGH 
PRESSURE LIQUID CHROMATOGRAPHY ANALYSIS OF STANDARD ANTIPYRINE 
SOLUTIONS VARYING FROM 2-20mg/ml.
Standard 20nvg/ml 15mg/ml 10mg/ml 5mg/ml 2mg/ml
concentration
1
2
3
4
5
6
7
8 
9
10
19.5
19.0 
20.8
19.8
18.9
21.0 
21.0
20.7 
20.3
20.8
13.7
14.3 
15.9
15.3
15.7
16.3
15.7
15.2
15.7
14.2
9.0
9.7
11.0
10.3 
9.4
10.4 
10.6 
10.0
10.4 
10.7
5.7
4.5
4.8
5.5
5.5
4.7
4.8
4.9 
5.0 
5.4
2.0
2.3
2.2
1.7
1.9 
2.0 
2.1
1.9 
2.0
1.9
Mean 20.18 15.2 10.15 5.1 2.0
Standard 0.82 0.85 0.62 0.41 0.17
Deviation
Standard 0.26 0.27 0.20 0.13 0.05
Error
Coefficient 4.1% 5.6% 6.1% 8.1% 8.2%
of Variance
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7.3 INDOCYANINE GREEN
7.3.1 Protocol
Indocyanine green was given as an intravenous bolus of 
0.5mg/kg body weight. The patients were fasted overnight, 
remained recumbent for 30 minutes prior to the injection and 
throughout the test. Venous blood samples were taken from the 
contralateral arm through an indwelling catheter at 3 minute 
intervals to 21 minutes. The samples were centrifuged and the 
plasma extracted Indocyanine green was assayed spectrophoto- 
metrically (CAESAR et al 1961).
7.3.2 Analytical Methods
All specimens were analysed photometrically using a Pye 
Unicam SP8-200uv/vis spectrophotometer. In an aliquot of 
plasma blank a known dye concentration of approximately 5ng per 
litre was prepared from the vial of dye administered to the 
patient. Fbr each patient plasma specimens and standards were 
read against the patient's plasma blank.
7.3.3 Reproducibility
The reproducibility of indocyanine green kinetics was 
assessed in 19 patients with chronic liver disease. Two sets of 
samples were taken within a 2 month period while the patients 
were clinically stable. The mean variance was 8.1% for the half 
life, 12.6% for the volume of distribution, 10.7% for the plasma 
clearance and 13.4% for the whole blood clearance (Table 7.3).
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MEPTAZINOL
1 Protocol
See chapter 13
2 Analytical Methods
The plasma samples were stored in glass tubes at -20 
degrees Centigrade prior to analysis.
Preparation of Standard Solutions
Standard solutions were prepared using meptazinol 
hydrochloride (Batch no. 3/E/11773), lOmg were added to 
100ml of methanol (MEOH) and mixed with a rotor for 15 
minutes. One ml of this solution was added to a further 
100ml of MeOH and mixed for 15 minutes. This working 
standard solution contains lOOug of meptazinol hydrochloride 
in 100ml MeOH.
Twenty milligrams of an internal standard (WY 32128A:
M-(1- Cyclopropylmethyl-3-Ethylhexahydro-lH-Azepin-3-YL 
Phenol) was mixed for 15 minutes with 100ml MeOH and one ml 
of this solution mixed with 100ml of MeOH for a further 15 
minutes. Ihe internal standard contained 200ug in 100ml 
MeOH.
A Buffer solution was prepared using 8.4grams of sodium 
bicarbonate in 100ml of water with the Ph adjusted to 9.7 
with strong sodium hydroxide.
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Preparation of samples
One ml of the unknown plasma was added to glass screw 
top test tubes. For the blanks and standard samples 1ml of 
pooled plasma was used. A range of standard solutions was 
produced containing 5,10,20,50,100,150 and 200ng of 
meptazinol hydrochloride.
To all the tubes except the blanks, 100ml (200ng) of 
the internal standard was added and the samples mixed.
200ml of the 1M NaHCo3 Buffer was added to all tubes and the 
samples were mixed. 5ml of Diehl or ome thane was added to 
each tube and they were immediately vortex mixed for 3 
seconds. All the samples were mixed for a further 15 
minutes in a flat mixer.
The samples were then spun at 2,500 rpm for 10 minutes. 
The top layer was pipetted off and the samples placed in a 
water bath at 50 degrees Centigrade and dried with an air 
blower. The dried samples were stores at -80 degrees 
Centigrade.
Chromatography
Ihe samples were reconstituted using MEOH prior to high 
pressure liquid chromatography. The reconstituted extracts 
(lOOnl) were injected using a WISP (Model 710B, Waters 
Associates Ltd., Hertfordshire) onto a 5 micron analytical 
column. This column was packed using Shandon column packer. 
The column was of 5mm internal diameter and 25cms in length. 
This column was used in conjunction with a pre-column of the
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same material and same size. A reciprocating HPLC pump 
(Gilson) was used to elute the column and the eluent 
composition was 50% acetenitryl and 50% amodium acetate 
solution (0.5% W/V) at a flow rate of 1.8ml/min (pressure 
approximately 2000 psi).
A fluourescent spectrometer (Model 3000, Perkin Elmer, 
Beaconsf ield, Bucks) assess an accentation wave length of 
282 nanometers and internal standard by means of their 
native fluourescence. Both monochromators were set with 10 
nanometer slit widths. Data handling was carried out by a 
computing integrator (Shimadzu C-Rib) operating at the peak 
area mode. A calibration curve was prepared from samples of 
drug free plasma to which meptazinol various concentrations 
was added. The peak areas were integrated and after 
calculating the peak area ratio (meptazinol - internal 
standard) the integrator computed the best fit line through 
the calibration points. The plasma concentrations of 
meptazinol were then calculated from this line. A typical 
tracing is shown in Fig. 7.2.
7.4.3 Repr oduc i bi1i ty
The laboratory error of this method was investigated by 
analysing 10 identical samples and 5 different concentrations.
The results of this analysis are shown in Table 7.4. The 
limited detection of meptazinol was lOng/ml.
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Figure 7.2 A TYPICAL HIGH PRESSURE LIQUID CHROMATOGRAPHY TRACE 
SHOWING PEAKS FOR MEPTAZINOL AND MEPTAZINOL INTERNAL 
STANDARD
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7.5 MIDAZOLAM
7.5.1 Protocol
See chapter 12
7.5.2 Analytical Methods
Plasma midazolam concentrations were determined using a gas 
chromatography method (HEINZMANN and VAN ALTEN 1981). This 
method has a sensitivity of 5ng/ml and a 6 point calibration 
curve was included in each sample batch along with quality 
assurance samples. This analysis was performed by Dr. Dixon at 
the Royal Bath Hospital, Harrogate.
7.6 PHARMACOKINETIC ANALYSIS
Fbr antipyrine and indocyanine green the pharmacokinetic 
constant of elimination (k) was calculated by the method of least
square regression analysis assuming a one compartment model. The
apparent volume of distribution (Vd) was calculated from the 
formula -
Vd = Dose/CD
where CD = the estimated concentration of the drug at time zero, 
extrapolated in a log-linear scale.
The apparent plasma clearance was calculated from the 
relationship -
Cl = Vd * K
For indocyanine green the plasma clearance was corrected by the 
haematocrit to give the whole blood clearance.
Area under the concentration/time curve was calculated by 
the trapezoidal rule.
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This analysis was performed on an 2pple H E  microcomputer and the 
programs used for antipyrine and indocyanine green are listed in 
Appendix 4.
The pharmacokinetic analysis of the midazolam and intravenous 
meptazinol data was performed using an iterative non linear least 
squares regression program (included in the VASP software package made 
available by Dr. A.W. Kelman, Department of Nuclear Medicine and 
Materia Medica, Stobhill Hospital, Glasgow) on a NODECREST V70 series 
digital computer. The data was fitted using one and two compartment 
models.
The function for the one compartment model was :
Y = Oo x e ”Ke t 
where Ke = Cl/vd
The two compartment model was fitted to a biexponential model 
using the function
Y _ Alpha, t + gg-Beta.t
where A and B were expressed using the parameters Cl, VI, K12, K21. 
where Cl = clearance
K12 = rate constant for the central to peripheral 
compartment
K21 = the rate constant for the peripheral to central 
conpartment 
VI = the volume of the central conpartment
The two models were compared using the F distribution where:
F = SSQ(R) - SSQ(F) / SSQ(F) 
df(R) - df (F) df (F)
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where SSQ(R) = Residual sum of squares for one compartment
model
SSQ(F) = Residual sum of squares for two compartment 
model
df(R) = Degrees of freedom for one compartment 
model
df (F) = Degrees of freedom for two conpartment
model
The one conpartment model was selected unless the 
significance of the F statistic was < 0.05.
7.7 PHARMACODYNAMIC ASSESSMENT
In the midazolam and meptazinol projects assessments were 
made of the degree of sedation and nausea induced by the drugs.
Psychomotor function was assessed using a Leeds Psychomotor 
tester. This measures the critical flicker fusion threshold 
(CFFT) and the choice reaction time (CRT). (HINDMARCH 1980). The 
CFFT is measured by asking the subject to observe 4 small red 
lights (Fig. 7.3). The frequency at which these lights flicker 
is then increased or decreased and the subject indicates the 
frequency at which the lights fuse or start to flicker by 
pressing a button. A mean of six readings are taken. The CRT 
measures the time the subject takes to move his finger from one 
button to another at a given signal (Fig. 7.4). The subject is 
presented with a choice of six buttons to which he must move his 
finger, each being indicated by a red light. The CRT is split 
into the CRT1 or recognition time which is the time taken from 
the indicator light being switched on to the subject lifting his 
finger from the base point. The total reaction time, or CRT2, is
172
the total time from the indicator light being illuminated to the 
subject moving his finger to the appropriate button. For each 
CRT reading a mean of 30 responses were taken. During the 24 
hours prior to the administration of the drugs the subjects had a 
minimum of three practice runs on the Leeds tester followed by a 
further 3 runs to establish a base line response. Ebr the 
analysis the difference between the mean CRT/CFET results and the 
patient's baseline results were calculated and the mean of these 
differences for each time point compared between the control and 
disease groups.
Simple visual analogue scales of: sedation and degree of 
nausea were also used. These were 10cm lines marked as follows:
Wide awake-----------------------------------Very sleepy
Not nauseated---------------------------------Fbeling very sick
The subjects were asked to record their feelings at each 
time point in these scales.
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FIGURE 7.3 CRITICAL FLICKER EUSION THRESHOLD
174
CHOICE REACTION TIME
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7.8 STATISTICAL METHODS
7.8.1 Standard Statistics
Standard parametric and non parametric statistical 
techniques have been used for comparing the various groups in 
this thesis. Where appropriate, Paired Wilcoxon, Mann Whitney U- 
tests and Kruskal Wallis analysis of variance, Student's t-test 
and parametric analysis of variance have been used. The specific 
tests used are indicated in the text. Non parametric correlation 
was performed using the Spearman Ranking procedure. The 
following microcomputer programs were used in the analysis:
a) MINITAB - (Minitab Incorporated, 215 Pond Laboratory, 
University Park, PA 16802). This program was modified for 
use on an Apricot microcomputer by the department of 
computing at Glasgow University and was supplied by them 
with a sub-license.
b) STATSTREAM. A program originally devised at the School of 
Biological Sciences, University of East Anglia, Norwich NR4 
7TJ. The program is written for an Apple II microconputer 
and is distributed through Elsevier - Biosoft, 68 Hills 
Road, Cambridge CB2 1LA.
c) BIODATA HANDLING BOR MICROCOMPUTERS. This program was 
written by R.B. Barker of the Department of Clinical 
Pharmacology, Bristol University and is also distributed by 
Elsevier-Biosof t.
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7.8.2 Proportional Hazards Regression
The simultaneous influence of a number of variables on the 
survival of the patients have been investigated using Cox's 
Proportional Hazard model (COX 1972). This type of analysis has 
been designed to take into consideration two characteristics of 
survival data. Firstly, the data usually contains incomplete 
observations. If a number of patients are followed for a period 
of time, a proportion are likely to survive to the time of 
analysis. The complete survival information is not available on 
on these patients. Nevertheless, the information that they 
survived for a certain.period of time can be used in the 
analysis. Secondly the distribution of survival times mean that 
standard multiple linear regression is not an appropriate 
statistical test for the analysis of such data. Proportional 
hazards regression does not assume a specific distribution of the 
data.
In the Cox's proportional hazard model the hazard or risk of 
death (H) at time t for a patient with variables Z1 to Zp is 
expressed by -
H(t) = Ho {B1 Z1 + Bp Zp) t > 0
where Ho is the underlying hazard and B1 ■---Bp are
regressional coefficients of variables Z1 to Zp. If regressional 
coefficient Bl is positive high values of the corresponding 
variable Z1 indicate a high hazard or worse progression and vice
versa if Bl is negative. If Bl is zero the corresponding
variable Z1 has no influence in survival.
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C H A P T E R  8
ANTIPYRINE METABOLISM IN PORPHYRIA IN RELAPSE AND REMISSION
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8.1 SUMMARY
Antipyrine kinetics following a single oral dose were 
obtained in porphyric patients in attack and in remission and in 
controls. The clearance of antipyrine was significantly lower 
during an acute porphyric attack (median: 0.34 ml/min-  ^ kg”-1-?
range: *0.1 - 0.71, P < 0.05) than in patients in remission 
(median 0.53 ml/min^kg"^, range: 0.28 - 0.87) or controls 
(median: 0.52 ml/min”l kg”-1-; range: 0.32 - 0.93). There was a 
significant negative correlation between weight-adjusted 
antipyrine clearance and the urinary excretion of the porphyrin 
precursors, delta-aminolaevulinic acid (r = -0.86, p< 0.001) and 
porphobilinogen (r = -0.82, p<0.002). These data suggest that 
the more severe the porphyric attack, the greater the impairment 
of hepatic monooxygenase activity.
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8.2 INTRODUCTION
The acute hepatic porphyrias are a group of rare conditions 
in which there are hereditary abnormalities in the biosynthesis 
of haem (GOLDBERG et al, 1983) (Figure 8.1). Patients can 
present with acute abdominal pain, autonomic dysfunction and 
neuropsychiatric disturbance (BRODIE and GOLDBERG 1980). During 
an acute attack an excess of the porphyrin precursors delta- 
aminolaevulinic acid (ALA) and porphobilinogen (PBG) is found in 
the urine. This abnormality persists when the acute attack 
remits although usually to a lesser degree. In all patients, 
hepatic haem synthesis is diminished due to reduced activity of 
one enzyme in the pathway specific for each type of porphyria. 
Consequently, the initial and rate-limiting enzyme, ALA-synthase 
(ALA-S), is derepressed by negative feedback. Elevated activity 
of this enzyme can be measured in circulating leucocytes (BRODIE 
et al, 1977b) and provides an inportant extra index for the 
identification of latent cases (McOOLL et al, 1982).
The majority of haem synthesised in the liver is utilised 
for the formation of the haemoprotein cytochrome P450 which forms 
the terminal component of the hepatic mixed function oxidase 
enzyme system (GOLDBERG et al, 1983).
The purpose of this study was to assess monooxygenase 
activity, as reflected by antipyrine metabolism, in patients with 
acute porphyria in attack and in remission, and to attempt to 
correlate this activity with the extent of the biochemical 
defect in haem biosynthesis.
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8.3 PATIENTS AND METHODS
The study was carried out in 16 patients (14 female, 2 male) 
with hereditary hepatic porphyria. Fourteen had acute 
intermittent porphyria (AIP) and 2 variegate porphyria (VP).
The diagnosis had previously been made by demonstrating increased 
porphyrin and precursor excretion together with reduced activity 
of the appropriate enzyme in circulating blood cells and 
elevation of leucocyte ALA-S activity. Eight patients (7 AIP,
1 VP) had typical symptoms of an acute attack (Group 1) and a 
further 8 (7 AIP, 1 VP) were clinically in remission (Group 2).
No patient was receiving any drug known to affect antipyrine 
metabolism. Eight non-medicated patients investigated for 
irritable bowel syndrome served as controls (Group 3). All 
patients had normal standard biochemical liver function tests. 
Ebmales predominated in each group with 8 in Group 1 and 7 each 
in the other 2 groups. One patient in Group 1 smoked fewer than 
10 cigarettes per day. No patient in the other two groups
smoked tobacco. The median age of the patients in the three 
groups was as follows: Group 1: 32 years (range 18-47), Group
2: 38 years (range 17-54), Group 3: 45 years (range 30-50). The 
patients with acute porphyria in attack were lighter than those 
in the other two groups but this difference was not statistically 
significant. [Group 1: median 55.8kg (range 43-71); Group 2:
median 66kg (range 52-74); Group 3: median 68.7kg (range 55- 
79)].
Antipyrine kinetics were determined using the Protocol in 
Chapter 7. Prior to the administration of the antipyrine dose,
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30ml of blood were withdrawn for immediate assay of leucocyte 
ALA-S activity and a 24 hour collection of urine for porphyrin 
and precursor measurement was commenced.
Leucocyte ALA-S activity (BRODIE et al, 1977b) and urinary 
ALA, PBG and total porphyrin content (MOORE 1983) were obtained 
using standard techniques.
Results are quoted as medians and ranges. The statistical 
analysis used Mann Whitney U tests and correlations were obtained 
by the Spearman ranking procedure.
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8.4 RESULTS
Leucocyte ALA-S activity and porphyrin precursor excretion 
in the porphyric patients together with the kinetics of 
antipyrine for all 3 groups are shown in Table 8.1. The 
porphyries in attack had significantly higher leucocyte ALA-S 
activity and increased urinary ALA, PBG and total porphyrin 
excretion compared with those in remission (all p<0.05). The 
weight-adjusted clearance of antipyrine was lower in these 
patients (median 0.34ml/min“  ^ kg”-*-; range 0.1-0.71; p<0.05, 
Figure 8.2) than in those in remission (median 0.53ml/min”-*- kg”-*-; 
range 0.28-0.87) and than in controls (median 0.52ml.min--*- kg”-*-; 
range 0.32-0.93). The volume of antipyrine distribution was 
reduced in both porphyric groups (attack: median 22.5L; range 
10.1-42.4; remission: median 23.2L; range 17.2-41.3; controls: 
median 37.3L; range 24.6-50.0, p<0.05). There were significant 
negative correlations between the antipyrine clearance (ml/min”-*- 
kg”-*-) and the urinary excretion of ALA (r = -0.86, p<0.001) and 
PBG (r = -0.82, p<0.002) but not with total porphyrins (r = - 
0.45) or the activity of leucocyte ALA-S (r = -0.45).
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8.5 DISCUSSION
This study confirms that acute attacks of porphyria are 
associated with temporary impairment of hepatic oxidation of 
antipyrine (ANDERSON et al 1977). Altered hepatic metabolism has 
also been reported for Salicylamide (SONG et’al 1974), and 
aminopyrine (OSTROWSKI et al 1983) but not for phenylbutazone 
(ANDERSON et al 1976) or indocyanine green (STEIN et al 1970).
The reduction in antipyrine volume of distribution in all the 
porphyric patients was unexpected and remains unexplained. It 
may reflect a diminution in muscle bulk consequent upon the motor 
neuropathy.
In the acute hepatic porphyrias there are various enzyme 
defects in the haem biosynthetic pathway which result in a 
relative deficiency of hepatic haem and an accumulation of 
circulating haem precursors. The majority of haem synthesised 
in the liver is incorporated into cytochrome P450 which forms the 
terminal component of the mixed function oxidase enzyme system 
(GOLDBERG et al, 1983). Antipyrine is almost completely 
metabolised in the liver by oxidative processes and the different 
rates of production of its metabolites reflect the activities of 
the enzymes producing them (BOOBIS et al 1981). Reduced 
elimination of antipyrine in patients with porphyria could be a 
consequence either of reduced cytochrome P450 necessary for its 
metabolism or from a functional inhibition of monooxygenase 
activity by circulating ALA or PBG. The significant negative 
correlation between the extent of porphyrin precursor excretion 
and the elimination of antipyrine can support either possibility. 
The correlation between leucocyte ALA-S activity and antipyrine
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clearance did not reach statistical significance. However, the 
patient numbers were small and the activity of ALA-S in 
leucocytes may not reflect that present in hepatic tissue.
The close correlation between the amount of both porphyrin 
precursors excreted in the urine and the antipyrine clearance 
suggests that the more severe the porphyric attack the greater 
is the impairment of hepatic monooxygenase activity.
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C H A P T E R  9
HEPATIC METABOLIC FUNCTION IN PATIENTS RECEIVING LONG TERM 
METHOTREXATE THERAPY: COMPARISON WITH TOPICALLY TREATED
PSORIATICS, PATIENT CONTROLS AND CIRRHOTICS
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9.1 SUMMARY
Standard biochemical liver function tests and the clearances 
of antipyrine and indocyanine green have been compared in 
psoriatic patients taking methotrexate, psoriatic patients on 
topical treatment, patient controls and patients with hepatic 
cirrhosis. The methotrexate-treated patients showed significant 
elevations in alkaline phosphatase (p<0.025) and gamma glutamyl 
transpeptidase activities (p<0.05) compared to topically treated 
psoriatics and patient controls. The clearance of antipyrine was 
reduced in the methotrexate treated group but not significantly 
( 0.1 > p > 0.05). In contradistinction, the weight-adjusted 
clearance of indocyanine green was significantly inpaired in the 
methotrexate group in comparison with the topically treated 
psoriatics (p < 0.01).
The clearance of both antipyrine and indocyanine green were 
markedly lowered in the cirrhotics (p < 0.001 against all other 
groups). These data suggest that the serial measurement of 
alkaline phosphatase and indocyanine green clearance may provide 
a non-invasive indicator of the development and progression of 
methotrexate-related liver injury.
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9.2 INTRODUCTION
Methotrexate has been enployed in the treatment of severe 
psoriasis for more than 25 years (EDMUNDSON & GUY 1958). The 
systemic use of this drug has been associated with hepatic 
fibrosis (DAHL et al 1971; ZACHERIAE et al 1975) and cirrhosis 
(ODE and BULL 1968; ZACHERIAE et al 1980). An increased 
mortality due to the hepatic complications has been reported 
(BAILIN et al 1975). Hie identification of patients developing 
progressive liver injury has not been possible with standard 
biochemical liver function tests (ROENIGK et al 1971) or. 
technetium 99 sulphur colloid liver scans (GERONEMUS et al 1982). 
The current policy is to recommend liver biopsy after each gram 
of methotrexate administered (ROENIGK et al 1982). This requires 
hospital admission and is associated with a small but significant 
morbidity and mortality (CALLEN & HANNO 1980; CRESWELL & BURROWS 
1980). In addition, a single biopsy may be unrepresentative of 
the overall liver architecture and gives no indication of the 
functional capacity of the liver.
Dynamic liver function tests are safe, inexpensive and can 
be performed on outpatients. These tests reflect aspects of the 
liver's metabolic function. The aim of this study was to 
investigate the clearances of antipyrine and indocyanine green in 
the assessment of hepatic function in patients with psoriasis 
receiving long term methotrexate therapy.
9.3 PATIENTS
Fbur groups of patients have been studied. The first group 
consisted of 11 patients (8 male, 3 female) on long term
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methotrexate therapy. The mean age of the group was 55.5 + 7.8 
years. The patients had been receiving regular weekly or 
fortnightly intravenous doses (5-15mg) of methotrexate for 1-16 
years, the mean total dose being 2168mg (range 620-3200mg). The 
second group consisted of 14 psoriatic patients (6 male, 8 
female) who had never received methotrexate. The third group was 
made up of 15 patients without psoriasis or liver disease who 
were regarded as patient controls. No patient in any of these 
three groups was known to abuse ethanol. The fourth group 
contained 15 non-dermatological patients with histologically 
proven hepatic cirrhosis. None of the patients in any of the 
groups was receiving drugs known to affect hepatic metabolic 
function or liver blood flow. The mean age of groups 2,3 and 4 
did not differ significantly from that of the methotrexate 
treated group (group 2 = 56.3 +_ 3.5 years; group 3 = 54.1 + 7.1 
years; group 4 = 54.0 + 5.6 years). All the cirrhotic patients 
and the patients receiving methotrexate had percutaneous liver 
biopsies performed for routine histological evaluation.
The study was performed with the approval of the local 
Ethical Committee and written informed consent was obtained from 
all patients prior to inclusion in the study.
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9.4 METHODS
See chapter 7.2 for antipyrine method.
See chapter 7.3 for indocyanine green method.
The data are expressed as means + the standard error of 
the mean unless otherwise stated. Statistical analyses were 
performed using Student's t-test with a one way analysis of 
variance. Correlation coefficients were obtained by the 
Spearman ranking procedure.
9.5 RESULTS
Serum alkaline phosphatase (p < 0.025) and gamma glutamyl 
transpeptidase (p < 0.05) activities were significantly elevated 
in the methotrexate treated patients compared to the topically 
treated psoriatics and the patient controls (Table 1). There 
were no other significant differences in the standard biochemical 
tests of liver function between these three groups. As expected 
all the standard biochemical liver function tests were disturbed 
in the group with cirrhosis conpared to the healthy controls (p < 
0.001).
Antipyrine and indocyanine green kinetic data for all four 
groups are shown in Table 2. There was a small fall in the 
antipyrine clearance (ml/min) in the methotrexate treated group 
compared to the healthy controls but this was only significant at 
the 10% level. Similarly when adjusted for body weight, 
antipyrine clearance (ml/min/kg) was not significantly different 
between the psoriatic groups and the patient controls (Fig. 1).
The indocyanine green plasma clearance was also reduced in 
the treated patients (576 + 163 ml/min) compared to the psoriatic
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control group (695 + 170 ml/min) and the healthy controls (726.8 
+ 252 ml/min), these differences being significant at the 10% and 
5% levels respectively. When the clearances were corrected for 
body weight these differences reached 5% and 1% significance 
levels (Fig. 2).
In the patients with proven hepatic cirrhosis there was a 
substantial reduction in the antipyrine and indocyanine green 
clearances (p < 0.001) compared to the other three groups.
There was no significant correlation between the total dose 
of methotrexate received and the weight adjusted antipyrine (r = 
0.03) and indocyanine green (r = 0.35) clearances or the alkaline 
phosphatase activity (r = 0.08). Histological evaluation of the 
liver biopsies in the methotrexate treated patients showed that 
only one patient had developed hepatic fibrosis. This patient 
had elevated alkaline phosphatase and gamma glutamyl trans­
peptidase activities (231 iu/1 and 46 iu/1 respectively) on 
antipyrine clearance of 0.34 ml/min/kg and indocyanine green, 
clearance of 6.26 ml/min/kg (Fig. 2).
9.6 DISCUSSION
The standard biochemical tests of liver function are not 
regarded as reliable screening tests for liver disease in 
patients taking methotrexate (ROENIGK et al 1971). However,
DAHL and his colleagues (1971) showed that a raised alkaline 
phosphatase activity was associated with the subsequent 
development of hepatic fibrosis. Alkaline phosphatase of 
hepatic origin is indicative of an obstruction to biliary flow.
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In this circumstance the concentration of alkaline phosphatase 
in the hepatocyte increases and then overspills into the 
circulation (PRICE & SAMMCNS 1976). We have demonstrated a 
significant elevation in alkaline phosphatase among psoriatics 
taking methotrexate. In only two patients was it elevated 
outwith the control range, and one of these patients had 
histological evidence of hepatic fibrosis. The methotrexate 
treated patients also had a significantly elevated gamma 
glutamyl transpeptidase activity. The activity of this enzyme 
is also increased in conditions which produce an obstruction to 
biliary flow (LUM & GAMBINO 1972) but this is less specific 
as its activity is also increased by ethanol excess (ROSALKI 
1975).
The clearances of antipyrine and indocyanine green were 
well preserved in the methotrexate treated patients compared to 
the florid deterioration in metabolic function observed in the 
cirrhotic patients. However, in comparison to the control 
population there is a tendency to a reduction in both 
clearances which reaches statistical significance for the 
indocyanine plasma clearance. This reduction in clearance may 
be due to a fall in liver blood flow (CAESAR et al 1961) or a 
reduction in the intrinsic uptake of the dye by the hepatocyte 
(HUET & VILLENEUVE 1983). In the methotrexate treated patients 
who otherwise appear to have well maintained hepatic metabolic 
function it is likely that the reduction in indocyanine green 
clearance is a reflection of reduced liver blood flow resulting 
from a distortion of the liver architecture. The clearance of
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bromosulphthalein (BSP) another highly hepatically extracted 
substance, has been shown to be impaired in patients with 
methotrexate induced liver injury (WEINSTEIN et al 1970), but no 
correlation was found between the degree of retention of BSP and 
the histological severity of the liver damage (DAHL et al 1971).
Despite these metabolic changes suggesting that the hepatic 
architecture is disturbed, examination of hepatic histology 
revealed only one patient with demonstrable hepatic fibrosis on 
light microscopy. The prevelance of methotrexate associated 
liver injury is low in this small series with only 1/9 patients 
affected. In previous studies 33-39% of patients had hepatic 
fibrosis or cirrhosis (DAHL et al 1971; ZACHERIAE et al 1975; 
WEINSTEIN et al 1970). We believe that this may be a reflection 
of the policy of giving doses of methotrexate intravenously at 
weekly or fortnightly intervals (ALMEYDA et al 1972; WARIN et al 
1975).
In this preliminary study the alkaline phosphatase 
activity was elevated and the indocyanine plasma clearance 
significantly lowered in a small group of psoriatics receiving 
systemic methotrexate. This combination of changes may be 
related to a fine distortion of the liver architecture which is 
not apparent on light microscopy of a single liver biopsy core. 
The serial measurement of serum alkaline phosphatase activity 
and indocyanine green clearance may provide a non-invasive 
method of assessing the development and progression of 
methotrexate associated liver injury. These tests may obviate 
the need for routine annual liver biopsies by identifying those 
patients with deteriorating liver function. Further studies
196
are needed to confirm these findings.
ACKNOWLEDGEMENT
I would like to thank Professor R.M. McKie for allowing us 
to study her patients, Professor R.N.M. MacSween for the 
histological evaluation of the liver biopsies, Dr. Claire 
Fitzsimmons and Dr. Douglas Czarnecki for their help in 
collecting the samples, and collating the data.
TA
BL
E 
9.
1 
ST
AN
DA
RD
 
BI
OC
HE
MI
CA
L 
LI
VE
R 
FU
NC
TI
ON
 
TE
ST
S 
IN 
AL
L 
PA
TI
EN
T 
GR
OU
PS
 
(m
ea
n 
+S
EM
)
c
•rH
6
3
cn
0
co
to(1) 44 
G fO
-H •£r—j OM (0 03 rH
o \
a * 3
to co
13 4->
0  rH
co \  
<0 3  S-l *H 
0
*4—1 ✓—
w  ir1
a § Sco p  cn<  44 —
0  r H
c•H
43
3
S-J
•rH
rH
•rH
CQ
rH 1 11 11 1
11 1\  1 1 1 1 4c 1cn i I 1 1 4c 11 1 1 4c 1co | 1 1 1 rH |in i CO 1 VO <S\ 1 co r- i in cn i1 i • 1 • • 1 * * l 9 9 1m i CN rH 1 rH O 1 rH O 1 rH CN |CO | I 'Ct* 1 "cr 1 CO 1
l 11 11 1 11I 1! 1I 11 1IrH 1 I 1 1
\  1 1 1 l 13 1 1 1 1 4c 1■H | *  I 1 ! 4c 11 4c | 1 1 4c 1O 1 CN I 1 1 <—1 Ir- i in co ] cn cn i rH O 1 CO CN |iH 1 • • j • • { * * 1 * * 1I i in t-" i cn r- i .H VO 1 cn i.H 1 CN rH | CO 1 00 1 cn cn iCN | rH 1 l 1 rH 1—' I 1 l!I I1 l 11 11 in i—iI I 1 I in CN o1 1 l 1 1 o O oI I I 1 • • .1 l 1 4c | o o oin i 1 1 1 4c 1\  ! 4c I I 1 4c 1 V V V3 1 CN | l I rH 1•H 1 CN ID 1 o  cn i O H1 I 00 O 1 & Oi CMI • * I * * l 9 9 1 * * 1O ! <n I h1 in i vo in i rH rH | II II IICO I ^  1 CO 1 CN 1 in in i1 I 1 1 I rH I 4c 4c 4cCO | 1 1 1 4c 4c
I 1j 1j 11 1j 4c1 1 1 1 1in i 1 1 1\  I ! 1 1 4C !rH 1 1 1 1 4c I1 4c 1C | 1 1 rH |3 1 in co i r- vo I CN 00 1 cn vo iI • • j 9 9 1 * * I * * 1in i id  in i CO ^  1 00 CO 1 in cn iin i CO I CN I CN | r- rH 11 ! ! 1 1 l 000 1 1 1 1 I O1 1 I l G! 1 1 1 l to1 1 I I •HJh 1 1 1 1 ! S-l\  1 1 1 ! 1 toiH 1 1 I 1 ! >1 I 4c Ig 1 1 1 4c 1 MH3 | 1 1 1 4c 1 O1 1 1 1 rH !03 | ID <n | VO IH 1 cn l cn co i CO*3* 1 * * 1 • 9 1 9 9 1 * * 1 •f—{ CQI I VO iH 1 CO CN I in cn i vo r"- i CQ i—1CN | CN | CN I CN | tn rH 1 >< OrH 1 1 1 l 1 r—1 S-l1 1 1 l (0 44| 1 1 1 1 G C! 1 1 to OrH ! 1 1 u\  1 i 1 1 I >1rH | 1 1 1 to o! 1 1 l •Hg 1 I 1 1 4c I 44
1 1 1 1 4c 1 0 CO" 1 1 1 1 4c 1 G •HCN | 1 1 1 i—1 i O S-lCN | o  m i cn r~" i Cn rH 1 O | O| | • • I • 9 1 9 9 1 * * 1 . *3 CQCO | O rH 1 Cn rH I cn rH 1 'cf O I G CQ Dm! l 1 in i—i i to CM1 I 1 3 *31 I I 44 O c! I 1 CQ S-l toI 1 l 1 I 0 cn
G  ! C 1 £ I C 1 44 CQ1 (3 32 1 to S 1 c3 a  I to a  i 1 0 rH1 0 H 1 0 H 1 0 H I 0 W 1 44 0 OI a  cn i a  w j a  in i a  in i S-l S-l1rH 1 i . i ! i CQ 5
44G
(3 0 1 i 1 i 44 OB Cn i i i 1 i C S-l 3S-i G 1 i i I i 0 0O eg 1 rH 1 1 in i in i 43 44JZ K 1 rH 1 rH 1 rH 1 rH | 3 44 G| 1 1 1 1 44 O 0| ! ! 1 I CQ •H| I 1 1 1 0 44
j | I 1 1 43 to1 0 I ! 1 1 43 43 DmI 4-1 1 1 1 1I tO I 1 1 1 CQ CQ CQX 1 3 1 CQ 1 U 3 31 0 1 •H CO I CO I •H 1 •H CQ CQ! S-i 1 44 rH 1 44 rH 1 CQ I 44 SH S-l1 4-» 1 (0 O ! C O i O 1 CQ 0 01 O CM 1 •H s-l 1 0 S-l 1 43 1 •H > >I 43 3 1 S-l 44 1 •H 44 | S-l 1 441 43 o 1 O G 1 44 C 1 S-l 1 to II II1 0 S-l 1 CQ O 1 to O 1 •H | 44
J a  cn 1 CM O | CM 3  1 U  1 in rH CN
97
TA
BL
E 
9.
2 
AN
TI
PY
RI
NE
 
AN
D 
IN
DO
CY
AN
IN
E 
GR
EE
N 
KI
NE
TI
CS
 
IN 
AL
L 
PA
TI
EN
T 
GR
OU
PS
 
(m
ea
n 
+ 
SE
M)
0
3
•rH
§
><
8
"8M
0  0  rH H H  g
3O
•rH 
u-l 4-5
° s(U *H 
3  E  5n 
CD 3  4->
(L) rH CQ 
Sn O  *r-l
O > D
0M-!•H
J
UH
rHto
0
3  3* 
to to - h  
E hiCQ tO
to a)
co
0) -iH
3  UH -P  
■H O 
S-l 
>1 0 Qi E •h 3 
-!-J rH
s g
0
44
•rH *— »*
i-3 CQ U
44 3  
•H O
,2 ^  EC
*
CN
O
.
VO
r -
in
*
CN 
rH ro  
• •
ro  o
cn ro  
• *
ro  o
o
r -
ro
cr> oo
ro  cn 
ro
00 C"- 
• •
ro  rH
S s0 H S CO
0
-P
tCX
0
S-l
4->
O Q*
3O
S-l
cn
rH i—I 
.  •
in  r"- <y> ^  
vo
oo cn 
.  .
ro  o
co cn 
.  *
ro  o
in  as
as ro  
ro
r -  CN
ro*sr
as o  
. •
CN iH
3  — 
3 £0 w
S  03
rH
u
•H  0  
-P rH
0 O 
•H S-i 
5-1 4->O 3 
0 O Ph u
00 vo 
. .
VO i—I 
CN VO
as cn 
• .
ro  o
00  rH 
* .
ro o
cn ro
CN ro
in  in
*=? CN
ro
cn r- 
. .
rH O
0 s0 &3 
S 03
in■—i
0
4J rH
3
0
•H
-P
0cu o
*
*
•K
H
in  iH  
• •
ro  as
in  rH 
CN
*
ro
rH CN 
* •
^ o
•K*
*
H i—I 
* .
^  rH i—I
**
* i—Ias cn 
• *
CO CN 
CN
in
o
v
in
CN
o
v
0*
*
*
! 0 .
1 U3
!1 0•rH1 SH01i >i
i 44
ij O
i 0
O  VO ! •rH
• • 1 0OS rH 1 >1
CO 1 rH111
0
S1
>11 011 Ss1
*  1 0* 1 3* ! O
1—t Ias as i r0
* * ! 3 0in  rH 1 0 04
CN | 3
-P O! 0 SH
! 0 CP
-P
C 1 1 00 S 1 4-5 0
0  EC ! SHS 03 ! 
!
0
5
! JL>1 3 SH
! 0 0
15 TS3 51 4-5 O1 03
1 011 > iX ! 5
I
1 0 00 1 U 3
•H  I •rH 0
0  I 4-5 SH
O 1 0 0
-3  1 •rH >
S-l 1 4-5
S-l 1 0 I
•H  I 4-5
U 1 03 rH
198
o
o
•
o
V
Qa
*
*
*
0
rH
0 o
i—1 SH
O 44
SH 3
44 O
3 U
O
o U
•rH
44 44
3 0
0 *H
•rH SH
44 O
0 0
O j a.
0 0
3 3
0 0
SH SH
0 0
> >
II II
CN ro
200
FIGURE 9.2 : INDOCYANINE GREEN CLEARANCE (ML/MIN/KG) IN ALL
PATIENT GROUPS. Bars represent mean + SEM. 
Statistics were obtained using one way analysis 
of variance.
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C H A P T E R  10
ANTIPYRINE AND INDOCYANINE GREEN KINETICS IN THE PREDICTION OF THE 
NATURAL HISTORY OF LIVER DISEASE.
202
10.1 SUMMARY
Data are presented in this chapter demonstrating the 
relative value of standard liver function tests, antipyrine and 
indocyanine green elimination in the assessment of the natural 
history of chronic liver disease. One hundred and sixteen 
patients with chronic liver disease were studied.
When the patients were divided by diagnostic groups there 
were similar changes in the standard liver function tests and 
kinetic parameters in all the groups. The only exception was. 
that patients with primary biliary cirrhosis had a marked 
reduction in the volume of distribution of antipyrine (controls =
36.3 + 13.7 1; PBC = 25.4 + 7.3 1 : p<0.005). This suggests that 
these patients have a reduced total body water, which may be a 
consequence of the hyperlipidaemia seen in this condition.
The patients were divided into those with and without the 
major complications of liver disease - Encephalopathy, ascites 
and portal hypertension. A reduction in antipyrine clearance of 
2,16 and 14% respectively was found in the patients with these 
couplications. The reductions in indocyanine green clearance 
were much greater at 44,48 and 37% respectively. The antipyrine 
clearance was reduced by 26% in patients with biopsy proven 
active cirrhosis compared to a reduction of 50% in the 
indocyanine green clearance. The non-survivors had a 3% 
reduction in antipyrine clearance, and a 75% reduction in 
indocyanine green clearance.
When these data were analysised by multiple regression and 
Cox's proportional hazard model, the most powerful of the 
kinetic parameters was the indocyanine green half-life. When
203
this was included with the patients age in the model all the 
other biochemical, histological and kinetic data became 
redundant.
These data show, that indocyanine green elimination provides 
important information regarding the severity of liver disease. 
The greater magnitude of change seen with indocyanine green 
compared to antipyrine suggests that an important determinant of 
the complications and survival in liver disease is the functional 
liver blood flow rather than the hepatic metabolic capacity.
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10.2 INTRODUCTION
The aim of this study was to explore the value of antipyrine 
and indocyanine green kinetic data in the evaluation of patients 
admitted to hospital with chronic liver disease. The kinetic 
data from these drugs were conpared to the clinical features of 
liver disease, biochemical and histological data. The patients 
with liver disease were divided by diagnostic group, hepatic 
complications, and into survivors and non-survivors.
10.3 PATIENTS AND METHODS
One hundred and sixteen patients with liver disease were 
studied. Histological diagnoses were alcohol-related liver 
disease [ALD](65), primary biliary cirrhosis [PBC] (25), chronic 
active hepatitis [CAH](12), cryptogenic cirrhosis (6), acute 
viral hepatitis (3), haemochromatosis (2), primary sclerosing 
cholangitis (2) and idiopathic portal hypertension (1). The last 
five diagnostic categories have been combined as "liver disease - 
other causes". A group of 40 patients with no clinical or 
biochemical evidence of liver disease was included as controls. 
These patients were all admitted to hospital for investigation 
of non-hepatological gastrointestinal synptoms. The majority had 
either peptic ulceration or severe constipation of non-organic 
origin.
The methods of data collection, correction, and transfer are 
described in Appendix 4.
The raw data obtained in this study was gathered as Appendix
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3. It is organised in three separate reports. The first report 
contains the basic clinical and biochemical data on the patients. 
The second includes the antipyrine and histological data, and the 
third lists the indocyanine green data.
The follow-up on the patients was taken from entry into the 
study to the last observation (either death or censoring). Gox 
multiple regression model was used for censored survival data 
(Cox 1972). Before inclusion in the Cox analysis, the 
distributions of the continuous variables were checked for 
normality and if necessary logarithmic or reciprocal 
transformations were made. In a skewed distribution any 
outlying results exert a disproportionate effect on multiple 
regressional analysis. However a normal distribution is not an 
absolute pre-requisite for this type of analysis, and the most 
appropriate transformation can be determined by repeated testing 
with the regressional analysis. In the regressional analysis 
variables which were significant at the 5% level were introduced 
into the model and they were discarded from the model if their 
significance failed to attain the 10% level.
The study had the approval of the local ethical committee 
and all patients gave written informed consent.
10.4 RESULTS
10.4.1 Results of Comparison Between Disease Groups
The age and sex data (Table 10.1) show a typical 
distribution for a large population of patients with liver 
disease. There was a significant predominance of females in the 
PBC (96%) and CAH (75%) groups and there was a slightly more
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males in the alcoholic (69%) and mixed liver disease groups 
(64%). The groups were well matched for age except for the PBC 
group, who were on average 10 years older that the other 
patients.
The prevalance of the three major complications of liver 
disease are shown in Table 10.2. The distribution of these 
complications was not significantly different in any group. 
However there was a tendency towards a lowsr prevalance of 
encephalopathy and ascites in the PBC group suggesting that this 
group had less severe liver disease.
The results of the standard biochemical tests of liver 
function are summarised in Tables 10.3a and 10.3b. As expected 
most of these were significantly abnormal conpared to controls in 
all the patient groups.
The antipyrine kinetic data are summarised in Table 10.4. 
There were significant deviations from the control results in all 
patient groups. Generally the pattern of abnormalities was 
similar in each patient group with a reduction in the plasma 
clearance and a prolongation in the half life, with no altertion 
in the volume of distribution The only deviation from this 
pattern occurred in the PBC group, where there was a significant 
reduction in the volume of distribution (Gontrols = 36.3 + 13.7 
1; PBC group = 25.4 + 7.3 1; P < 0.005). This offset the 
reduction in the clearance so that there was not a significant 
alteration in the half life.
The indocyanine green kinetics are summarised in Table 10.5. 
The general pattern is similar to that seen with antipyrine but
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the overall differences were greater.
10.4.2 Encephalopathy
There was a clinical history of encephalopathy in 32 (27%) 
of the patients with liver disease. The results of standard 
biochemical liver function tests, antipyrine and indocyanine 
green kinetic data for patients with and without encephalopathy 
are summarised in Tables 10.6, 10.7 and 10.8. The serum albumin 
was significantly reduced in the encephalopathic group 
(Encephalopathy = 29.8 + 6.8 g/1: No Encephalopathy = 36.5 +
6.7 g/1, P < 0.005). The serum bilirubin was higher in the 
encephalopathic patients (Encephalopathy = 94.8 + 113.9mmol/l;
No encephalopathy = 25.4 + 24.2mmol/l; P < 0.001). There was no 
significant alteration in the other standard liver function tests 
including aspartate transaminase, alanine transaminase and the 
gamma glutamyl transpeptidase (Table 10.6).
The antipyrine kinetics show a curious pattern with a marked 
increase in the volume of distribution in the encephalopathic 
patients (Encephalopathy group = 39.8 + 17.3 L: No
encephalopathy = 30.2 + 8.9 L; P < 0.001). There was a 
concomitant small increase in the elimination half life but no 
alteration in the plasma clearance (Table 10.7).
The indocyanine green kinetic data also show a small 
increase in the volume of distribution in the encephalopathic 
patients. However, for this drug there is a marked reduction in 
the clearance (Encephalopathy group = 231.2 + 240.2ml/min; No 
encephalopathy = 406.2 + 214.7ml/min, P < 0.001). Consequently
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the elimination half life is markedly prolonged in the 
encephalopathic group (Encephalopathic group = 21.6 + 13.0min;
No encephalopathy = 8.9 + 9.2 ml/min; P < 0.001) (Table 10.8).
10.4.3 Ascites
There was clinical evidence of ascites in 40 (34%) of the 
liver disease patients studied. The results of the standard 
biochemical liver function tests, antipyrine and indocyanine 
green kinetic data are shown in Tables 10.9, 10.10 and 10.11.
The standard biochemical tests showed significant elevations 
of the serum bilirubin and a significant reduction in the serum 
albumin (Table 10.9).
The antipyrine kinetic data showed a small but significant 
increase in the volume of distribution (Ascites = 37.0 + 16.5 
L; No ascites = 30.8 + 9.4 L; P < 0.05). There was a small but 
insignificant reduction in the plasma clearance. However, the 
combination of these two changes resulted in a major prolongation 
of the elimination half life (Ascites = 31.1 + 22.2 hrs; No 
ascites = 16.5 + 8.6 hrs; <0.001) (Table 10.10).
The indocyanine green kinetic data shows marked differences 
in all the parameters studied with a significant increase in the 
volume of distribution and half life with a reduction clearance 
(Ascites = 227.3 + 211.1 L; no ascites = 435.9 + 212.9 L: 
p<0.001) (Table 10.11).
10.4.4 Portal Hypertension
In the liver disease group there were 2 patients (2%) with 
surgical portocaval shunts, 19 (17%) who had previous bleeding
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from oesophageal varices and 16 (14%) who had oesophageal varices 
on routine barium swallow. These 37 patients (33%) were combined 
to form a portal hypertension group.
There were only small changes in the standard biochemical 
liver function tests between the two groups (Table 10.12). 
Similarly there were no significant alterations in the kinetics 
of antipyrine (Table 10.13). However, the indocyanine green 
kinetics were significantly altered (Table 10.14) in the portal 
hypertension group with a significant increase in the half life 
and volume of distribution with a reduction in the plasma 
clearance (Portal hypertension = 254.1 + 131.5ml/min; no portal 
hypertension 407.9 + 256.2ml/min: p<0.005). Although these
changes were significant they were less marked than those seen in 
the encephalopathy and ascitic group.
10.4.5 Histological Qassification
On the basis of the findings on histological examination of 
the liver biopsies the patients were divided into four groups. 
There were 33 patients who had evidence of an active cirrhosis. 
These patients had histological evidence of both cirrhosis and an 
active hepatitis with most of these patients having an alcoholic 
aetiology. Five patients had an inactive cirrhosis and in 35 
patients the liver histology showed evidence of liver disease 
which had not progressed to cirrhosis. In a further 32 patients 
liver biopsy was not performed either because it was judged to be 
too hazardous or because it was not clinically indicated.
The results of the standard biochemical liver function tests
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are shown in Table 10.15. The patients without biopsy evidence 
of cirrhosis had significantly elevated levels of gamma glutamyl 
transpeptidase. This probably reflects the disproportionate 
number of patients with primary biliary cirrhosis in this group. 
The serum albumin was also significantly higher indicating 
better metabolic function in the non cirrhotic group compared to 
the cirrhotic patients.
Similar patterns are seen for antipyrine and indocyanine 
green (Tables 10.16 and 10.17). The clearance of both drugs is 
significantly reduced in the active cirrhotic group compared to 
the non cirrhotic group. Small increases occurred in the volume 
of distribution of both drugs, together with a marked 
prolongation of the half life. Once again the changes were 
greater for indocyanine green than antipyrine.
10.4.6 Comparison Between Survival Groups
During the study 29 patients died with liver disease, the 
details of the diagnosis, age, sex, follow up and cause of death 
are shown in Table 10.17. The majority of these deaths were as 
a direct result of one of the complications of liver disease. 
However, three patients died of disseminated non hepatic 
malignancy, two of which were bronchogenic carcinomas and one 
cervical carcinoma.
The results of the standard biochemical tests for the non­
survivors and survivors is shown in in Table 10.18. Comparison 
between the survivors and non-survivors shows that the serum 
albumin is signficiantly low (Survivors = 36.9 + 6.9g/l; Non­
survivors 28.8 + 6.5g/l; P<0.001), and serum bilirubin elevated
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(Survivors = 28.4 + 49.4umol/l : Non-survivors = 86.7 + 95.5 
umol/1 : P<0.001) in non-survivors. The non-survivors also 
showed higher serum globulins concentrations together with higher 
aspartate transaminase and gamma glutamyl transpeptidase 
activities. The alanine transaminase and alkaline phosphatase 
activities did not differ significantly between survivors and 
non-survivors.
The results of antipyrine kinetic in the survivors and non­
survivors are shown in Table 10.19. There were significant 
differences between the patients with liver disease and the 
control group for both the half-life and the clearance. Only the 
differences in the half-lives were signficantly different between 
survivors and non-survivors. (Survivors = 19.3 + 15.3hrs: Non­
survivors = 28.3 + 17.9hrs : PC0.05) (Figure 10.1).
The kinetic data for indocyanine green in survivors and non­
survivors are summarised in table 10.20. There are highly 
signficant alterations in all the kinetic parameters between the 
survivors and non-survivors. (Figure 10.2).
10.4.7 Multiple Regression Analysis
Analysis 1: The first analysis was designed to assess the
prognostic value of the antipyrine and indocyanine green 
kinetic data. The multiple regression analysis program was 
started with the patients age. The program was then offered 
all the antipyrine and indocyanine green kinetic parameters 
and their logarithmic transformations. The result of the
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initial step of the regressional analysis is shown in Table 
10.22. Any variable with a Chi-square > 4 and a P value < 
0.05 has additional prognostic value. The most useful 
antipyrine parameter was the half-life (Chi-square = 9.69) 
and the strength of this variable was irproved by log 
transformation (Chi-square = 11.57). None of the other 
antipyrine data had prognostic value.
Several of the ICG parameters were of prognostic 
inportance and the most powerful of the was the log of the 
half-life (Chi-square = 38.61). This variable was added to 
the age because it was the most powerful prognostic variable 
offered and the program is rerun. The results of the 
analysis are shown in Table 10.22 At this stage of the 
analysis none of the Chi-square or P values for inclusion in 
the model were significant.
Analysis 2; This analysis repeated Analysis 1 using the 
square root and reciprocal of the ICG half-life. The 
results of this analysis are shown in Table 10.23. The most 
powerful mathematical transformation of the ICG half-life 
was its reciprocal (Chi-square = 45.02; P<0.001)
Analysis 3: The following variables were used in this 
analysis;- Age, albumin, log bilirubin concentration, Log 
AST activity, Log GGT activity, prothrombin time, presence 
of portal hypertension, sex, presence of ascites, presence 
of encephalopathy, Childs Classification, reciprocal of ICG
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half-life and reciprocal of antipyrine half-life.
Results of this initial step of this analysis are shown 
in Table 10.24. The serum bilirubin is the only standard 
liver function test which significantly contributed to the 
analysis and in the next four steps the program eliminates 
ALT, Prothrombin time, AST and GGT (Table 10.25). At this 
stage the program accepted the reciprocal of the ICG half- 
life with the result that the serum bilirubin became 
redundant and was removed. The final result of the second 
analysis is shown in Table 10.26. There were now only three 
significant variables age, serum albumin concentration and 
the reciprocal of ICG half-life. Of these, the serum 
albumin was exerting only a very weak influence (Chi-square 
= 2.75; P=0.097).
Analysis 4: This analysis repeated analysis 2 using all the 
same variables but on this occasion not allowing the 
redundant variables to be discarded. Again the program was 
started with age and the standard biochemical liver function 
tests and these variables are forced to stay in the 
analysis. Only the presence of ascites and the reciprocal 
of ICG half-life exceeded the limits for inclusion (Table 
10.27) but when the ICG tl/2 was included then the 
significance of ascites was lost (Chi-Squared = 0.99, p = 
0.319).
10.5 CONCLUSION
This is the first large study which compares kinetic data
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for the elimination of low and high hepatic extraction ratio 
drugs using multiple regressional analysis. It confirms previous 
work showing that liver disease is associated with impairment of 
the excretion of antipyrine (BRANCH et al 1973 and 1976(b); 
ANDREASEN 1974, 1975, 1976(a); FARRELL et al 1978; KRAUS et al 
1980) and indocyanine green (BRANCH et al 1976(b); GILMORE et 
al 1982).
For the different diagnostic groups the pattern of 
abnormality in the kinetic data generally shows a reduced 
clearance of both drugs with little change in the volume of 
distribution, so that there is a concomitant increase in the 
elimination half life. The only exceptions were the 23 patients 
with primary biliary cirrhosis where there was a marked reduction 
in the volume of distribution of antipyrine. This change in 
distribution was not seen with indocyanine green. This does not 
reflect the severity of the disease in the PBC group as they 
appeared to have relatively mild liver disease, judged from the 
standard liver function tests and the incidence of complications. 
However, one of the features of primary biliary cirrhosis is a 
marked increase in the total serum lipids particularly the 
phospholipids and total cholesterol (SHERLOCK 1975). These 
changes are not seen to the same degree in other forms of liver 
disease. Measurement of the distribution of antipyrine is a 
standard method for determining total body water (SOBERMAN et al 
1949) and so the changes seen in primary biliary cirrhosis may 
reflect a reduction in the total body water content, consequent 
upon an increase in total body lipid content. A previous study 
of antipyrine metabolism in patients undergoing dietary
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manipulation, showed that following a high saturated fat diet 
there was a rise in the serum cholesterol and a fall in the 
volume of distribution of antipyrine (ANDERSON et al 1979).
The differences in indocyanine green clearance tended to be 
greater than the differences in antipyrine clearance in all the 
groups. In the encephalopathic patients there was a 45% 
reduction in 103 clearance and a 2% reduction in AP clearance, 
similarly for the ascitic group (54% vs 16%) and for the portal 
hypertension group (39% vs 14%). Indocyanine green is extracted 
and excreted by the liver without biochemical transformation. It 
has a high hepatic extraction ratio so that its rate of 
elimination is primarily dependent on the functional liver blood 
flow. For antipyrine the rate of elimination is primarily 
dependent on hepatic metabolism. If the primary factor 
determining the occurence of a complication of liver disease was 
the hepatic metabolic capacity then the clearance of antipyrine 
should be a more sensitive indicator of complicated liver disease 
than indocyanine green. The observation that indocyanine green 
appears to be a better indication of liver dysfunction suggests 
that the functional liver blood flow is more important than 
hepatic metabolic capacity in determining the occurence of 
conplications. In chronic liver disease there is a reduction in 
functional liver blood flow because of the porto-systemic 
shunting of blood through extra and intrahepatic connections 
(POPPER et al 1952).
This concept is further supported by the observation that 
concentrations of cytochrome P-450, and activities of aminopyrine 
demethylation, P-nitrosonisole demekthylation and NADPH-
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cytochrome C reductase in liver biopsies show little alteration 
in mild liver disease (MAY et al 1974) and are only reduced in 
the presence of very severe disease (SCHOENE et al 1972). The 
relative importance of ICG elimination as a test of liver 
function is further emphasised by the 57% reduction in non­
survivors with liver disease compared to a reduction of 44% in 
antipyrine clearance and 22% in serum albumin. The only factor 
which showed a greater percentage change in the non-survivors was 
the serum bilirubin which was elevated by 96%.
The Cox Proportional hazard analysis suggests that ICG 
elimination has prognostic importance independent of any other 
factor measured with the exception of age. The analysis also 
reveals that the strongest ICG parameter is the half life. 
Previous studies of the use of drugs as probes of liver 
dysfunction have tended to concentrate on the measurement of the 
clearance of the drug as it is a purer measurement of organ 
function. The half life is dependent on the clearance and the 
volume of distribution. Both of these factors are altered in 
liver disease so that the half life may be a more suitable 
measurement of the severity of liver disease.
These data suggest the relative importance of indocyanine 
green elimination as a measurement of the severity of liver 
disease. They suggest that an important factor in determining 
the deterioration of function that occurs in liver disease is the 
mismatching of functional hepatocytes with blood flow as a result 
of intra and extrahepatic portosystemic shunting.
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TABLE 10.1 DETAILS OF AGE AND SEX IN CONTROL SUBJECTS
AND PATIENTS WITH LIVER DISEASE
AGE (yrs) SEX
n Mean SD SEM Female(%) Male(%)
CONTROL 40
LIVER DISEASE 116
PRIMARY BILIARY 25 
CIRRHOSIS
CHRONIC ACTIVE 
HEPATITIS
12
ALCOHOLIC LIVER 65 
DISEASE
OTHER LIVER 
DISEASE
14
54.1 13.4 2.1 18 (46) 21 (54)
53.9 12.0 1.1 59 (51) 57 (49)
61.3++ 9.3 1.9 24 (96) 1*(4)
53.6 13.7 3.9 9 (75) 3 (25)
51.6 11.4 1.4 21(31) 44 (69)
51.8 13.3 3.6 5 (36) 9 (64)
Statistics by Chi-squared best Comparison with Control Group 
* = p < 0.05
Statistics by analysis of variance Comparison with Control Group
-r+ =  p  <  0 . 0 0 1
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TABLE 10.2 DETAILS OF THE MAJOR COMPLICATIONS OF LIVER
DISEASE IN EACH DIAGNOSIS GROUPS
PRIMARY CHRONIC ALCOHOLIC OTHER
LIVER BILIARY ACTIVE LIVER LIVER
DISEASE CIRRHOSIS HEPATITIS DISEASE DISEASE
n (%) n (%) n (%) n (%) n (%)
ENCEPHALOPATHY
Absent
Present
84 (73) 
32 (27)
23 (92) 
2 (8)
9 (75) 
3 (25)
42 (65) 
23 (35)
10 (71) 
4 (29)
ASCITES
Absent 76 (66) 22 (88) 8 (67) 36 (55) 10 (71)
Present 40 (34) 3 (12) 4 (33) 29 (45) 4 (29)
PORTAL HYPERTENSION
No Varices 76 (67) 18 (72) 10 (84) 42 (65) 9 (64)
Var ices 16 (14) 6 (24) 1 (8.5) 9 (14) 0 (0)
Previous
Variceal
Bleeding 19 (17) 1 (4) 0 (0) 14 (21) 4 (29)
Portocaval
Shunt 2 (2) 0 (0) 1 (8.5) 0 (0) 1 (7)
No significant differences by Chi-Squared Test
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TABLE 10.18 CAUSE OF DEATH IN 29 PATIENTS DYING WITH LIVER DISEASE
NO. DIAGNOSIS AGE SEX FOLLOW UP 
(months)
CAUSE OF DEATH
1 PBC 67 F 36 Variceal Bleed
3 PBC 59 F 8 Hepatorenal Failure
130 PBC 67 M 20 Hepatorenal Failure
2 CAH 74 F 15 Encephalopathy
32 CAH 39 F 17 Encephalopathy
111 CAH 58 M 4 Liver Failure
150 CAH 63 F 1 Liver Failure
191 CAH 45 F 14 Carcinoma of Cervix
6 ALD 50 F 32 Liver Failure
10 ALD 58 M 20 Myocardial Infarct
16 ALD 65 F 32 Septicaemia
24 ALD 58 F 35 Bronchogenic Carcinoma
25 ALD 62 M 24 Variceal Bleed
53 ALD 66 F 27 Bronchogenic Carcinoma
63 ALD 68 M 4 Liver Failure
76 ALD 62 F 1 Liver Failure
94 ALD 61 M 4 Variceal Bleed
127 ALD 50 M 4 Liver Failure
139 ALD 56 M 4 Hepatocellular Carcinoma
144 ALD 61 M 1 Liver Failure
152 ALD 61 M 3 Liver Failure
159 ALD 68 M 10 Hepatorenal Failure
205 ALD 67 M 16 Liver Failure
210 ALD 48 F 3 Liver Failure
233 ALD 40 M 1 Hepatorenal Failure
5 IPH 58 M 28 Hepatorenal Failure/Portal 
vein thrombosis
14 CC 64 F 14 Cardiac Failure
26 CC 64 F 14 Liver Failure
86 CC 76 M 12 Hepatorenal Failure
PBC = PRIMARY BILIARY CIRRHOSIS 
CAH = CHRONIC ACTIVE HEPATITIS 
ALD = ALCOHOLIC LIVER DISEASE 
IPH = IDIO PORTAL HYPERTENSION 
CC = CRYPTOGENIC CIRRHOSIS
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TABLE 10.22 RESULTS OF THE INITIAL STEP OF SURVIVAL ANALYSIS 1
VARIABLE CHI-SQUARE 
TO ENTER
CHI-SQUARE 
TO REMOVE
P-VALt
AGE - 4.26 0.039
Antipyrine Tl/2 9.69 - 0.002
Antipyrine Vd 5.04 - 0.025
Antipyrine VdAg 5.64 - 0.018
Antipyrine TB cl 0.84 - 0.360
Antipyrine TB cl/kg 1.27 - 0.261
ICG Tl/2 20.77 - <0.001
ICG Vd 5.29 - 0.021
ICG vdAg 2.72 - 0.010
ICG TB cl 25.79 - <0.001
ICG TB ciAg 24.54 - <0.001
ICG WB cl 26.06 - <0.001
ICG WB ciAg 28.41 - <0.001
LOG Antipyrine Tl/2 11.57 - <0.001
LOG Antipyrine Vd 5.86 - 0.016
LOG Antipyrine VdAg 4.75 - 0.029
LOG Antipyrine TB cl 3.54 - 0.060
LOG Antipyrine TB cl/kg 4.61 - 0.032
LOG ICG Tl/2 41.62 - <0.001
LOG ICG Vd 5.90 - 0.015
LOG ICG vdAg 4.00 - 0.046
LOG ICG TB cl 25.10 - <0.001
LOG ICG TB ciAg 21.58 - <0.001
LOG ICG WB cl 25.96 - <0.001
LOG ICG WB ciAg 29.01 - <0.001
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TABLE 10.23 FINAL RESULT OF SURVIVAL ANALYSIS 1
VARIABLE CHI-SQUARE 
TO ENTER
CHI-SQUARE 
TO REMOVE
P-VALUE
AGE - 13.96 0.0002
ANTIPYRINE Tl/2 0.14 - 0.7090
ANTIPYRINE Vd 0.02 - 0.9004
ANTIPYRINE Vd/kq 0.02 - 0.8930
ANTIPYRINE TB Cl 0.34 - 0.5613
ANTIPYRINE TB CiAg 0.32 - 0.5701
ICG Vd 0.26 - 0.6128
ICG vdAg 0.69 - 0.4075
ICG TB Cl 0.27 - 0.6058
icg ciAg 0.85 - 0.3566
ICG WB Cl 0.34 - 0.5577
icg w b ciAg 1.23 - 0.2682
LOG ANTIPYRINE Tl/2 0.11 - 0.7357
LOG ANTIPYRINE Vd 0.19 - 0.6601
LOG ANTIPYRINE VdAg 0.06 - 0.8045
LOG ANTIPYRINE TB cl 0.23 - 0.6304
LOG ANTIPYRINE TB ciAg 0.09 - 0.7658
LOG ICG Tl/2 - 41.62 0.0001
LOG ICG Vd 0.10 - 0.7568
LOG ICG vdAg 0.28 - 0.5998
LOG ICG TB cl 0.00 - 0.9972
LOG ICG TB ciAg 0.00 - 0.9881
LOG ICG WB cl 0.02 - 0.8832
LOG ICG w b ciAg 0.18 - 0.6749
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TABLE 10.24 MULTIPLE REGRESSION ANALYSIS OF VARIOUS TRANSFORMATIONS 
OF INDOCYANINE GREEN HALF LIFE
VARIABLE CHI-SQUARE CHI-SQUARE P-VALUE
TO ENTER TO REMOVE
AGE - 4.43 0.035
ICG Tl/2 20.77 - <0.001
LOG ICG Tl/2 38.61 - <0.001
SQUARE ROOT ICG Tl/2 29.84 - <0.001
RECIPROCAL ICG Tl/2 45.02 - <0.001
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TABLE 10.25 INITIAL STEP OF ANALYSIS 3
STEP 1
VARIABLE CHI-SQUARE 
TO ENTER
CHI-SQUARE 
TO REMOVE
P-VALUE
AGE - 4.09 0.043
ALBUMIN - 2.31 0.129
LOG BILIRUBIN - 8.48 0.004
LOG AST - 1.29 0.256
LOG ALT - 0.40* 0.525
LOG GGT - 3.52 0.061
PROTHROMBIN TIME - 0.80 0.370
SEX 1.53 - 0.216
PORTAL HYPERTENSION 1.22 - 0.269
ASCITES 4.64 - 0.031
ENCEPHALOPATHY 2.00 - 0.158
CHILDS 0.65 - 0.419
RECIPROCAL ICG Tl/2 9.73 - 0.002
RECIPROCAL ANTIPYRINE 
Tl/2
0.00 0.948
* REMOVED
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TABLE 10.26 SUMMARY OF STEPS FOR ANALYSIS 3
STEP VARIABLE
ENTERED
VARIABLE
REMOVED
IMPROVEMENT IN 
CHI-SQUARED P VALUE
1 - ALT 0.403 0.525
2 - PROTHROMBIN TIME 0.714 0.398
3 - AST 0.540 0.463
4 - GGT 1.966 0.161
5 RECIPROCAL ICG 
Tl/2
9.702 0.002
6 — BILIRUBIN 1.405 0.236
TABLE 10.27 RESULTS OF ANALYSIS 3
-
VARIABLE COEFFICIENT
STANDARD
ERROR
CHI-SQUARE 
TO REMOVE P-VALUE
AGE 0.08 0.03 12.17 0.005
ALBUMIN -0.07 0.04 2.75 0.0974
Reciprocal ICG 
Tl/2 -24.66 7.67 17.05 <0.0001
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TABLE 10.28 FINAL RESULTS OF ANALYSIS 4
VARIABLE
CHI-SQUARE 
TO ENTER
CHI-SQUARE 
TO REMOVE
AGE
ALBUMIN
BILIRUBIN (LOG)
J
ALT ] - are
i
in and may not be removed
J
AST ]
J
GGT ]
iJ
PROTHROMBIN TIME ]
SEX 2.36 0.125
PORTAL HYPERTENSION 1.88 0.170
ASCITES 5.84 0.016
ENCEPHALOPATHY 1.54 0.215
CHILDS 0.22 0.639
RECIPROCAL OF ICG Tl/2 6.38 0.012
RECIPROCAL OF ANTIPYRINE 
Tl/2
0.05 0.822
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FIGURE 10.1 ANTIPYRINE HALF-LIFE IN CONTROL SUBJECTS, SURVIVORS AND 
NON SURVIVORS WITH LIVER DISEASE (means +1 SD) 
Statistics by one way analysis of variance.
ANTIPYRINE 
HALF LIFE 
(hours)
X
***
40- * * * = P < 0 . 0 0 1  
Disease group vs Control - 3 f * = P < 0  01 
Survivors vs Non survivors X = p<0 .05
**
30-
20-
10-
,
( |
CONTROLS SURVIVORS
(n*32) (n= 75)
i
NON SURVIVORS
(n=27)
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FIGURE 10. INDOCYANINE GREEN HALF-LIFE IN CONTROL SUBJECTS, 
SURVIVORS AND NON-SURVIVORS WIIH LIVER DISEASE (means + 
I SD) . Statistics by one way analysis of variance.
INDOCYANINE 
HALF LIFE 
(min)
X X X
* * *
30-
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FIGURE 10 MA1HEMETICAL TRANSFORMATIONS OF INDOCYANINE GREEN HALF- 
LIFE.
No. of Observations
25n
9 13 17 21 25 29 33 37 41 45 51 55 <55Middle of
Interval
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LOG OF INDOCYANINE GREEN HALF LIFE
5
5
5
Middle of 0 -45  105 -165 -225 -285 -345 -405 -465
Interval
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FIGURE .4 ESTIMATES OF SURVIVAL FUNCTIONS FOR DIFFERENT VALUES 
OF INDOCYANINE GREEN HALF-LIFE IN A PATIENT AGED 50.
ESTttMTED INDOCYANINE GREEN
SURVIVAL FUNCTION HALF LIFE (mins)
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C H A P T E R  11
BETA-ADRENERGIC BLOCKADE .WITH NADOLOL IN PORTAL HYPERTENSION
250
11.1 SUMMARY
The effect of Nadolol 160mg/day on antipyrine and 
indocyanine green kinetics and wedged hepatic vein pressure was 
assessed in 6 patients with hepatic cirrhosis and portal 
hypertension. There was a significant reduction in wedged 
hepatic vein pressure during treatment with nadolol (Nadolol =
13.1 + 3.6 'iranHg: Placebo = 19.9 + 5.6 mmHg). There were no
significant alterations in the standard liver function tests, 
antipyrine or indocyanine green kinetics.
These data show that Nadolol produces a fall in portal 
pressure similar to that of propranolol. Nadolol is excreted by 
the kidney so that its elimination should be predictable even in 
patients with severely compromised liver function.
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11.2 INTRODUCTION
A mortality of up to 80% is associated with bleeding from 
oesophageal varices (ORIOFF et al 1967, GRAHAM and SMITH 1981). 
In the acute management of variceal bleeding drugs have been used 
to lower the portal pressure. Initially vasopressin (BAUM and 
NAUSBAUM 1971, CONN et al 1975) was popular, then its synthetic 
analogue triglycyl vasopressin (Glypressin) (FREEMAN et al 1982) 
and more recently with somatostatin (THULIN et al 1979, BOSCH et 
al 1981). These agents have to be administered parenteral ly and 
are therefore unsuitable for chronic administration either in 
the primary prophylaxis of variceal bleeding or in the secondary 
prevention of rebleeding.
A reduction in portal pressure has been demonstrated with 
the beta-adrenergic blocking drugs propranolol (HILION et al 
1982, LEBREC et al 1981 and 1982, RECTOR 1986), atenolol (HILLON 
et al 1982), and metoprolol (WESTABY et al 1985), a selective 
beta 2 blocker (BIHARI et al 1984), and the alpha receptor 
blocker prazosin (MILLS et al 1984). These drugs can be 
administered chronically and the use of these drugs in the 
secondary prevention of variceal bleeding has been investigated 
with inconclusive results. In a selected group of patients with 
portal hypertension a reduction in the incidence of rebleeding in 
patients treated with propranolol has been shown (LEBREC et al 
1981). Similar studies have failed to confirm this finding 
(BURROUGHS et al 1983, CONN 1982 and 1984).
Propranolol is a lipid soluble drug with a high first pass 
metabolism with a low systemic availability. In patients with
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chronic liver disease there is an increase in its systemic 
availability (BRANCH et al 1976, PESSA¥RE et al 1978), with 
marked increases in the steady state concentrations (WOOD et al 
1978), and an increase in the unbound fraction of the drug, all 
of which result in an increased pharmacodynamic response (ARTHUR 
et al 1985). The therapeutic dose of propranolol is therefore 
difficult to predict in cirrhotic patients and concern has been 
expressed over the possibility of excessive beta-blockade in 
these patients (POSNER et al 1982, BURROUGHS et al 1983). 
Propranolol also produces a marked reduction in liver blood flow 
(WEISS et al 1978). This reduction in liver blood flow may 
theoretically reduce liver function in a group of patients with 
already compromised liver function. There are therefore doubts 
about the efficacy and suitability of propranolol as a 
therapeutic agent for the treatment of portal hypertension.
Nadolol is a water soluble non-cardioselective beta- 
adrenergic blocking drug with a long duration of action (OPIE
1980), which is mainly excreted by the kidney (HEEL et al 1980). 
The aim of this study is to evaluate the effect of nadolol on 
portal pressure, hepatic monoxygenase enzyme activity and 
apparent liver blood flow.
11.3 PATIENTS AND METHODS
Six patients admitted with upper gastrointestinal bleeding 
from oesophageal varices were studied. The source of blood loss 
was demonstrated by endoscopy, at which the varices were
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injected with ethanolamine oleate. Hepatic cirrhosis was proven 
histologically and was attributed to alcohol in all 6. Only one 
patient was female. A double blind placebo controlled crossover 
study design was used. When the patients had been haemo- 
dynamically stable for at least five days with no evidence of 
blood loss, they were randomly allocated to receive either 
nadolol 160mg per day or a matching placebo tablet. Ihey 
continued this medication for 28 days as an outpatient.
Clinical laboratory and haemodynamic measurements were made 
following the first 28 day treatment period and again after the 
patient had been crossed over onto the other medication for a 
further 28 day treatment period. Clinically the patients were 
assessed for evidence of porto-systemic encephalopathy, ascites 
and the resting pulse and blood pressure were measured.
Laboratory tests included the measurement of haemoglobin, serum 
urea, creatinine, electrolytes, and standard biochemical liver 
function tests. Ihe portal pressure was determined by passing a 
Cournand catheter through the femoral vein into the hepatic vein 
for the measurement of free and wedged hepatic vein pressure. The 
difference between these two measurements is termed the porto- 
hepatic venous pressure gradient and is accepted as an indirect 
measurement of portal pressure (BOYER et al 1977). Cardiac output 
was measured by a thermodilution method using a Swan-Ganz 
catheter passed into the main pulmonary artery (FORRESTER et al 
1972). A mean of three measurements was used.
Antipyrine clearance and indocyanine green clearance were 
measured using the protocols discussed in Chapter 7. During the 
two months treatment period no further gastrointestinal bleeding
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occured, and the patients received no other medication. In one 
patient no catheterisation data is available because of technical 
problems with the equipment.
The results are express as means + the standard deviation.
In order to avoid making assumptions about the distributions of 
the data the groups were analysed using paired Wilcoxon sign rank 
tests. All patients gave informed written consent and the 
project was approved by the local ethical committee.
11.4 RESULTS
There was no alteration in the standard biochemical liver 
function tests (Table 11.1). No patient developed evidence of 
gastrointestinal blood loss, ascites or portosystemic 
encephalopathy during the study. There was no significant 
alteration in the disposition of antipyrine or indocyanine green 
between the two phases (Table 11.2). There was a significant 
reduction in the wedged hepatic vein pressure in patients during 
the nadolol phase compared to the placebo phase (19.9 + 5.6 mmHg 
vs 13.1 + 3.6 mmHg: PC0.05). There was a significant reduction in 
the heart rate and a trend towards a reduced cardiac output 
during the nadolol phase but this failed to reach statistical 
significance.
11.5 DISCUSSION
This study demonstrates a reduction in wedged hepatic vein 
pressure of 34% following one months treatment with nadolol. This 
reduction is similar to that previously demonstrated with nadolol
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GATTA et al 1984), and other non cardioselective beta blockers.
It is greater than that seen with the cardioselective beta 
blockers atenolol (MILLS et al 1984) or metoprolol (WESTABY et al 
1984, WESTABY et al 1985).
Ihe portal tract is devoid of beta receptors (RICHARDSON and 
WITHRINGTON 1981). The major effect of betablockers in portal 
hypertension is to reduce cardiac output, which results in a 
reflex constriction of the hepatic artery, as a consequence of 
the reduction of the inflow to the liver there is a fall in 
portal pressure. The non cardioselective beta blockers have an 
additional action by blocking the vasodilator beta 2 receptors in 
the splanchnic circulation this leading to unopposed alpha 
stimulation and vasoconstriction and a fall in the blood flow 
into the portal circulation (LEBREC et al 1982). This additional 
mode of action may explain the greater reduction in portal 
pressure with the nonselective beta blockers.
There was no significant alteration in either the 
disposition of antipyrine or indocyanine green during therapy 
with nadolol. Similar results have been demonstrated in healthy 
volunteers (PARKER et al 1984). Propranolol has been shown to 
inhibit the clearance of antipyrine (GREENBLATT et al 1978) and 
indocyanine green (PARKER et al 1984). Propranolol has been 
shown to produce a marked reduction in effective liver blood flow 
which was not seen with the cardioselective beta blocker 
metoprolol (WESTABY et al 1984). The reduction of liver blood 
flow by propranolol has been implicated in the production of 
portosystemic encephalopathy (TARVER et al 1983).
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This study demonstrates that nadolol has a similar effect on 
portal pressure to other noncardioselective beta blockers. In 
patients with abnormal liver function nadolol has several 
theoretical advantages. It is excreted by the kidney so that its 
elimination should be predictable even in severe liver failure. 
There is no inhibition of the hepatic monooxygenase enzymes and 
this reduces the likelihood of major drug interactions. The 
failure to reduce indocyanine green clearance suggests that total 
liver blood flow may be relatively unimpaired during nadolol 
therapy but this requires confirmation by a more direct 
measurement of liver blood flow. This suggests that nadolol may 
be a more suitable beta blocking drug for use in patients with 
severely compromised liver function.
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Table 11.1 NADOLOL STUDY - STANDARD BIOCHEMICAL LIVER FUNCTION TESTS
ALBUMIN BILIRUBIN SGOT SGPT GGT
(g/i) (mmol/1) (iu/1) (iu/1) (iu/1)
PLACEBO
1. 30 18 114 46 242
2. 32 10 22 14 254
3. 33 32 32 24 57
4. 51 15 50 53 224
5. 42 17 54 42 71
6. 37 15 41 34 113
MEAN 37.5 17.8 52.2 35.5 160.1
SD 7.9 7.5 32.5 14.5 89.9
SEM 3.2 3.0 13.3 5.9 36.7
NADOLOL
1. 34 24 109 36 807
2. 31 15 21 22 268
3. 34 5 25 70 52
4. 48 21 46 69 275
5. 38 15 58 38 58
6. 36 17 42 38 122
MEAN 36.8 16.2 50.2 45.5 263.7
SD 5.9 6.5 31.9 19.5 283.7
SEM 2.4 2.7 13.0 8.0 115.8
STATISTICS BY PAIRED WILCOXON SIGN RANK TESTS
P VALUE NS NS NS NS NS
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C H A P T E R  12
PHARMACOKINETIC AND PHARMACODYNAMIC RESPONSES TO MIDAZOLAM IN PATIENTS 
WITH HEPATIC CIRRHOSIS AND NORMAL CONTROLS
261
12.1 SUMMARY
Midazolam kinetics and psychomotor function were studied 
after an intravenous dose of 0.075 mg/kg body weight in 7 
patients with alcoholic cirrhosis and 8 patient controls. Pour of 
the 7 cirrhotics died of conplications of their liver disease 
within 6 months of completion of the study. The clearance of 
midazolam was significantly impaired in the cirrhotic patients 
(Cirrhotics = 4.0 + 0.4 ml/ml/kg; Oontrols = 15.5 + 4.7 
ml/min/kg: p < 0.003). These patients also had evidence of 
greater sedation than the control group for up to 6 hours after 
the dose was administered (p<0.05). The clearance of midazolam 
did not correlate significantly with the serum albumin or 
bilirubin or with the kinetics of antipyrine or indocyanine 
green. This study demonstrates significant delay in the 
elimination of midazolam and reduction in psychomotor function in 
patients with severe alcoholic liver disease. Caution should be 
exercised in using this drug for pre-medication in such patients 
prior to endoscopic examination.
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12.2 INTRODUCTION
In chronic liver disease tine disposition and elimination of 
many lipid soluble drugs are altered (HOYUMPA et al 1978, KOCH- 
WESER and WILLIAMS 1983). The hepatic metabolism of these agents 
may be determined by the capacity of the oxidising and 
conjugating enzyme systems and the liver blood flow (ROWLAND et 
al 1973), both of which may be inpaired in the presence of 
cirrhosis (WILKINSON and SHAND 1976). The pharmacological 
response to a drug may also be abnormal in liver disease and, in 
particular, the cerebral sensitivity to sedative drugs may be 
increased (READ et al 1969).
Patients with chronic liver disease are frequently referred 
for upper gastrointestinal endoscopy either for the diagnostic 
assessment of gastrointestinal haemorrhage or dyspepsia or for 
therapeutic injection sclerotherapy of oesophageal varices 
(MacDOUGALL et al 1982). Diazepam is commonly used as the 
premedicating sedative, but in patients with liver disease the 
half life of this drug may exceed 100 hours (KLOTZ et al 1973), 
and some patients exhibit increased cerebral sensitivity 
(McCONNELL et al 1982, BRANCH et al 1976).
Midazolam is a new benzodiazepine consisting of an imidazole 
ring fused at the 1.2 position with a diazepine ring (Figure 
12.1). Its hypnotic action is brief and its elimination half- 
life is under four hours and in some patients is as short as two 
hours (ALLONEN et al 1981, GREENBLATT et al 1981, SMITH et al
1981). These properties make it a potentially useful sedative 
for minor invasive procedures. It is metabolised in the liver by 
hydroxylation and conjugation with glucuronic acid (HEIZMANN and
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ZEIGLER 1981). It has a high hepatic extraction ratio (ALLONEN 
et al 1981) and so its elimination would be expected to be 
dependent on liver blood flow.
The aims of this study were to compare the pharmacokinetic 
profile and pharmacodynamic response following an intravenous 
dose of midazolam in patients with hepatic cirrhosis and those 
with normal liver function. Secondly, to assess the value of 
antipyrine and indocyanine green kinetics in predicting midazolam 
pharmacokinetics and dynamics.
12.3 PATIENTS
Seven patients with hepatic cirrhosis and eight patient 
controls agreed to take part in the study. All gave written 
informed consent to inclusion in the study which was approved by 
the local hospital ethical committee.
The cirrhotic patients were aged between 39 and 54 years and 
all had biopsy proven alcoholic cirrhosis. They were referred 
for endoscopy for the assessment of portal hypertension. Five of 
the 7 patients had previously bled from oesophageal varices. Two 
had previous episodes of portosystemic encephalopathy, but there 
was no clinical evidence of this on entry to the study. Four of 
these patients died within six months of completion of the study 
from complications of their liver disease.
The patient controls were aged between 37 and 62 years,
They showed no clinical evidence of liver disease and had normal 
biochemical liver function tests. They were all referred for 
diagnostic upper gastrointestinal endoscopy for suspected peptic 
ulcer disease.
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No patient was receiving any drug known to alter hepatic 
drug metabolism or liver blood flow and all patients were 
instructed to abstain from ethanol for one week prior to the 
study.
12.4 METHODS
See Chapter 7.2 for antipyrine method.
See Chapter 7.3 for indocyanine green method.
See Chapter 7.5 for Midazolam method.
See Chapter 7.6 for pharmacokinetic analysis.
See Chapter 7.7 for pharmacodynamic assessment.
12.5 RESULTS
All patients became overtly sedated as a result of the 
administration of midazolam and endoscopy was accomplished with 
minimal difficulty. The standard biochemical liver function 
tests were all significantly deranged in the cirrhotic patients 
(TABLE 12.1).
Pharmacok inet ics
The elimination of antipyrine and indocyanine green in the 
two groups is shown in TABLE 12.2? there was a highly significant 
prolongation of the half lives of both drugs in the cirrhotic 
patients (p<0.001), with a concomitant reduction in the 
clearance (p<0.05 and p<0.001).
The metabolism of midazolam was inpaired in the cirrhotic 
group compared to the controls. In two patients ( A and B in 
figure 12.2) high plasma levels of midazolam were found
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throughout the duration of the study. If the values are true 
then the greatly prolonged estimated half life would preclude 
the calculation of acceptable kinetic parameters. Another 
possibility is that these results are due to some substance 
interfering with the assay, but attempts have failed to identify 
an interfering peak. The analytical data form these patients are 
therefore plotted separately and are not included in the 
statistical analysis of the midazolam kinetics. Using a two 
compartment model the clearances of midazolam were reduced in the 
cirrhotics (cirrhosis = 4.6 + 5.7ml/min/kg vs controls = 15.5 + 
4.7ml/min/kg: p<0.003). There was no significant alteration in 
the volume of distribution between the two groups (cirrhotics =
29.1 + 4.1 L; controls = 29.5 + 6.5 L).
There were no significant correlations between the clearance 
of midazolam with the serum albumin, serum bilirubin, or with the 
clearances or half lives of antipyrine or indocyanine green.
Pharmacodynamics
All the control and cirrhotic patients were included in these 
analyses.
1. Choice Reaction Time
The CRT 1 (recognition time) and CRT 2 (total reaction 
time) values for both groups are compared in FIGURES 12.3 
and 12.4. There was no significant difference in the mean 
baseline CRT 1 or CRT 2 between the cirrhotic and control 
groups. Neither the CRT 1 nor CRT 2 were significantly 
prolonged in the control patients at any time during the 
course of the study. In the cirrhotic patients both the CRT
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1 and 2 were prolonged conpared to the baseline values at 
all time points following the administration of midazolam 
and these differences were statistically significant at 1, 4 
and 6 hours (p<0.025). Comparison of the cirrhotic and 
control patients showed significant prolongation of the CRT 
1 at one hour (p<0.025), 4 hours (p<0.05) and 6 hours 
(p<0.025), and of the CRT 2 at 1, 2, and 6 hours (p<0.025 at 
all points) in the cirrhotic group (2 tailed Mann Whitney 
U-test).
2. Critical Flicker Elision Time
CFFI values for both groups are shown in FIGURE 12.5. 
The base line values in the cirrhotic patients were 
significantly lower than in the control group (p<0.05). In 
the control group there was a reduction in the threshold at 
60 minutes (p<0.05) after which the threshold returned to 
normal. In the cirrhotic patients the threshold was 
significantly reduced at 60, 120 and 240 minutes (p<0.025). 
Direct comparison between the groups was not performed 
because of the differing baseline values.
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12.6 DISCUSSION
.This study has demonstrated altered pharmacokinetics of 
midazolam in patients with chronic liver disease. There was a 
significant prolongation of the elimination half life of the drug 
with a concommitant fall in its clearance. The two patients with 
apparently high levels remain unexplained. If these are true 
levels the patients did not appear to be excessively sedated. 
Similar high levels have been demonstrated in critically ill 
patients receiving repeated doses of midazolam (ByATT et al 1984, 
BYRNE et al 1984).
The only objective evidence of psychomotor inpairment in the 
control patients was a reduced CFFT at one hour. Subjectively 
they were sedated sufficiently to allow endoscopy to be 
performed. Using the recognition time and the total reaction 
time there was objective evidence of psychomotor inpairment in 
the cirrhotic patients which was significant for up to 6 hours 
after the administration of midazolam. The maximum prolongation 
in CRT occurred in the cirrhotics at 2 hours (Figures 12.3 and 
12.4). This occurred when there was a small but significantly 
higher plasma midazolam than in the control patients. These 
results could be interpreted to suggest that there maybe 
increased cerebral sensitivity to midazolam in these patients 
with chronic liver disease.
The results of the critical flicker fusion threshold are 
difficult to interpret because of the significantly reduced 
baseline in the cirrhotic patients (this problem has also 
occurred in a similarly designed study, with another psychoactive 
agent [PARKER and ROBERTS 1983]). If this apparent initial
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abnormality represents subclinical portosystemic encephalopathy 
then the CFFT merits further study as a possible simple means of 
identifying and monitoring the early stages of this inportant 
complication.
The effect of chronic liver disease on the pharmacokinetics 
and pharmacodynamics of the benzodiazepines varies between the 
drugs (WILLIAMS and MAMELOCK 1980). The elimination half-life of 
diazepam is prolonged in cirrhotics, mainly due to a reduction in 
the volume of distribution (BRANCH et al 1976). A similar 
reduction in the elimination half-life of lorazepam has been 
attributed to a fall in the volume of distribution. (KRAUS et al 
1978). Chlordiazepoxide has a low intrinsic clearance and a 
high level of protein binding. In cirrhosis its both are reduced 
and the volume of distribution is increased producing a half-life 
which is markedly prolonged (ROBERTS et al 1978). The 
elimination of oxazepam, a conjugated benzodiazepine, appears to 
be unaltered in both acute viral hepatitis or in cirrhosis 
(SHULL et al 1976). Direct comparisons of midazolam and 
diazepam in patients without liver disease undergoing diagnostic 
endoscopy suggest that midazolam produces a more rapid onset of 
sedation, The degree of sedation is similar and the patient 
recall is less (CDLE et al 1983, WHITWAM et al 1983). This study 
demonstrates asignificant delay in the elimination of midazolam 
and increase in the degree of sedation produced for up to 6 hours 
following its administration to patients with severe alcoholic 
liver disease. Caution should therefore be exercised in
administering the drug to patients with chronic liver disease. 
These changes, however, may be less than those occurring with
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diazepam and midazolam may prove to be the benzodiazepine of 
choice in providing premedication for such patients who require 
to undergo a diagnostic or therapeutic endoscopic procedure.
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TABLE 12.1
CLINICAL DETAILS AND BIOCHEMICAL LIVER FUNCTION 
TESTS (Mean + SEM) IN CIRRHOTICS AND CONTROLS
ODNTROLS CIRRHOTICS
n = 8 n = 7
PGE RANGE (YRS) 37 - 42 39 - 54
WEIGHT (KG) 60.6 + 4.0 71.3 + 4.3
DOSE OF MIDAZOLAM (MG) 4.5 +0.1 5.4 + 0.3
BILIRUBIN (umol/L) 9.1 + 0.2 71.7 + 35.9 ***
ALKALINE PHOSPHATASE(iU/L) 87.9+6.1 231.2+61.0 ***
ALANINE TRANSFERASE (iU/L) 23.3 + 1.2 60.0 + 9.4 ***
ASPARTATE TRANSFERASE(iU/L) 22.6 + 2.6 39.7 + 7.4 *
GAMMA GLUTAMYL
TRANSPEPTIDASE (iU/L) 24.9+3.6 164.4 + 54.2 ***
ALBUMIN (g/1) 44.0 + 0.9 33.0 + 2.9 *
Statistics obtained by Mann Whitney U tests
* = p < 0.05
** = p < 0.025
*** = p < 0.001
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TABLE 12.2
ANTIPYRINE, INDOCYANINE GREEN AND MIDAZOLAM 
KINETICS (MEAN + SEM) IN CIRRHOTICS AND 
CONTROLS
CONTROLS 
n = 8
CIRRHOTICS 
n = 7
ANTIPYRINE
Half life (hours) 9.8 + 1.1 19.6 + 1.6 ***
Volume of Distribution 
(litres)
45.5 + 4.3 60.7 + 7.2
Clearance (ml/min/kg) 1.0 + 0.2 0.6 + 0.1 *
INDOCYANINE GREEN
Half life (mins) 4.1 + 0.3 27.9 + 8.3 ***
Volume of Distribution 
(litres)
4.1 + 0.4 4.5 + 0.3
Clearance (ml/min/kg) 12.4 + 1.4 2.6 + 0.7 ***
X
MIDAZOLAM
Clearance (ml/min/kg) 15.5 + 4.7 4.0 + 0.6 **
Volume of distribution 
(litres)
29.1 + 4.1 29.5 + 6.5
Statistics obtained by Mann Whitney U tests
x
cirrhotics n = 5
* = p < 0.05
** = p < 0.025
*** = p < 0.001
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FIGURE 12.1 CHEMICAL STRUCTURE OF MIDAZOLAM
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FIGURE 12.2: MIDAZOLAM PLASMA CONCENTRATIONS MEAN +SEM) IN 8 CONTROL
AND 5 CIRRHOTIC PATIENTS FOLLOWING AN INTRAVENOUS DOSE 
OF 0.075mg/kg BODY WEIGHT. ACTUAL PLASMA 
CONCENTRATIONS ARE PLOTTED FOR PATIENTS A AND B.
STATISTICAL ANALYSIS BY MANN WHITNEY U-TESTS.
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FIGURE 12. : RECOGNITION TIME (CRT 1; MEAN + SEM) IN 8 CONTROL
PATIENTS AND 7 CIRRHOTIC PATIENTS AFTER AN INTRAVENOUS
BOLUS OF 0.075 MG/KG OF MIDAZOLAM.
STATISTICAL ANALYSIS BY MANN WHITNEY U-TESTS COMPARING 
THE DIFFERENCE OF THE RESULTS AND THE BASELINES IN EACH 
GROUP.
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FIGURE 12. : TOTAL REACTION TIME (CRT 2; MEAN + SEM) IN 8 CONTROL
PATIENTS AND 7 CIRRHOTIC PATIENTS AFTER AN INTRAVENOUS
BOLUS OF 0.075 MG/KG OF MIDAZOLAM.
STATISTICAL ANALYSIS BY MANN WHITNEY U-TESTS COMPARING 
THE DIFFERENCE OF THE RESULTS AND THE BASELINES BETWEEN 
EACH GROUP.
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FIGURE 12. 5: CRITICAL FLICKER FUSION THRESHOLD (CFFT; MEAN + SEM)
IN 8 CONTROL PATIENTS AND 7 CIRRHOTIC PATIENTS AFTER AN
INTRAVENOUS BOLUS OF 0.075 MG/KG OF MIDAZOLAM.
STATISTICAL ANALYSIS BY MANN WHITNEY U-TEST ON THE 
COMPARISONS WITH THE BASELINE RESULTS FOR EACH GROUP. 
THE BASELINE DIFFERED SIGNIFICANTLY (P < 0.025)
BETWEEN THE GROUPS.
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C H A P T E R  13
GASTROINTESTINAL INTOLERANCE TO MEPTAZINOL IN CIRRHOSIS - A 
PHARMACOKINETIC EXPLANATION ?
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13.1 SUMMARY
Kinetic analysis was performed following single intravenous 
(25mg) and oral (200mg) doses of the novel partial opioid agonist 
meptazinol (Meptid) in patients with non-cirrhotic liver disease 
(NCLD) and biopsy-proven cirrhosis. Gomparison was made with a 
group of patients with normal hepatic function. There was no 
significant alteration in the plasma clearance of the drug 
(cirrhotics = 83.5 + 8.7 L/hr; NCLD = 98.4 + 11.0 L/hr; control 
= 78.5 + 7.3 L/hr). Following the oral dose, 7 out of 15 
cirrhotic patients vomited but only 1 patient in each of the 
other groups was unable to tolerate the drug (p = 0.06). This 
may be explained by very much higher peak meptazinol 
concentrations in the cirrhotic (n=8; 184 + 37ng/ml, p<0.01) and 
NCLD (n=8; 131 + 38ng/ml, p<0.05) patients than those of the 
controls (n=7; 53+ 12ng/ml) reflecting a mean four fold and two 
fold increase in oral bioavailability respectively (cirrhotics: 
n=8? 27.9 + 5.3%: p< 0.001? NCLD: n=7; 13.7 +3.9%: p<0.05?
controls: n=7; 6.5 + 1.3%). There.was no evidence of 
accumulation following chronic dosing with 20Omg meptazinol four 
times daily for 13 doses in 7 control, 7 NCLD and 6 cirrhotic 
patients as would be predicted by the lack of change in drug 
clearance. There were no detectable differences in psychomotor 
function measured objectively using the Leeds Psychomotor Tester 
or subjectively by linear analogue scoring between the groups in 
all three parts of the study.
The oral use of meptazinol in patients with chronic liver 
disease is limited by the development of nausea and vomiting 
rather than by the risk of excessive sedation. These data
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suggest that dosage reduction in cirrhotic patients is advisable 
when the drug is taken by mouth as the bioavailability is 
markedly increased but that none is necessary when meptazinol is 
administered parenteral ly.
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13.2 INTRODUCTION
Analgesics may precipitate episodes of portosystemic 
encephalopathy in patients with chronic liver disease (EESSEL & 
OONN 1972). This results from a combination of inpairment of 
the hepatic and/or renal elimination mechanisms for the drug and 
increased cerebral sensitivity to its pharmacodynamic properties. 
The metabolism of many commonly used analgesics, including 
pethidine (KLOTZ et al 1974), methadone (NOVICK et al, 1980), 
paracetamol (EORREST et al, 1977) and pentazocine (NEAL et al, 
1979), is inpaired in patients with hepatic cirrhosis. The 
elimination of morphine is only minimally reduced in such 
patients (PATWARDHAN et al 1981), although there is evidence of 
increased cerebral sensitivity to the drug (LAIDLAW et al 1969). 
This apparent increase in sedation may be the result of an 
increase in the free (unbound) fraction of the drug (OLSEN et al 
1975) or an increased density of opiate receptors in the frontal 
lobes and hypothalamus (ZENEROLI et al 1985).
Meptazinol (Meptid) (Figure 13.1) is a novel synthetic 
opioid analgesic which is effective in relieving pain associated 
with surgery (PAYMASTER 1977; HEDGES et al 1980), trauma 
(COPELAND 1983), renal colic (OOUTINHO 1980), and childbirth 
(NICHOLAS and ROBSON 1983). Its use is associated with less 
psychomotor inpairment than is seen with pentazocine (STACKER et 
al 1983) or with 0.8 mg/kg of ethanol (TEDESCHI et al 1984). 
Reported side effects have been minor, but about 10% of patients 
experience nausea and vomiting (DAVIES et al 1982; MOYES et al 
1979). Fbllowing oral administration meptazinol is rapidly 
absorbed from the gastrointestinal tract and is subject to
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substantial hepatic first pass metabolism with a bioavailability 
of around 9% in healthy subjects (NORBURY et al 1983). Within 
the liver, the major metabolic route is by conjugation with 
glucuronic acid and less than 5% of an administered dose is 
recovered unchanged from the urine (FRANKLIN et al 1976). 
Elimination half-life is around 2 hours and the binding to 
plasma protein is low at 27% (NORBURY et al 1983).
Meptazinol may be a suitable analgesic for use in patients 
with impaired liver function for two reasons. Firstly, hepatic 
conjugation is usually well maintained in liver disease (KRAUS et 
al 1978; SHULL et al 1976) and secondly, the low protein binding 
of the drug ensures that circulating concentrations of free drug 
would not be grossly altered from normal in patients with 
hypoproteinaemia. The aim of this study was to assess the 
pharmacokinetic profile and pharmacodynamic response to 
meptazinol in patients with cirrhotic and non-cirrhotic liver 
disease (NCLD) and to correlate any such changes with the 
standard biochemical liver function tests and the clearances of 
the model substances, indocyanine green and antipyrine.
13.3 PATIENTS
A total of ten patient controls, nine NCLD patients and 
fifteen patients with cirrhosis agreed to take part in the study. 
Eight of the cirrhotic patients were also taking spironolactone, 
but none of the other patients were on medication known to alter 
hepatic metabolism or liver blood flow. All gave written 
informed consent to their inclusion in the study, the protocol 
for which was approved by the Western Infirmary Ethical
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Committee.
The cirrhotic patients were aged between 28 and 68 with a 
mean age of 53 years. All had biopsy proven hepatic cirrhosis. 
Eleven patients had alcoholic liver disease, two had primary 
biliary cirrhosis, and one each had chronic active hepatitis and 
primary sclerosis cholangitis. Eleven of these patients had 
episodes of bleeding from oesophageal varices and six had 
previous evidence of portosystemic encephalopathy. No patient 
was frankly encephalopathic on admission to the study.
The NCLD patients were aged from 24 to 81 with a mean age of 
50 years. The aetiology of the liver disease was proven by liver 
biopsy in all cases and was due to alcohol in 6, pre-cirrhotic 
primary biliary cirrhosis in 2 and congenital hepatic fibrosis in 
1. This last patient was included in the NCLD group because he 
did not fulfil the histolological criteria for the diagnosis of 
cirrhosis. However, he had severe portal hypertension with large 
oesophageal varices. None of the patients had a history of 
portosystemic encephalopathy.
The control patients were aged between 21 and 65 with a mean 
age of 39 years. Two patients had duodenal ulcers, four had 
chronic constipation and four were undergoing investigation of 
chronic abdominal pain. None had clinical evidence of liver 
disease and all had normal biochemical liver function tests.
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13.4 METHODS
See Chapter 7.2 for antipyrine method.
See Chapter 7.4 for meptazinol method.
See Chapter 7.6 for pharmacokinetic methods.
See Chapter 7.7 for pharmacodynamic assessment.
The pharmacokinetics of meptazinol were studied after an 
intravenous dose of 25mg, and an oral dose of 200mg given in 
random order, with a delay of at least two weeks between each 
part of the study. The patients were fasted overnight prior to 
each study day and food was allowed 2 hours after meptazinol 
administration. The oral kinetics were then repeated following 
the chronic administration of the drug in a dose of 200mg four 
times daily for thirteen doses. Venous blood samples were taken 
at 0.25,0.5,0.75,1,1.5,2,3,4,6,8,12 and 24 hours after the 
intravenous dose and after the first and thirteenth oral dose of 
the drug. The samples were collected into glass lithium heparin 
tubes and centrifuged immediately. The plasma was separated and 
stored in glass tubes at -20 degrees Centigrade.. Plasma 
concentrations of meptazinol were determined by a modified" 
(NORBURY et al 1983) high pressure liquid chromatography method 
using fluorescence detection (FROST 1981). All samples for each 
patient were run in a single batch. The lower limit of detection 
of meptazinol was lOng/ml and the coefficient of variation was 5% 
at lOOng/ml and 9.9% at of lOng/ml.
The pharmacokinetic methods are described in Chapter 7.6.
The data was fitted using a one and a two compartment model and
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the comparison of these models is summarised in Table 13.4. For 
each patient the one conpartment model was selected unless the F 
statistic indicated that a two compartment model was more 
appropriate.
13.5 RESULTS '
Haemoglobin and creatinine concentrations together with the 
standard biochemical liver function tests are shown in Table 13.1. 
Ps expected evidence of inpaired hepatic function was seen for 
both liver disease groups.
The pharmacokinetics of antipyrine and indocyanine green are 
shown in Table 13.2; there were substantial prolongations of the 
half lives of both drugs in the cirrhotic group (p < 0.01 and p < 
0.001) compared with the controls indicating the severity of 
liver disease in this group of patients. The elimination of 
antipyrine was not significantly altered in the NCLD group but 
there was a small fall in the clearance of indocyanine green (p 
< 0.01) in these patients (Table 13.2).
13.5.1 Meptazinol Kinetics
Following the intravenous bolus of 25mg of meptazinol, there 
was no significant difference in the volume of distribution 
between the different patient groups (control = 175 + 21.5 
litres; NCLD = 144.0 + 22.8 litres; cirrhotic = 186.0 + 20.9 
litres. There were no differences in the total plasma clearance 
of meptazinol between the groups (control = 78.5 + 7.3 L/hr; NCLD 
= 98.4 + 11.0 L/hr; cirrhotic = 83.5 + 8.7 L/hr). Seven of the
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cirrhotics, and one each of the NCLD and control patients were 
unable to conplete the protocol because of severe nausea and 
vomiting following a single oral dose of the drug (Chi-Square 
Test : p = 0.06). The plasma concentration/time curves following 
the oral dose in those patients tolerating the drug are shown in 
Figure 13.3. The peak concentration attained was much higher in 
the patients with liver disease (cirrhosis: n=8, 184 + 37ng/ml/? 
p<0.002; NCLD: n=8, 131 + 38ng/ml; p<0.05; control: n=7, 53 + 
12ng/ml). The oral bioavailability of meptazinol was greatly 
increased in the cirrhotic patients (bioavailability = 27.9 +
5.3%; p<0.001) and NCLD group (bioavailability = 13.7 + 3.9%; 
p<0.05) compared to the controls (bioavailability = 6.5 + 1.3%) 
[Figure 13.4]. There was a significant correlation between the 
bioavailability of meptazinol and the serum bilirubin (r = 0.50; 
p < 0.05) and negatively with serum albumin (r = -0.46; p < 0.05) 
but not with the antipyrine (r = -0.37) or indocyanine green (r = 
-0.32) clearance.
Following chronic oral dosing for three days there was no 
significant increase in the area under the concentration time 
curves, time to maximum concentration, or the maximum 
concentration achieved in any of the groups compared to the 
values obtained following the single dose (Table 13.3).
13.5.2 Pharmacodynamics
There were no significant alterations in the CRT 1, CRT 2 or 
the CFFT at any time point in any of the groups following the 
single intravenous and oral doses or chronic administration of 
meptazinol (Figures 13.5, 13.6, 13.7). Analysis of the visual
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analogue scales showed no evidence of excessive sedation in any 
of the groups during any phase of the study.
13.6 DISCUSSION
This study has demonstrated the inportance of assessing the 
oral bioavailability of drugs in patients with liver disease, 
particularly those which undergo a substantial degree of first 
pass elimination. In cirrhotics, the clearance of meptazinol was 
reduced by only 13% but there was a 300% increase in the oral 
bioavailability of the drug. Three factors could contribute 
towards this latter finding. Firstly, the bioavailability of 
meptazinol is dependent on the rate of absorption of the drug 
from the gastrointestinal tract (NORBURY et al 1983). When 
absorption is rapid the capacity of the conjugating enzymes may 
be saturated resulting in an increased bioavailability. In this 
study the time to maximum concentration did not differ 
significantly between the three groups indicating that it is 
unlikely that there were major differences in the rates of 
absorption. Secondly, the ability of the hepatocytes to remove 
the drug from the blood may be reduced. The primary route of 
metabolism of meptazinol is by conjugation. The elimination of 
drugs which are conjugated is usually little altered in liver 
disease e.g. oxazepam (SHULL et al 1976), morphine (PATWARDHAN et 
al 1980) and lorazepam (KRAUS et al 1978). In contradistinction, 
the hepatic clearance of oxidised drugs is invariably reduced in
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patients with cirrhotic liver damage (WILLIAMS and KOCH-WESER 
1983). In the present study there was no reduction in the 
clearance of meptazinol in cirrhotics. Thirdly, the intra- and 
extrahepatic portosystemic shunts which occur in cirrhosis can 
dramatically reduce the contact of the drug with the sites of 
hepatic elimination with a resulting increase in the 
bioavailability. More than 50% of the total portal blood flow 
may be shunted directly into the systemic circulation in 
cirrhotics (GROSZMANN et al 1972). In our study the majority of 
the cirrhotic patients studied had well established portal 
hypertension and 11/15 had previously bled from oesophageal 
varices. It is probable that this last factor explains the 
substantial increase in oral meptazinol bioavailability in 
cirrhosis. Interestingly one of the patients in the NCLD group 
had congenital hepatic fibrosis associated with large oesophageal 
varices and his meptazinol bioavailability was 26.1% which is 
comparable to the cirrhotic patients. Spironolactone was the only 
drug which these cirrhotic patients were receiving which may 
alter hepatic drug metabolism. This drug is a weak inducer of 
hepatic oxidation in healthy volunteers (TAYLOR et al 1972; 
HUFFMAN et al 1973), and much less so in patients with hepatic 
congestion associated with cardiac failure (OHNHADS and GERBER- 
TARAS 1984). If spironolactone did influence meptazinol 
metabolism, it would be expected to reduce its oral 
bioavailability.
Antipyrine has a low hepatic extraction ratio and is 
extensively oxidised in the liver (BOOBIS et al 1981).
Indocyanine green is a flow-dependent compound which is excreted
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in the bile without being metabolised (WHEELER et al 1958? 
CHERRICK et al 1960). Both agents have been used as probes in the 
assessment of patients with liver disease and particularly in the 
detection of patients with altered drug metabolism (BRANCH 1982). 
Significant correlations between the metabolism of antipyrine and 
the elimination of lorcainide (KLOTZ et al 1979), lignocaine 
(PERRUCA et al 1980), phenylbutazone (DAVIES and THORGEIRSON 
1971(a)), oxyphenylbutazone (DAVIES and THORGEIRSON 1971(b)), 
diazepam, prazepam, clonazepam, flurazepam (GREENBLATT et al 
1981) and oxazepam (KELLERMAN and LUYTEN-KELLERMAN 1979), have 
been reported but not with the clearances of lorazepam, temazepam 
(GREENBLATT et al 1981) or triazolam (KELLERMAN and LUYTEN- 
KELLERMAN 1979). Indocyanine green clearance correlated poorly 
with the elimination of diazepam and aminopyrine (HEPNER et al 
1977) but positively with the clearance of antipyrine (BRANCH et 
al 1976). In this study there was no useful relationship between 
the bioavailability or clearance of meptazinol and the clearance 
of antipyrine or indocyanine green. This lack of a correlation 
with antipyrine is not surprising as meptazinol is conjugated and 
antipyrine is oxidised within the liver. However, both 
meptazinol and indocyanine green are highly extracted by the 
liver and so a correlation between their clearances might be 
expected. Both the serum albumin and bilirubin were better 
predictors of meptazinol bioavailability.
The pharmacokinetic changes in meptazinol handling in the 
cirrhotic patients were accompanied by an increased incidence of 
vomiting when the drug was given orally. This occurred very 
shortly after administration on the upstroke of the absorption
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curve. Despite the high plasma levels by patients tolerating the 
drug there was no evidence of excessive sedation in any of the 
groups measured subjectively by sedation scoring or objectively 
using reaction times.
In conclusion the oral bioavailability of meptazinol is 
greatly increased in patients with chronic liver disease.
However, the drug can be used in such patients without producing 
excessive sedation. In order to avoid nausea and vomiting on 
oral administration in patients with cirrhosis or with portal 
hypertension the dose should be reduced to 25-50% of that 
normally prescribed. If such a dose is insufficient to produce 
analgesia the dose and/or frequency of administration can be 
increased to the limits of gastrointestinal tolerance.
Meptazinol dosage need not be altered in patients with liver 
disease in whom the drug is administered parenteral ly.
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TABLE 13.1
STANDARD LABORATORY TESTS (mean+ SEM) IN ALL CONTROL 
NON-CIRRHOTIC LIVER DISEASE (NCLD) AND CIRRHOTIC PATIENTS
Haemo
globin
(g/1)
Bili
rubin
(umol/1)
Alkaline
Phosphatase
(iu/1)
Albumin
(g/i)
Ctr eat GGT 
inine
(umol/1) (iu/1)
CONTROL (n = 10)
Mean 13.0 11.4 50 41.1 80.4 21
SEM 0.3 .2.0 10 0.8 5.7 4
NCLD (n = 9)
Mean 13.6 18.3 141 41.7 70.7 108
SEM 0.6 6.4 56 2.1 3.4 27
CIRRHOTIC (n = 15)
Mean 12.1 32.6 172 34.5 90.2 161
SEM 0.5 15.4 38 2.0 7.1 39
KRUSKAL WALLIS
P = 0.76 0.02 0.004 0.01 0.10 0.0001
MANN WHITNEY U TESTS
CONTROL vs NS NS NS NS NS <0.001
NCLD
CONTROL vs NS <0.05 <0.05 <0.01 NS <0.001
CIRRHOTIC
NCLD vs NS <0.05 NS <0.01 NS NS
CIRRHOTIC
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TABLE 13.2
ANTIPYRINE AND INDOCYANINE GREEN KINETICS (MEAN + SEM) 
IN CONTROL, NON-CIRRHOTIC LIVER DISEASE (NCLD) AND 
CIRRHOTIC PATIENTS.
<--
Half
life
(hrs)
--ANTIPYRINE— ------- X
Volume Clear Clear 
of ance ance 
distri 
bution
(1) (ml/min) (ml/min 
Ag)
Half
life
(min)
-INDOCYANINE GREEN--- >
Volume Clear Clear 
of ance ance 
distri 
bution
(1) (ml/min) (ml/m]
Ag)
CONTROL (n = 10)
Mean 12.2 25.6 29.0 0.43 3.8 3.8 704 11.7
SEM 1.4 1.7 4.6 0.04 0.2 0.4 98 2.0
NCLD (n = 9)
Mean 11.4 38.8 40.5 0.61 4.5 3.1 554 8.8
SEM 1.9 4.5 6.8 0.10. 0.7 0.3 71 1.2
CIRRHOTIC (n = 15)
Mean 31.3 27.3 14.7 0.18 9.2 4.2 364 5.0
SEM 6.5 3.6 2.2 0.05 1.3 0.4 44 0.6
KRUSKAL WALLIS
P = 0.003 0.07 0.004 0,.0008 0.004 0.14 0.004 0.001
MANN WHITNEY U-TESTS
CONTROL vs NS NS NS NS NS NS <0.01 <0.01
NCLD
CONTROL vs <0.01 NS <0.01 <0.01 <0.001 NS <0.001 <0.001
CIRRHOTIC
NCLD vs <0.01 NS <0.001 <0.001 <0.01 NS <0.01 <0.01
CIRRHOTIC
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TABLE 13.3
MEPTAZINOL KINETICS (MEAN + SEM) FOLLOWING SINGLE AND 
THIRTEENTH 200mg ORAL DOSE IN CONTROL, NON-CTRRHOTIC LIVER 
DISEASE (NCLD) AND CIRRHOTIC PATIENTS.
IV
AREA
UNDER
CURVE
(ng/hr/ml)
<---- SINGLE ORAL
AREA MAXIMUM 
UNDER CONCENT 
CURVE RATION 
CP (MAX) 
(ng/hr/ml) (ng/ml)
dose----
BIOAVAIL
ABILITY
(%)
> <CHRONIC DOSING>
AREA MAXIMUM 
UNDER CONCENT 
CURVE RATION 
CP (MAX) 
(ng/hr/ml) (ng/ml)
CONTROLS (n = 9)
Mean 337 163 53 7 112 49
SEM 35 35 12 1 21 7
NCLD (n = 3)
Mean 299 311 131 14 105 42
SEM 25 78 38 4 17 5 •
CIRRHOTIC (n = 8)
' Mean 391 794 184 28 903 302
SEM 44 148 37 5 247 92
KRUSKAL WALLIS
P = 0.5 0.003 0.02 0.01 0.03 0.06
MANN WHITNEY U TESTS
CONTROL vs NA 0.09 0.04 0.1 0.4 NS
NCLD
CONTROL vs NA 0.0001 0.002 0.001 0.02 NS
CIRRHOTIC
NCLD NA 0.01 0.12 0.04 0.007 NS
vs CIRRHOTIC
NA = not applicable
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TABLE 13.4 MEPTAZINOL STUDY - Intravenous dose. Comparison of One 
and Two Gompartment Models by Comparison of Residual 
Sum of Squares.
Residual Sum of 
Squares 
Two One 
Gompartment Compartment
F
Statistic
Compartment
Selected
Cl
L/hr
vd
L
1. 109.8 461.7 6.4* Two 116 269
2. 502.2 711.5 0.8 One 58 138
3. 136.2 135.9 0.0 One 57 225
4. 214.6 258.8 0.4 One 92 204
5. 54.5 991.2 33.9* Two 80 114
6. 129.4 121.5 0.0 One 60 215
7. 128.3 1840.0 36.6* Two 91 102
8. 269.1 1618.0 10.1 One 74 134
9. 65.1 1246.0 36.9* Two 87 119
10. 130.1 471.7 5.2* Two 79 198
11. 35.6 1132.0 61.6 Two 104 45
12. 196.4 403.8 2.1 One 173 92
13. 36.5 538.7 27.6* Two 85 170
14. 953.5 1232.0 0.6 One 85 125
15. 192.7 312.0 1.2 One 81 254
16. 187.4 197.4 0.1 One 93 145
17. 124.5 123.4 0.0 One 42 231
18. 190.4 201.3 0.1 One 66 211
19. 69.0 884.1 23.5* Two 54 178
20. 143.8 288.8 2.0 One 114 278
21. 932.2 166.8 0.0 One 72 105
22. 80.2 167.1 2.2 One 126 237
23. 133.6 311.5 2.7 One 99 206
24. ' 145.4 282.6 1.9 One 104 200
25. 78.0 2000.0 49.3* Two 65 54
26. 3699.0 4658.0 0.5 One 93 158
(VI = 2 V2 = 6)
* = p < 0.05
FIGURE 13.1
THE CHEMICAL STRUCTURE OF MEPTAZINOL
H
OH
c 2 h 5
HC1
CH
Half-life 2hours 
Bioavailability 9%
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FIGURE 13.2
PLASMA CONCENTRATION TIME CURVES (MEAN + SEM) FOLLOWING AN 
ORAL DOSE’OF 200mg OF MEPTAZINOL IN CONTROL (n=7), NON­
CIRRHOTIC LIVER DISEASE (NCLD) (n=8) AND CIRRHOTIC PATIENTS (n=8)
Statistics by Kruskal Wallis analysis of variance and Mann
*
Whitney U-tests.
PLASMA MEPTAZINOL 
(ng/m l)
160“
140“
120“
80“
60“
20“
*
12
*
296
FIGURE 13.3
PERCENTAGE ORAL BIOAVAILABILITY OF MEPTAZINOL (MEAN + SEM)
IN CONTROL, NON-CIRRHOTIC LIVER DISEASE (NCLD) AND CIRRHOTIC 
PATIENTS.
Statistics by Kruskal Wallis analysis of variance and Mann 
Whitney U-tests.
MEPTAZINOL 
ORAL BIOAVAILABILITY
(%) p < 0.05 p <0.001
40"
20 '
(NCLD)Controls Cirrhotic
(n=7) (n=7) (n=8)
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C H A P T E R  14
IMPAIRED DRUG METABOLISM IN PATIENTS WITH CARDIAC FAILURE: STUDIES
WITH ANTIPYRINE AND INDOCYANINE GREEN.
301
14.1 SUMMARY
The disposition of antipyrine (AP) and indocyanine green 
(ICG) was studied in 11 patients with congestive cardiac failure 
(CCF) before and after treatment and 32 control patients. The 
antipyrine distribution was not significantly altered in patients 
with CCF. The indocyanine green half life was significantly 
prolonged in patients with CCF (CCF = 10.0 + 8.0 min; Control =
4.2 + 1.1 mins: p < 0.01). The indocyanine green disposition
was not significantly altered in a further 12 patients with 
valvular heart disease but without evidence of CCF. There was a 
close correlation between the ICG half life and the clinical 
assessment (r = 0.99; p < 0.001).
In the 12 patients without CCF there was no correlation 
between cardiac pressure measurements and the disposition of 
antipyrine or indocyanine green.
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14.2 INTRODUCTION
The disposition and elimination of many drugs are altered in 
patients with congestive CCF (BENOWITZ & MEISTER 1976). Two 
mechanisms for these alterations have been suggested. Firstly, 
there is a reduction in cardiac output and an increase in hepatic 
venous pressure. These changes result in a fall in the total 
liver blood flow (BRAUER 1963). This is one of the important 
determinants of the elimination of drugs, particularly those with 
a high hepatic ratio (See Chapter 4.2.5). Secondly, as a result 
of ischaemia and hepatic necrosis there is necrosis of the 
centrilobular hepatocytes (SHERLOCK 1951). These hepatocytes 
have particularly high concentrations of Cytochrome P-450 
(SWEENEY et al 1978) which is the major enzyme complex 
responsible for drug metabolism within the liver. (GUMUCIO and 
MILLER 1981). Reduction in the Cytochrome P-450 activity of the 
liver leads to a reduced capacity to eliminate drugs which are 
extensively oxidised within the liver, for example, antipyrine.
The aims of this study are to investigate the relative 
importance of these two mechanisms in determining drug 
elimination in patients with CCF. The elimination of a low 
hepatic extraction ratio drug (antipyrine) and a high hepatic 
extraction ratio drug (indocyanine green) has been studied in 
patients with CCF before and after treatment.
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14.3 METHODS AND PATIENTS
Three groups of patients were studies. Group 1 consisted of 
11 patients urgently admitted to hospital because of congestive 
cardiac failure. These patients were studied within 24 hours of 
admission to hospital and were re-studied after there was 
clinical improvement in the cardiac failure at the time of study. 
Group 2 consisted of 12 patients with valvular heart disease who 
did not have clinical evidence of cardiac failure. Group 3 is a 
control group and consisted of 37 patients admitted to hospital 
for the investigation of various gastrointestinal symptoms. 
These patients had no clinical or biochemical evidence of liver 
disease and no clinical evidence of congestive cardiac failure.
The patients in Group 1 were graded for the severity of 
cardiac failure according to the scheme in Table 14.1. Each sign 
is graded on a score of 1-3 and the scores for each patient are 
summed to give a "Cardiac Failure Index" (CFI). Patients had to 
have a CFI of at least 5 to enter the study. A subtotal of the 
right ventricular features (jugular venous pressure, oedema, 
hepatomegaly) has also been calculated and designated as the 
"Right Ventricular Index" (RVI). The patients were treated for 
congestive cardiac failure with the drugs summarised in Table 
14.2. Following treatment the clinical grading assessment was 
repeated.
Standard liver function tests, antipyrine kinetics and 
indocyanine green kinetics have been obtained using the 
protocols and methods described in Chapter 7.
The patients in Group 2 all had valvular heart disease and
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were in hospital for cardiac catheterisation to assess the 
severity of their valvular disease.
14.3 RESULTS
In Group 1 there was a significant improvement in the 
"Cardiac Failure Index" (p < 0.001) and the "right ventricular 
index (p < 0.004) following treatment for congestive cardiac 
failure (Table 14.3).
Prior to treatment the serum bilirubin, aspartate 
transaminase, and alanine transaminase were all outwith the 
normal laboratory range. There was a tendency for these tests to 
return to normal following treatment (Table 14.4). This trend 
was statistically significant for the serum bilirubin. Prior to 
treatment = 23.1 + 14.9 mmol/1: After treatment = 18.8 + 14.6
mmol/1: P < 0.05).
Ihe antipyrine half life was significantly prolonged in the 
Group 1 patients prior to treatment in comparison to the healthy 
controls (Group 1 = 19.3 + 15.0 hrs: Healthy Controls = 11.8 +
3.5 hrs: P < 0.05). The antipyrine clearance was also reduced
(Group 1 = 25.9 + lO.lml/min: Healthy Controls = 37.2 + 15.1
ml/min: P < 0.05). There was no significant alteration in the 
antipyrine volume of distribution (Table 14.5).
A similar pattern was seen with indocyanine green, although 
the magnitude of the differences was greater. In patients with 
CCF the half life of ICG was prolonged by 138% compared to 33% 
for antipyrine. Similarly the ICG clearance was reduced by 37% 
compared to a 29% reduction for antipyrine (Table 14.5).
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In the Group 1 patients after treatment of CCF there was a 
tendency for the half lives to fall and the clearances to 
increase but these changes failed to reach statistical 
significance (Table 14.5, Fig. 14.1).
The correlation of the kinetic parameters of antipyrine and 
ICG with the clinical assessment of the degree of cardiac failure 
is shown in Table 14.6. There were no significant correlations 
between the clinical indices, of CCF and antipyrine kinetics but 
there was a close correlation of the ICG half life and the CFI 
(Fig. 14.2) and the RVI.
The patients in Group 2 all had cardiac catheter is at ion 
studies performed to determine the nature of their heart disease. 
The results of the pressure study are shown in Table 14.7 and the 
antipyrine and ICG kinetic data in Table 14.8. There were no 
significant correlations between the kinetic parameters and the 
mean right atrial pressure or the mean wedged and free pulmonary 
artery pressure.
14.4 DISCUSSION
Congestive cardiac failure is associated with a reduced 
capacity to eliminate various drugs including Lignocaine (THOMSON 
et al 1973; PRESCOTT et al 1976; BAX et al 1980), Aminopyrine 
(HEPNER et al 1978, PIROTTE et al 1983), Antipyrine (PRESCOTT et 
al 1976, RISSAM et al 1983) and Theophylline (PIAFSKY et al 
1974). The elimination of other drugs is little altered 
including Digoxin (DOHERTY et al 1961, 1962; MARCUS 1964). The 
mechanisms by which changes occur in the disposition of drugs in
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congestive cardiac failure include reduced absorption, 
hepatocellular damage secondary to hepatic congestion and reduced 
liver blood flow (BENOWITZ & MEISTER 1976).
This study demonstrates that in CCF the clearance of ICG is 
reduced by 37% and the half life prolonged by 138%. There was a 
good correlation between the clearance of ICG and the clinical 
severity of the CCF. ICG is not metabolised within the liver but 
has a high hepatic extraction ratio so that its elimination is 
primarily dependent on liver blood flow. A major determinant of 
liver blood flow is the cardiac output (STENSCN et al 1971). A 
previous study failed to demonstrate any alteration in ICG 
elinination in patients with CCF (BAX et al 1980).
In the sane group of patients the clearance of antipyrine 
was reduced by 30% and the half life prolonged by 33%. These 
changes are less marked than was seen with ICG. Antipyrine is 
extensively oxidised within the liver and has a low hepatic 
extraction ratio. Its elimination is primarily dependent on the 
rate of hepatic oxidation and it is relatively independent of 
liver blood flow.
This study demonstrates that the elimination of high and low 
extraction ratio drugs is reduced in CCF. The changes are 
greatest for high extraction ratio drugs, and for these molecules 
the changes correlate closely with the clinical severity of the 
cardiac failure. These data suggest that alterations in liver 
blood flow are relatively more important than reduced hepatic 
metabolic capacity in determining changes in liver blood flow. 
The magnitude of the changes in the elimination of antipyrine and
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indocyanine green in CCF are similar to those seen on a large 
group of patients with mixed liver disease (Table 14.5). If 
these alterations are primarily due to changes in liver blood 
flow then it is likely that they may alter rapidly as the heart 
fails further or responds to therapy. This suggests that the 
elimination of high hepatic ratio drugs is likely to be 
particularly variable and unpredictable in patients with CCF.
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TABLE 14.1 CLINICAL GRADING OF THE SEVERITY OF CARDIAC FAILURE
PULSE (Beats/min) 
JVP (cms)
OEDEMA 
HEPATOMEGALY 
PLEURAL EFFUSION 
BREATHLESSNESS 
CARDIOMEGALY 
TRIPLE RHYTHM 
BASAL CREPITATIONS
> 90
> 5 
MILD 
PRESENT 
PRESENT 
WALKING 
PRESENT 
PRESENT 
PRESENT
> 100 
> 10
MODERATE
DRESSING
SEVERE
AT REST
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TABLE 14.2 DRUGS TAKEN BY 11 PATIENTS WITH CONGESTIVE CARDIAC
FAILURE BEFORE AND AFTER TREATMENT
A A B B B D D F F F I M P P S T V V
M M A E U I I L R R S E A 0 P E E I
I P R N M A G U A U 0 T R T I M N T
L I B D E Z 0 R N S S H A A R A T A
0 C I R T E X B 0 E 0 Y C S 0 Z 0 M
R I T 0 A P I I L M R L E S N E L I
I L U F N A N P I B D T I 0 P I N
D L R L I M R D I 0 A U L A N S
E I A U D 0 E D P M M A M
N T A E F E A 0 C
E Z E L T
I N 0
D N
E E
1 - BEFORE * * *
- AFTER * * *
2 - BEFORE * *
- AFTER * *
3 - BEFORE * ■* * *
- AFTER * * * *
4 - BEFORE * * * ' * *
- AFTER * * *
5 - BEFORE * * *
- AFTER * * *
6 - BEFORE * *
- AFTER * *
7 - BEFORE *
- AFTER * *
8 - BEFORE * * *
- AFTER * * *
9 - BEFORE * * *
- AFTER * * *
10 - BEFORE * * * * *
- AFTER * * * * *
11 - BEFORE 
- AFTER
*
*
*
*
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TABLE 14.3 CLINICAL ASSESSMENT OF 11 PATIENTS WITH CARDIAC 
FAILURE BEFORE AND AFTER TREATMENT
 < b E F 0 R E > * <- A F T E R--------- >
 <----- T R E A T M E N  T-----— > * <----- T R E A T M E N  T------->
P J O H E B C  T C R T *  P J O H E B C T C R T  
U . E E F R A R R  . 0 * U . E E F R A R  R . O
L V D  P F E R I E V T  * L V D  P F E R I E V T
S . E  A U A D P P . A * S . E  A U A D P P . A
E P M R S T I L I L * E P M R S  T I L I T L
A I H O  E T S  * A I H 0 E T O
O L M  A C  S *  O L M  A T S
N E E R T O C *  N E E R T A C
S G H I R 0 * S G H I L O
S A Y 0 E R * S A Y O R
N L T N  E *  N L T N  E
E Y H * E Y H
S M * S M
S * S
1 0 2 2 0 0 1 0 0 1 4 6 * 0 1 1 0 0 1 0  0 1 2  4
2 0 2 2 1 0 3 1 0 1 5 10 * 2 1 1  0 0 2 1  0 0 2 7
3 2 2 1 0  0 3 1 0 1 3 10 * 1 1  1 0 0 1 1 0 0 2 5
4 0 1  1 0 0 3 0 0 1 2  15 * 0  2 0 0 0 2 0 0 1 2  5
5 0 2 3 1 1 2 1 0 1 7 11 * 0 0 1 0  0 0 1 0 1 1  3
6 2 0  0 1 0  2 0  0 0 1 5 * 2 0 0 0 0  0 1 0 1 0  4
7 2 1  1 0  0 2 1 0 1 2 8 * 0 0 0 0 0 0 0 0 1  0 1
8 0 2 2 1 1 3 1 0 1 6 11 * 1 1 1 0 0 0 1 0 1 2 5
9 2 1 3 1 0 2 0 0 1 5 10 * 0 0  3 0 0  2 0 0 1  3 5
10 1 1  2 0 1 2 1  0 1 4 9 *  0 1 1  0 1 2 1 0 1  3 7
11 2 2 2 0 1 2 0 0 0 4 9 * 1 0 0  0 1 0 0 0 0  1 2
MEDIAN 4 9 2+ 5++
Statistics by Mann-Whitney U Test 
+ p = 0.005
++ p = 0.001
TABLE 14.4 STANDARD BIOCHEMICAL TESTS OF LIVER FUNCTION IN 11 
PATIENTS BEFORE AND AFTER TREATMENT OF CONGESTIVE 
CARDIAC FAILURE.
<-------- B E F 0 R E---------> <---  A F T E R-- ------->
<------T R E A T M E N T~____> <----- -T R E A T M E N T---- >
BILI
RUBIN
AST ALT ALK
PHOS
ALBU
MIN
BILI
RUBIN
AST ALT ALK
PHOS
ALBU
MIN
MMOL/L IU/L IU/L IU/L G/L MMOL/M IU/L IU/L G/L G/L
1 13 9 24 114 34 7 21 21 112 34
2 32 57 158 148 36 44 52 .139 129 35
3 13 79 46 125 36 7 14 20 112 37
4 14 20 16 94 33 8 19 13 83 38
5 12 22 26 97 40 6 27 25 71 45
6 40 45 70 129 34 21 19 24 119 40
7 14 324 63 119 42 15 64 72 121 33
8 13 121 52 115 39 5 14 26 115 40
9 35 22 13 135 37 25 26 13 145 37
10 55 77 138 163 32 16 23 35 98 28
11 13 17 15 65 36 13 14 9 76 41
MEAN 23.1 72.1 56.5 117.6 36.3 18.8* 26.6 36.1 107.4 37.1
S.D. 14.9 90.3 49.5 27.8 3.1 14.6 16.4 38.1 23.0 4.6
Statistics by Paired Wilcoxon Sign Rank Test
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TABLE 14.6 CORRELATION OF ANTIPYRINE AND INDOCYANINE GREEN KINETIC 
DATA WITH INDICES OF CONGESTIVE CARDIAC FAILURE AND 
RIGHT VENTRICULAR FAILURE, (r VALUES)
ANTIPYRINE INDOCYANINE GREEN Congestive
Cardiac
Half Life Clearance Half Life Clearance Index
Antipyrine
Clearance 0.83***
I.C.G.
Half Life 0.25 0.29
I.C.G.
Clearance -0.35 0.47* 0.81**
CCF INDEX 0.27 -0.32 0.99** 0.81**
RV Index 0.21 -0.15 0.50* -0.39 0.49*
Statistics by Spearman Rank Correlation 
* = p < 0.05
** = p < 0.001
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TABLE 14.8 INDOCYANINE GREEN AND ANTIPYRINE KINETIC DATA ON 12 
PATIENTS UNDERGOING CARDIAC CATHETERISATION
Half
Life
(min)
Vd
(1)
Clearance
(ml/min)
Half
Life
(hrs)
Vd
(1)
Clearance
(ml/min)
1. 5.9 3.2 378.2 22.9 38.7 19.5
2. 3.8 2.8 512.2 25.0 32.2 14.9
3. 3.8 3.5 634.4 18.0 40.9 26.2
4. 4.0 4.3 736.4 15.1 37.7 28.8
5. 3.0 2.6 565.4 15.6 37.1 27.4
6. 4.0 2.3 402.0 10.1 43.8 50.0
7. 3.4 3.9 795.5 11.8 59.7 58.5
8. 4.8 2.6 380.0 10.4 35.2 39.2
9. 3.2 2.8 620.9 6.0 35.7 68.4
10. 6.7 3.0 309.3 11.7 32.2 31.8
11. 4.1 3.2 542.9 15.5 50.6 37.6
12. 3.5 2.1 411.9 12.1 37.7 35.6
Vd = Volume of Distribution
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FIGURE 14.1 ANTIPYRINE AND INDOCYANINE GREEN HALF LIVES IN ALL 
PATIENTS BEFORE AND AFTER TREATMENT OF CONGESTIVE 
CARDIAC FAILURE.
ANTIPYRINE INDOCYANINE GREEN
HALF LIFE HALF LIFE
(hours) (mins)
60
50- 30-
40-
20-
30-
20-
10-
10-
BEFORE BEFOREAFTER AFTER
TREATMENT TREATMENT
(n = 11) (n = 11)
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FIGURE 14.2 CORRELATION BETWEEN INDOCYANINE GREEN HALF LIFE AND
CONGESTIVE CARDIAC FAILURE INDEX
INDOCYANINE 
HALF LIFE 
(min)
30-
20-
10-
Spearman Rank Correlation
r= 0.57 
p< 0.05
X
X
X
X
!
10 11
CONGESTIVE CARDIAC FAILURE INDEX
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CONCLUSION AND FURTHER RESEARCH
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The severity of liver disease has traditionally been described in 
histological terms. Patients who had progressed to cirrhosis were 
considered to have severe liver disease, with severe functional 
inpairment and a poor prognosis. As knowledge has progressed it has 
become obvious that this is not an accurate assessment. Many patients 
with cirrhosis survive for many years with very little or no evidence 
of functional impairment. The biochemical liver function tests have 
not been much more satisfactory. Many of these tests do not even 
reflect a liver function at all but are dependent on hepatocellular 
destruction and bile duct patency. Only the serum bilirubin and 
albumin concentrations together with the prothrombin time have been 
found to have prognostic importance. These tests can be difficult to 
interpret because they are dependent on several different factors 
extraneous to the liver. These difficulties have given rise to the 
concept of studying liver function using the clearance of probe 
molecules. A further stimulus to this area of research has been the 
increasing need for an accurate test of the severity of liver 
disease. This need has been created by the increasing sophistication 
and cost of the treatment available, including the possibility of 
hepatic transplantation. Bbr a new liver function test to be accepted 
into clinical practice it nust satisfy two major criteria:-
Firstly, it must have an advantage over the currently available 
tests as either a screening test, a diagnostic test or as a test of 
the severity of liver disease.
Secondly, it mast be sinple to perform.
This thesis demonstrates that indocyanine green clearance is 
sensitive to the subtle changes in liver function that occur in
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patients on methotrexate. However this is not a particularly typical 
form of liver disease in that the histological abnormality is a 
progressive hepatic fibrosis. This results in distortion of the liver 
architecture without gross hepatocellular destruction. Indocyanine 
green clearance is primarily dependent on liver blood flow which is 
likely to be sensitive to changes in liver architecture. So that 
while ICG clearance may be a suitable screening test for methotrexate 
associated liver disease it is unlikely that this observation can be 
extrapolated to liver disease in general. In most "civilised" 
populations the most common form of liver disease in the community is 
related to alcohol abuse. This can be sensitively detected by 
measuring the serum gamma glutamyl transpeptidase. It is unlikely 
that a relatively complex clearance test such as ICG clearance, which 
requires seven blood samples, could replace a simple single sanple 
test like the measurement of GGT as a screening test in these 
populations.
Another major area of interest in the use of clearance tests of 
hepatic function has been in their use as model drugs to predict the 
elimination of similar molecules. This thesis provides further 
evidence that Antipyrine and Indocyanine green clearance perform 
poorly in this function. The correlation of the elimination of these 
drugs with Midazolam and Meptazinol elimination was poor. Bor both 
these drugs the pharmacokinetics were markedly abnormal in patients 
with liver disease. With Midazolam this predictably led to excessive 
sedation, but for Meptazinol the result was gastrointestinal 
intolerance. These two studies again emphasis the importance of 
examining the pharmacokinetic and dynamic responses of new drugs in
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patients with liver disease.
The chapter on the effect of Nadolol on wedged portal vein 
pressure provides evidence that this may be a suitable beta-blocker to 
use in patients with portal hypertension. The concept that portal 
hypertension could be treated like systemic hypertension arose in the 
early 1980’s from the observations of Lebrec. He demonstrated that 
propranolol reduced portal pressure, and that this was of clinical 
benefit to patients who had bled from oesophageal varices. However 
propranolol it extensively metabolised within the liver, so that the 
pharmacodynamic response may be difficult to predict in patients with 
liver disease. Nadolol is primarily excreted by the kidney so that it 
its effect should be easier to predict in the presence of hepatic 
impairment. Unfortunately other workers have been unable to confirm 
the clinical benefit of beta blocker therapy in portal hypertension. 
There is a need for more evidence in this area. A study has been in 
progress in Glasgow for the past four years to study the effect of 
propranolol on the secondary prevention of variceal bleeding.
Although this study is not yet complete an interim analysis, following 
the randomisation of 80 patients, suggests that propranolol reduced 
the incidence of rebleeding by approximately 20%. Further studies 
are required especially to assess if beta-blockade has any part to 
play in the primary prevention of variceal bleeding. The data on 
Nadolol in this thesis suggests that it may be a suitable drug for 
such a study.
The study in porphyric patients shows the value of antipyrine as 
a noninvasive assessment of hepatic drug oxidation. Tnis study 
suggests that porphyric patients have a deficiency of hepatic haem. 
Tnis observation requires is confirmation by direct measurement of
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cytochrome P450 in liver biopsy specimens from porphyric patients.
The study in patients with cardiac failure shows that the changes 
in the elimination of antipyrine and indocyanine green are as marked 
in this condition as they are in liver disease. Interestingly there 
is a close correlation between the severity of the cardiac failure and 
the clearance if indocyanine green. This suggests that patients with 
CCF may be highly sensitive to drugs with a high hepatic extraction 
ratio, and that this sensitivity has the potential to alter rapidly in 
response to the patients cardiac output.
The chapter on the natural history of liver disease shows that 
indocyanine green is a powerful liver function test with independent 
prognostic value. This is a surprising result because it suggests 
that the complications and prognosis of liver disease are primarily 
dependent on changes in functional liver blood flow rather than 
hepatic metabolic capacity. This observation support's the "intact 
hepatocyte" model of liver dysfunction. In that it is not the 
function of individual hepatocytes that determines the severity of 
liver disease, rather it is the mismatching of liver blood flow to 
functional hepatocytes which is inportant. EUrther research into the 
use of high hepatic extraction ratio drugs requires to be done in 
particular several inportant questions remain.
What is the rate limiting step in the excretion of indocyanine 
green ? In this thesis it has been assumed that because 103 is not 
metabolised within the liver that the limiting factor for its 
elimination is the rate of delivery of the drug to functioning 
hepatocytes. This assumption is not proven and it is possible that 
the "function" which these changes reflect is not the functional liver
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blood flow but a change in the permeability of the hepatocyte 
membrane.
The value of indocyanine green elimination in specific situations 
requires further exploration. Is there a critical level of ICG 
elimination from which death is inevitable ? Can ICG elimination be 
used as a day to day assessment of liver function in patients with 
fulminant hepatic failure ? If this were possible then a critical 
level of liver function could defined to logically select a group of 
patients for transplantation.
Are there other high hepatic extraction ratio drugs which provide 
similar results ? In particular an oral clearance test would 
theoretically be more sensitive, provided that no changes in 
absorption occured. For a clearance test to become widely adopted in 
hepatology the sanpling method should be as sinple as possible. 
Traditionally ICG clearance is deduced from 7 blood samples over a 21 
minute period. This has been sinplif ied in some centres to a 
retention test requiring only two sairples. A further modification to 
the test uses a dichromatic light sensor attached to the patients ear 
lobe instead of blood sanpling. Research needs to be done to assess 
other high hepatic extraction ratio drugs as clearance tests in 
hepatology. In particular HIDA is an interesting compound. This 
radi©pharmaceutical can be administered intravenously with the . 
clearance measure by scanning over the liver. A good correlation 
exists between the clearance of HIDA measure by this method and both 
the plasma clearance of HIDA and ICG clearance. A clearance test 
based on this molecule would provide the advantage of a simultaneous 
imaging and functional assessment, which require no blood sanpling.
Medicine has advanced to the state where accurate liver function
324
testing is required. Clinical and histological assessment of liver 
function does not provide accurate functional information. It is 
hoped that such a test will soon be validated because it is likely 
that it will open the door to improvements in the therapy for liver 
disease.
.oooOooo.
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APPENDIX 4
METHODS OF DATA COLLECTION AND DATA HANDLING
The data and references used in this thesis have been collected 
and organised using microcomputers. Three file structures have been 
used:-
1. Liver Function Data File
2. Drug Data File
3. References
1. Liver Function Data File
The liver function data has been collected on an Apple H E  
microcomputer using the DB Master Database version 4 published 
by Stoneware Incorporated of San Rafael, California. This 
database allows the storage of 100 fields or pieces of
information in each record and the database was structured so
that each time a patient was assessed they had a new record 
filled out. The data collected is discussed in Chapter 7. The 
data was edited and corrected on the Apple microcomputer and then 
written out of the database as a straight text file.* This file 
was then directly transferred using an on line Apple IIE computer 
to the University main frame computer for analysis.
FILE DEFINITION - LIVER FUNCTION
Primary Second Read Field Field
Field Field Key Key Protected Type Length
No. Label
1 DIAGNOSIS YES NO NO 0-255 3
2 STUDY NUMBER YES NO NO ALPHA 3
3 LAST NAME YES NO NO ALPHA 12
4 FIRST NAME NO NO NO ALPHA 12
5 HOSPITAL NUMBER NO NO NO NUMER 6
6 DATE OF BIRTH NO NO NO DATE 8
7 AGE NO NO NO 0-255 3
8 SEX NO NO NO • 0-255 1
9 RACE NO NO NO 0-255 1
10 HEIGHT NO NO NO NUMER 5
11 WEIGHT NO NO NO NUMER 4
12 OTHER DIAGNOSIS 1 NO NO NO 0-255 3
13 OTHER DIAGNOSIS 2 NO NO NO 0-255 3
14 OTHER DIAGNOSIS 3 NO NO NO 0-255 3
15 OTHER DIAGNOSIS 4 NO NO NO 0-255 3
16 MEAT CONSUMPTION NO NO NO 0-255 1
17 VEG. CONSUMPTION NO NO NO 0-255 1
18 . BEER NO NO NO INTGR 3
19 SPIRITS NO NO NO INTGR 3
20 WINE NO NO NO INTGR 3
21 TOTAL ALCOHOL NO NO NO 0-255 2
22 PIPE SMOKING NO NO NO 0-255 1
23 CIGARETTES NO NO NO 0-255 2
24 COFFEE NO NO NO 0-255 2
25 TEA NO NO NO 0-255 2
26 LIVER NO NO NO 0-255 2
27 SPLEEN NO NO NO 0-255 2
28 PORTAL H.T. NO NO NO INTGR 1
29 ASCITES NO NO NO 0-255 1
30 ENCEPHALOPATHY NO NO NO 0-255 1
31 HAEMOGLOBIN NO NO NO NUMER 4
32 PROTHROMBIN NO NO NO 0-255 2
33 CONTROL NO NO NO NUMER 4
34 BILIRUBIN NO NO NO INTGR 3
35 SGOT NO NO NO INTGR 5
36 SGPT NO NO NO INTGR 5
37 ALKALINE PHOSPHATE NO NO NO INTGR 4
39 ALBUMIN NO NO NO INTGR 2
40 GLOBULIN NO NO NO INTGR 2
41 CREATININE NO NO NO 0-255 3
42 LIVER VOLUME NO NO NO INTGR 6
43 CHILD'S NO NO NO 0-255 1
44 DRUGS 1 NO NO NO INTGR 3
45 2 NO NO NO INTGR 3
46 3 NO NO NO INTGR 3
47 4 NO NO NO INTGR 3
48 5 NO NO NO INTGR 3
49 6 NO NO NO INTGR 3
50 7 NO NO NO INTGR 3
51 8 NO NO NO INTGR 3
52 9 NO NO NO INTGR 3
53 10 NO NO NO INTGR 3
54 ANTIPYRINE KINETICS NO NO NO DATE 8
55 HALF LIFE NO NO NO NUMER 5
56 CORRELATION COEF NO NO NO NUMER 3
57 VOLUME OF DIST. NO NO NO NUMER 5
58 VOLUME/KILOGRAM NO NO NO NUMER 3
59 TOTAL BODY CLEARANCE NO NO NO NUMER 5
60 CLEARANCE/KILOGRAM NO NO NO NUMER 5
61 K NO NO NO NUMER 3
62 CONCENTRATION AT 0 NO NO NO NUMER 5
63 INDOCYANINE GREEN NO NO NO DATE 8
64 HALF LIFE NO NO NO NUMER 5
65 CORRELATION COEF NO NO NO NUMER 3
66 VOLUME OF DIST. NO NO NO NUMER 5
67 VOLUME/KILOGRAM NO NO NO NUMER 5
68 TOTAL BODY CLEARANCE NO NO NO NUMER 5
69 CLEARANCE/KILOGRAM NO NO NO NUMER 5
70 K NO NO NO NUMER 5
71 CONCENTRATION - 0 NO NO NO NUMER 5
72 W.B. CLEARANCE NO NO NO NUMER 5
73 W.B. CLEARANCE/KG NO NO NO COMP. 5
74 ACID GLYCOPROTEIN NO NO NO NUMER 5
75 HISTOLOGY NO NO NO DATE 8
76 ARCH-NORMAL NO NO NO 0-255 1
77 -DISSARAY NO NO NO 0-255 1
78 -CIRRHOSIS (ACT) NO NO NO 0-255 1
79 -CIRRHOSIS (INAC) NO NO NO 0-255 1
80 NECROSIS-ABSENT NO NO NO 0-255 1
81 -DIFFUSE NO NO NO 0-255 1
83 -SPOTTY NO NO NO 0-255 1
84 -PIECEMEAL NO NO NO 0-255 1
85 -CONFLUENT NO NO NO 0-255 1
86 GRADE 1 NO NO NO 0-255 1
87 2 NO NO NO 0-255 1
88 3 NO NO NO 0-255 1
89 4 NO NO NO 0-255 1
90 FATTY CHANGE NO NO NO 0-255 1
91 PAREN IRON NO NO NO 0-255 1
92 BALLOONING NO NO NO 0-255 1
93 A1 NO NO NO ALPHA 10
94 A2 NO NO NO ALPHA 10
95 A3 NO NO NO ALPHA 10
96 N1 NO NO NO NUMER 5
97 N2 NO NO NO NUMER 5
98 N3 NO NO NO NUMER 5
99 N4 NO NO NO NUMER 5
100 N5 NO NO NO NUMER 5
The database can be searched rapidly on the fields in the primary 
key, i.e. fields 1-3. It will "find" any record within 5-10 seconds 
if given the information in the primary key. The data is stored in 
the file in the order of its first field. By making this field the 
diagnostic field, the reports will naturally group together patients 
with the same diagnosis. This database has the facility of 
translating a numerical code into text in the printed reports. The 
following fields were coded.
: l PRIMARY BILIARY CIRRHOSIS
2 = CHRONIC ACTIVE HEPATITIS
3 = ALCOHOLIC LIVER DISEASE
4 = IDIOPATHIC PORTAL HYPERTENSION
6 = CRYPTOGENIC CIRRHOSIS
7 = PRIMARY SCLEROSING CHOLANGITIS
8 = HAEMACHROMATOSIS
9 = DIAGNOSIS OBSCURE
100 = CONTROL
101 = METHOTEXATE STUDY
FIELD NO 8 CODE 0 = FEMALE
1 = MALE
FIELD NO 28 CODE 0 = NO EVIDENCE OF PORTAL HYPERTENSION
1 = OESOPHAGEAL VARICES PRESENT
2 = BLEEDING OESOPHAGEAL VARICES
3 = PORTACAVAL SHUNT
FIELD NO 29 CODE 0 = NO ASCITES
1 — ASCITES
FIELD NO 30 CODE 0 = NO ENCEPHALOPATHY
1
=
ENCEPHALOPATHY
FIELD NO 43 CODE 1 _ CHILD'S GRADE A
2 = CHILD’S GRADE B
3 = CHILD'S GRADE C
4 = CONTROL
FIELD NOS 44,45,46,47,48,49,50,51,52,53.
1 = PENICILLAMINE 36 = CEPHRADEINE
2 = KETO CON AZOLE 37 = VITAMIN D
3 = CHLORPROPAMIDE 38 = VITAMIN C
4 = CHOLESTYRAMINE 39 = METFORMIN
5 = RANITIDINE 40 = ISOSORBIDE
6 = KANAMYCEN 42 = INDOMETHACXN
7 = BETNESOL 43 = SULPHAS ALAZINE
8 = AZATHIOPRINE 44. = ISPAGHULA
9 = NEOMYCIN 45 = TEMAZEPAM
10 = BROMO CRYPTINE 46 = PHENERGAN
11 = LACTULOSE 47 = HYDRO CDRTISONE
12 = NITRAZEPAM 48 = ATENOLOL
13 = SPIRONOLACTONE 49 = CHLORTHALIDONE
14 = VITAMIN K 52 = HALOPERIDOL
15 = CHLORMETHIAZOLE 53 = GLIPIZIDE
16 = OROVITE 54 = PARACETAMOL
17 = FERROUS SULPHATE 55 = FENOPROFEN
18 = FOLIC ACID 56 = TRIAMTERENE
19 = GMETIDINE 57 = ALLOPURINOL
20 = CHLORDIAZEPOXIDE 58 = GTN
21 = DIAZEPAM 59 = NADOLOL
22 = INSULIN 60 = METHOTREXATE
23 = FRUSEMIDE 61 = LORAZEPAM
24 = PROCHLORPERAZINE 63 = PSORALENS
25 = AMILORIDE/HYDROCHLORTHIAZIDE 64 = FLURAZEPM
26 = IBUPROFEN 66 = METOPROLOL
27 = POTASSIUM 67 = AMITRIPTYLINE
28 = PREDNISOLONE 68 = BENDROFLUAZIDE
29 = PARENTEROVTTE 69 = ORPHENEDRINE
30 ■ = AMPICILLIN 70 = PIROXICAM
31 = AMILORIDE 72 = PROPRANOLOL
32 = THYROXINE 73 = ME FAN AMI C ACID
33 = MEBEVERINE
34 = BC 500
35 = QUININE
FIELD NOS 76-92 CODE - HISTOLOGY FIELDS
These fields are marked with a 1 when the 
histological feature measured in the field is 
present and a 0 when that feature is absent.
FIELD NOS 93-100
In the original file definition these fields were 
designed as enpty fields. The first three (93,94 
and 95) are alpha-numeric fields and the other 
fields are numeric fields.
Field 93 has been used to include a clinical 
description of the type of liver disease present.
1 = Clinically non-cirrhotic
2 = Clinically cirrhotic
3 = Clinically hepatitic
4 = Control
Field 96 contains information about the survival 
of the patient.
1 = The patient still alive
2 = The patient died of liver disease
3 = Unrelated death
Field 95 contains the months of follow up since 
the antipyrine and indocyanine green appearances 
were estimated. This field is globally edited on 
patients still alive and the values were those 
current on 1st January 1985.
2. DRUG DATA FILE
Ihe DB Master Database has also been used to extract 
information for the production of appendices 1 and 2. Ihe 
database was structured to allow the entry of information from 
papers on drug metabolism in liver disease and using the report 
facility in DB Master the percentage changes between control and 
disease groups were calculated for each of the pharmacokinetic 
parameters entered.
Ihe following file definition was used:
FILE DEFINITION - DRUGS
FIELD LABEL
PRIMARY
KEY
SECONE
KEY
) READ 
PROT
FIELD
TYPE
FIELD
LEN
1 DRUG NAME YES NO NO ALPHA 15
2 REF NUMBER YES NO NO NUMER 4
3 ENTRY NUMBER YES NO NO 0-255 1
4 ROUTE OF ADMINISTRATION NO NO NO 0-255 1
5 1 DOSE NO NO NO ALPHA 8
6 CONTROL NO NO NO NO 0-255 3
7 CONTROL TYPE NO NO NO 0-255 3
8 DISTRIBUTION HALF LIFE NO NO NO NUMER 5
9 UNITS NO NO NO 0-255 2
10 ELIMINATION HALF LIFE NO NO NO NUMER 5
11 UNITS NO NO NO 0-255 2
12 VOLUME OF DISTRIBUTION NO NO NO NUMER 5
13 UNITS NO NO NO 0-255 2
14 STEADY STATE VD NO NO NO NUMER 5
15 UNITS NO NO NO 0-255 2
16 CLEARANCE NO NO NO NUMER 5
17 UNITS NO NO NO 0-255 2
18 CLEARANCE/KG NO NO NO NUMER 5
19 UNITS NO NO NO 0-255 2
20 PATIENT NO. NO NO NO 0-255 3
21 PATIENT TYPE NO NO NO 0-255-3
22 DISTRIBUTION HALF LIFE NO NO NO NUMER 5
23 ELIMINATION HALF LIFE NO NO NO NUMER 5
24 VOLUME OF DISTRIBUTION NO NO NO NUMER 5
25 STEADY STATE VD NO NO NO NUMER 5
26 CLEARANCE NO NO NO NUMER 5
27 CLEARANCE/K NO NO NO NUMER 5
28 P VALUE - T 1/2 DIS NO NO NO ALPHA 7
29 P VALUE - T 1/2 EL NO NO NO ALPHA 7
30 P VALUE - VD NO NO NO ALPHA 7
31 P VALUE - VD SS NO NO NO ALPHA 7
32 P VALUE - CL NO NO NO ALPHA 7
33 P VALUE - CL/KG NO NO • NO ALPHA 7
34 CORRELATION WITH NO NO NO ALPHA 8
35 BILIRUBIN (R) NO NO NO ALPHA 5
36 P VALUE NO NO NO ALPHA 7
37 ALBUMIN (R) NO NO NO ALPHA 5
38 P VALUE NO NO NO ALPHA 7
39 SGOT (R) NO NO NO ALPHA 5
40 P VALUE NO NO NO ALPHA 7
41 SGPT (R) NO NO NO ALPHA 5
42 P VALUE NO NO NO ALPHA 7
43 GGT (R) NO NO NO ALPHA 5
44 P VALUE NO NO NO ALPHA 7
45 A. P. (R) NO NO NO ALPHA 5
46 P VALUE NO NO NO ALPHA 7
47 PT (R) NO NO NO ALPHA 5
48 P VALUE NO NO NO ALPHA 7
49 ANTIP (R) NO NO NO ALPHA 5
50 P VALUE NO NO NO ALPHA 7
51 ICG (R) NO NO NO ALPHA 5
52 P VALUE NO NO NO ALPHA 7
53 SPECIFY NO NO NO 0-255 3
54 (R) NO NO NO ALPHA 5
55 P VALUE NO NO NO ALPHA 7
56 SPECIFY NO NO NO 0-255 3
57 (R) NO NO NO ALPHA 5
58 P VALUE NO NO NO ALPHA 7
59 BIOAVAILABILITY NO NO NO NUMER 5
60 DIS NO NO NO NUMER 5
61 PROTEIN BINDING NO NO NO NUMER 7
62 DIS NO NO NO NUMER 7
63 EXTRACTION R/T NO NO NO NUMER 7
64 DIS NO NO NO NUMER 7
65 COMMENT NO NO NO ALPHA 80
FIELD NOS 
1/4,5
2,3
8-19
22-27
28-33
34-52
EXPLANATION
Contain information of drug route of 
administration and dose used.
Contain reference number and entry number.
Contain pharmacokinetic parameters for 
control group together with the unit in which 
they are expressed.
Contain pharmacokinetic parameters for the 
disease group.
Contain the p values for the differences 
between the control and disease groups. 
Contain the correlations between the stated 
pharmacokinetic parameters and standard liver 
function tests, antipyrine and indocyanine 
green and there are 2 blank fields at the end 
of this group (53 and 56) for specified 
parameters correlating pharmacokinetic 
parameters. The r values and p values are 
included.
CODES FOR DRUG/DISEASE TYPE FIELD 7 AND 21
1. CIRRHOSIS 45. CIRRHOSIS - COMPENSATED
2. CIRRHOSIS + PSE 46. CIRRHOSIS - DECOMPENSATED
3. CIRRHOSIS + PHT 47. PSE
4. ACUTE HEPATITIS 48. PSE ON RECOVERY
5. MIXED LIVER DISEASE 51. URAEMIA
6. CHOLESTASIS 52. URAEMIA + PHENOBARBITONE
7. MILD ALD 53. MALNUTRITION
8. MODERATE ALD 54. UNDERNOURISHED
9. SEVERE ALD 55. IDIOPATHIC HYPOALBUMINAEMIA
10. CAH - HEP B 56. CHRONIC HEPATITIS
11. FATTY LIVER 57. LIVER FIBROSIS
12. HEPATITIS - ALD 58. HEPATORENAL SYNDROME
13. CAH - LUPOID 59. LIVER FAILURE
14. PC ANASTOMOSIS 100. CONTROLS
15. ASCITES 101. CONTROL - SALIVA
16. ABN LFT/NORMAL HIST 102. MALES
17. ABN LFT/MILD ABN HIST 103. FEMALES
18. ABN LFT/SEVERE ABN HIST 104. NON SMOKERS
19. POLYCYSTIC LIVER DISEASE 105. SMOKERS
20. HEPATIC NEOPLASM 106. NORMAL SMOKERS
21. EXTRAHEPATIC CHOLESTASIS 107. YOUNG MALES
22. INTRAHEPATIC CHOLESTASIS 108. OLD MALES
23. CIRRHOSIS - POST NECROTIC 109. YOUNG FEMALES
24. IDIOPATHIC PORTAL HT 110. OLD FEMALES
25. CIRRHOSIS - DECOMPENSATED 111. SUDANESE IN ENGLAND
26. CIRRHOSIS - + PROPRANOLOL 112. SUDANESE IN SUDAN
27. CIRRHOSIS - ALD 113. ORAL ADMINISTRATION
28. CIRRHOSIS - PBC 114. IV ADMINISTRATION
29. PYREXIA 115. NOON
30. CIRRHOSIS + CIMETIDINE 116. MIDNIGHT
31. LD + ENZYME INDUCERS 117. GENERAL ANAESTHESIA
32. CIRRHOSIS + ALB < 35 G 118. GAMBIANS
33. ROTOR SYNDROME 119. VEGETE RIANS
34. PARACENTESIS 120. NON-VEGETARIANS
35. PORTAL VEIN THROMBOSIS 121. SUMMER
36. BUDD CHIARI SYNDROME 122. WINTER
37. AMOEBIC LIVER DISEASE 123. EXERCISE
38. GILBERTS SYNDROME 124. ELDERLY
39. CPH 125, VIT C DEFICIENCY
40. FHF - SURVIVORS 126. < 70 YS OLD
41. FHF - NON SURVIVORS 127. EPILEPTICS
42. CAH + BRIDGING NECROSIS 128. EPILEPTICS + ABN LIVER HISTOL
43. CAH = CIRRHOSIS 129. ANOREXIA NERVOSA
44. PORPHYRIA 130. HIGH CHO DIET
131. HIGH FAT DIET
132. HIGH PROTEIN DIET
133. RAPID ACETYLATORS
134. SLCW ACETYLATORS
135. PARKINSONISM
136. TWINS
137. CHILDREN + CYSTIC FIBROSIS
138. HYPERTHRYOIDISM
139. HYPOTHYROIDISM
140. SPROCJTS/CABBAGE DIET
141. 2/52 FAST
142. FLUID DEPRIVATION
143. FLUID DEPRIVATION/HEAT/EXERC.
144. HEAT
145. HEAT + EXERCISE
146. CRITICALLY ILL-SURVIVORS
147. CRITICALLY ILL-NON SURVIVORS
148. DEBRISOQUINE METAB +++
149. DEBRISOQUINE METAB +
150. L500 CALORIE DIET
151. L800 CALORIE DIET
152. 3000 CLAORIE DIET
153. 72 HR FAST
154. HYPERTROPHIC PYLORIC STENOSIS
155. H.P.S. AFTER SURGERY
156. CCF
157. BED REST
158. ALCOHOLICS
159. 18 - 39
160. 40 - 59
161. 60 - 92
162. NO COFFEE
163. < 5 CUPS COFFEE/D
164. > 5 CUPS COFFEE/D
165. NON SMOKER
166. MODERATE SMOKER
167. HEAVY SMOKER
168. 200G POTATO DIET
169. TPN - DEXTROSE
170. TPN - AMINOACIDS
171. VITAMIN A DEFICIENCY
172. SUPINE
173. STANDING
174. SITTING
175. EXERCISE
176. 500 ML MILK
200. PHENOARBITONE
201. MIXED ENZYME INDUCERS
202. INDUSTRIAL SOLVENTS
203. VITAMIN C
204. ANTIPYRINE
205. CANNABIS
206. ORAL CONTRACEPTIVE
207. PHENYTOIN
208. PHENYTOIN + CIMETIDINE
209. RANITIDINE
210. PROPRANOLOL
211. ATENOLOL
212. LABETOLOL
213. RIFAMPICIN
214. GLUTEIHEMIDE
215. SULPHINPYRAZONE
216. CIMETIDINE
217. LOW DOSE COMBINED OC
218. PROGESTERONE ONLY OC
219. ANFLURANE
220. MEDROXYPROGESTERONE
221. VITAMIN SUPPL
222. ETHANOL
223. DEXAMETHASONE
224. ACTH
225. AMINOPYRINE
226. AMYLOBARBITONE
227. NITRAZEPAM
228. MANDRAX
229. METHAQUALONE
230. DIPHENHYDRAMINE
231. HYDROCORTISONE
232. DISULFIRAM
233. FENFLURAMINE
234. HALOFENATE
235. LEVODOPA
236. METHYLDOPA HYDRAZINE
237. LDOPA+MD HYDRAZINE
238. ALLOPURINOL
239. NORTRIPTYLINE
240. TESTOSTERONE
241. SPIRONOLACTONE
242. AZATHIOPRINE
243. FRUSEMIDE
244. CARBAMAZEPINE
245. ETHINYL OESTRADIOL
246. CHLORINATED HYDROCARBONS
247. PIRENZEPINE
248. ANTIPYRINE + PHENOBARB
249. ANTIPYRINE + RIFAMPICIN
250. ASTEMIZOLE
251. COCAINE
252. GIN
253. PHENOXYBENZAMINE
254. ISONIAZID
CODES FOR UNITS
FIELDS NO 9,11,13,15,17 and 19
1. HRS 15. ML/MIN/L LIVER
2. ML/MIN 18. L/HR/KG
3. ML/MIN/KG 19. % DOSE @ 2 HR
4. LITRES 20. % MIN
5. MIN 21. % @ 45 MIN
6. L/KG 22. L/MIN
7. L/HR 23. MG/KG/HR
8. ML/KR/KG 24. MG/100ML/HR
9. ML/MIN/KG-WB 25. UG/MIN
10. ML/KG 26. UMOL/MIN/KG
11. ML/M-2 27. MMOL/MIN/KG
12. ML/MIN/M-2 28. MG/MIN
13. % DOSE/HR
14. % DOSE @ 1 HR
CODES FOR FIELDS 53 and 56
1. BSP 100. CHOLESTEROL
2. GALACTOSE 101. APOPROTEIN
3. PARACETAMOL 200. AMINOPYRINE DEMETHYLA
4. LIGNOCAINE 201. ANILINE HYDROXYLASE
5. OXAZEPAM 202. NADPH CYTOCHROME C
6. VIT C REDUCTASE
7. DIAZEPAM BT 203. P450
8. DIAZEPAM 204. WEIGHT
9. DESMETHYL DIAZEPAM 205. AGE
10. DESALKYLFLURAZ EPAM 206. IV VS ORAL
11. LORAZEPAM 207. PLASMA VS SALIVA
12. TEMAZEPAM 208. ARYL HYDROCARBON
13. SERUM FLUORIDE HYDROLASE
14. ANTIPYRINE CL 209 BILIRUBIN CLEARANCE
15. ANTIPYRINE Tl/2 210. ASCITES
50 LIVER VOLUME 211. PSE
51. LIVER VOL AFTER 212. SERUM ZINC
PHENOBARBITONE 213. SERUM COPPER
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3. REFERENCES FILE
Ihe references for this thesis were organised on an Apricot 
Microcomputer using the Comsoft Delta database. The file was 
originally created on an Apple H E  computer but was transferred 
to an Apricot because of the increase floppy disc storage space 
on this conputer. Ihe Apricot microcomputer with double density 
floppy disks has a storage capacity of 750k per disk drive 
compared to 110k per disk drive on the Apple microcomputer.
Ihis results in an increased capacity to store references from 
about 250-300 on the Apple up to over 1000 references on the 
Apricot. This capacity can be further increased by the addition 
of a hard disc. The database has a theoretical maximum of 7 
megabite of data storage which should allow for the storage of 
approximately 10,000 references in a single file.
The original Apple file in the DB master database was 
written out as a straight text file. The floppy discs were 
converted to PRO-DOS discs. The Apple IIE and Apricot were 
linked together using a serial interface. Both conputers were 
configured as terminals using the ASYNC program on the Apricot 
and Access on the Apple. The data was then transferred to the 
Apricot as a straight text file. The data was checked using 
the Wordstar word processing package. A file was configured 
using Comsoft delta and the data was taken into this file using 
the link and copy facility in comsoft delta.
FILE DEFINITION - REFERENCES
Delta file name: REF
File Title: REFERENCE INDEX. 
Date created: 16-JUL-85
Last Updated: 16-JUL-85
Number of Fields: 12
Record Length: 621
Transaction Groups: 0
Field No. Field Name Field Type Field U
1. ref numb C 4
2. title C 65
3. title 1 C 65
4. title 2 C 65
5. title 3 C 65
6. authors C 65
7. authors 1 C 65
8. ref C 65
9. ref 1 C 65
10. keywords C 80
11. def 1 0 4
12. def 2 0 4
EXPLANATION
This file definition stores the references by reference 
number. The title is stored across three fields, the authors 
across two fields and the reference across two fields. There is 
then a single field for keywords. These are words which the 
computer can rapidly search for in order to extract groups of 
references with a common theme. There are two blank fields at 
the end of the file definitions - def 1 and def 2 - which are 
numerical fields. These allow groups of references to be 
numbered.
The following report formats were used from this file definition.
1. A numerical reference list.
2. A journal list. This report re-organises the references by
the first line of the reference. This allows for the
checking of anomalies in the journals and allows correction
of the abbreviations for the journal titles.
3. Extract reports. Various extract reports were produced from 
this list by extracting records on the keyword e.g. a group 
of references were extracted where antipyrine was included 
as a keyword and another group where indocyanine green was 
included as a key word.
4. Alphebetical Reference list. For this report the references 
are extracted in alphabetical order from the main file. The 
DEF.l field is then used with a process file to number the 
references.
297 FOR I = 1 TO XI
300 HOME : INVERSE : PRINT "ENTRY NO. ";I: NORMAL : PRINT
310 INPUT "TIME AND CONCENTRATION (X,Y) ”;X(I),Y(I)
315 IF X(I) > 48 THEN PRINT ">48 HRS"; GOTO 310
330 GOSUB 700
340 NEXT I
350 N = XI
355 PR£ 1
360 FOR I = 1 TO N: PRINT X(I) , EXP (Y(I)) : GOSUB 760
370 NEXT I
380 R1 = SQR (R /  (R +  G))
385 V  = SQR (V / (N - 2))
390 PRINT " "
400 PRINT " DATA SET NUMBER ";JJ
410 PRINT " -------- — -----------------------__n
420 PRINT ""
425 GOSUB 845
430 PRINT "HALF LIFE.................. .,=";T2
440 PRINT "CORRELATION COEFFICIENT. .=" Rl; " FOR " ;N;" OBSERVATIONS’
450 PRINT "APPARENT V.D............ =" GA;" LITRES "
460 PRINT "V.D./KG BODY WT............ =" HA
470 PRINT "TOTAL BODY CLEARANCE..... =" IA; "ML/MIN"
480 PRINT "CLEARANCE/KG BODY WT. ....=" JA; "ML/MIN/KG"
490 PRINT "ESTIMATED VALUE OF K....=" K
500 PRINT "CONCENTRATION AT TIME 0..=" CO;" MG "
520 ‘D'DT'KTTl 11____________________________________irKliNl ------------------------------------
522 PR£ 0
525 PRINT "TO CONTINUE PRESS SPACE BAR11 ;A$
526 GET A$
530 PRINT : PRINT : PRINT : PR£ 0
540 GOSUB 1000
550 I = 0:R = 0:S1 = 0:S3 = 0:S4 = 0:S5 = 0:V = 0:G = 0
580 HOME : PRINT "DO YOU WANT TO AMEND ANY INPUTS";: GET Y$
590 IF Y$ = "N" THEN PRINT : PRINT "RUNNING PROGRAM FROM THE 
BEGINNING": FOR I = 1 TO 1000: NEXT : HOME : GOTO 190
595 IF Y$ < > "Y" THEN PRINT G$: GOTO 580
597 HOME
600 PRINT : PRINT "TO DELETE DATA TYPE 
TYPE ’A 1"
’D1": PRINT "TO AMEND DATA
602 VTAB 12: HTAB 10
605 PRINT "INPUT YOUR CHOICE ";: GET CH$
607 IF CH$ = "A" OR CH$ 1 "D" THEN 609
608 IF CH$ < > "A" AND CH$ < > "D" THEN PRINT G$: GOTO 597
609 IF CH$ = "D" THEN 640
610 IF CH$ = "A" THEN PRINT : PRINT "THERE ARE n;Xl;" ENTRIES": INPUT 
"WHICH ONE DO YOU WISH TO CHANGE?";I
615 FOR T = 1 TO X1:Y(T) = EXP (Y(T)) : NEXT
620 PRINT : INPUT "INPUT YOUR NEW VALUES (X,Y) ";X(I),Y(I)
625 FOR I = 1 TO XI: GOSUB 700: NEXT
630 GOTO 350
640 PRINT : PRINT "THERE ARE ":Xl;" ENTRIES": INPUT "WHICH ONE DO 
YOU WISH TO DELETE" ;T •
648 FOR I = 1 TO T - 1:J = J +1:X(J) = X(I) :Y(J) = Y(I) :NEXT 
650 FOR I = T + 1 TO XI:J = J + 1:X(J) = X(I) :Y(J) = Y(I) : NEXT 
655 XI = XI - 1
660 FOR I = 1 TO XI:Y(I) = EXP (Y(I)) : GOSUB 700: NEXT I 
670 GOTO 350 
680 PR£ 0
690 END
700 Y(I) = LOG (Y(I))
710 SI = SI + Y(I)
720 S3 = S3 + X(I)
730 S5 = S5 + X(I)
740 S4 = S4 + X(I) * Y(I)
750 RETURN
760 S2 = N
770 M = SI / S2
780 K = (SI * S3 - S4 * S2) / (S5 * S2 - S3 2)
790 CO = EXP ((SI + S3 * K) / S2):T2 = LOG (2) / K
800 G = G + (Y(I) - LOG (CO) + K * X(I)) 2
820 R = R + (M - LOG (CO) + K * X (I)) / K) 2
830 V = V + (X(I) - ( LOG (CO) - Y(I)) / I<) 2
840 RETURN
845 RA = R1 * 1000:RA = INT (RA) :RA$ = STR$ (RA): IF RIGHT$ (RA$,1)
' = > "5" THEN RA = RA + 10:RA = RA / 10: RA = INT (RA) : R1 = RA /
100: GOTO 850 
847 RA = RA / 10:RA = INT (RA) :R1 = RA / 100
850 GA = (D / CO) * 1000:GA = INT (GA) :GA$ = STR$ (GA) : IF RIGHT$
(GA$,1) = > "5" THEN GA = GA +10:GA = GA / 10:GA = INT (GA) :GA = 
GA / 100: GOTO 860 
855 GA = GA / 10:GA = INT (GA) :GA = GA / 100
860 HA = ((D / CO) / BW) * 1000:HA = INT (HA) :HA$ = STR$ (HA):
IF RIGHT$ (HA$,1) = > "5" THEN HA = HA + 10: HA = HA / 10:HA =
INT (HA) :HA = HA / 100: GOTO 870 
865 HA = HA / 10:HA = INT (HA) : HA = HA / 100
870 IA = (((D / CO) * K) * 1000 / 60) * 1000:IA = INT (IA) :IA$ = STR$ 
(IA): IF RIGHT$ (IA$,1) = > "5" THEN IA = IA + 10:IA = IA /
10:IA = INT (IA) :IA = IA / 100: GOTO 880
875 IA = IA / 10:IA = INT (IA) :IA = IA / 100
880 JA = (((D / CO) * K / BW) * 1000 / 60) * 1000:JA = INT (JA) :JA$ =
STR$ (JA) : IF RIGHT$ (JA$,1) = > "5" THEN JA = JA + 10:JA = JA /
10:JA = INT (JA) : JA = JA / 100: GOTO 890 
885 JA = JA / 10:JA = INT (JA) :JA = JA / 100
890 KA = K* 1000:KA = INT (KA) :KA$ = STR$ (KA): IF RIGHT$ (KA$,1) .= >
"5" THEN KA = KA + 10:KA = KA / 10:KA = INT (KA) :KA = KA / 100: 
GOTO 900
895 KA = KA / 10:KA = INT (KA) :K = KA / 100
900 LA = CO * 1000:LA = INT (LA) :LA$ = STR$ (LA): IF RIGHT$ (LA$,1) =
> "5" THEN LA = LA + 10:LA = LA / 10:LA = INT (LA) :CO = LA / 100: 
GOTO 910
905 LA = LA / 10:LA = INT (LA) :CO = LA / 100
910 RETURN
1000 REM ********
1010 REM * PLOT *
1020 REM ********
1025 FOR I = 1 TO N
1026 IF X(I) > 48 OR X(I) < 0 OR EXP (Y(I)) > 150 OR EXP (Y(I)) < 0 
THEN HOME : X$ = "CANNOT PLOT AS DATA IS OUT OF BOUNDS"": GOSUB 
6000: RETURN
1027 NEXT I
1030 HGR : HCOLOR=3
1032 HPLOT 2,2 TO 2,157 TO 277,157
1034 FOR X = 2 TO 277 STEP 275 / 49: HPLOT X,157 TO X,159: NEXT: FOR
X = 157 TO 2 STEP - 10: HPLOT 2,X TO 0,X: NEXT X
1035 HPLOT 2,157
1037 HPLOT 2 + (5.612 * X(l)),157 - EXP (Y(I))
1040FOR I = 2 TO N: HPLOT TO 2 + (5.612 * X(I)),157 - EXP (Y(I)):
NEXT I
1041 FOR I = 1 TO N: HPLOT 2 + (5.612 * X (I)),157 - EXP (Y(I)) TO 2 + 
(5.612 * X(I)) ,154 - EXP (Y(I)): NEXT I 
1043 HPLOT 2,157
1045 YY = K * 0 + (157 - CO)
1046 YZ = K * 48 + (157 - CO): HPLOT 2,YY TO 271.388,YZ
1050 VTAB 24:X$ = "TIME (HRS)": GOSUB 6000
1100 VTAB 24: PRINT "RUN PROGRAM AGAIN?";: GET A$: IF A$ = "N" THEN 
TEXT : HOME : PRINT "PROGRAM IS FINISHED": END
1110 IF A$ < > "Y" THEN PRINT G$: GOTO 1100
2000 TEXT : HOME : RETURN
5999 REM * CENTRE STRING *
6000 HT = (40 - LEN (X$)) / 2: HTAB HT: PRINT X$: RETURN
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10 REM PROGRAM FOR CARDIOGREEN ANALYSIS - ORIGINALLY WRITTEN IN 
MICROSOFT BASIC
40 DIM A(10),C(10,M(10)fT(10)
50 HOME : VTAB 3
60 PRINT "CARDIOGREEN ANALYSIS"
70 PRINT i i
80 VTAB I
130 INPUT1 "WHAT IS THE SUBJECTS NAME? - IF NO MORE SUBJECTS TYPE -
DONE '';N$
140 IF N$ = "D;ONE" THEN 690
150 PRINT
160 INPUT "WHAT IS HIS/HER LABORATORY NO. ? " ;M$
170 PRINT
180 INPUT "ENTER THE DATE OF ANALYSIS - ";D$
190 PRINT
200 INPUT "WHAT WAS THE DRUG DOSE (MGS) ? ";D
210 PRINT
220 INPUT " - THE BODY WEIGHT IN KGS ";BW
230 PRINT
240 INPUT " - AND THE PCV ";PC
250 PR£ 1
255 PRINT "NAME OF SUBJECT - "N$
257 PRINT "---------------- ": PRINT
260 PRINT "LAB.NO: ";M$;" DATE: ";D$
265 PRINT
300 PRINT "DOSE: " ;D;" MGS WEIGHT: ";BW;" KG PCV: ";PC
320 PR£ 0
330 INPUT "WHAT WAS THE ABSORBANCE OF THE 5MG/LITRE STANDARD ? ";Q9
335 PRINT
340 C9 = Q9 / 5
350 PR£ 1
355 PRINT : PRINT
360 PRINT "STANDARD 5MG/LITRE —  ABSORBANCE ";Q9
370 PR£ 0
380 INPUT "HOW MANY SAMPLES DO YOU HAVE ? ";N9
390 HOME
395 PRINT "SAMPLE TIME (MINS) AND ABSORBANCE "
396 PRINT
397 PRINT "CONCENTRATION (MG/L)".
398 PRINT
400 PRINT "NOW INPUT THE TIME (MINS) AND ABSORBANCE FOR EACH SAMPLE,
SEPARATING THE "PRINT "2 VARIABLES BY A COMMA"
420 PRINT
430 FOR I = 1 TO N9
440 PRINT " SAMPLE - ";
450 INPUT M(I) ,A(I)
460 C(I) = A(I) / C9
470 T (I) = M(I) / 60
480 NEXT I
490 PR£ 1
494 PRINT : PRINT
495 PRINT "SAMPLE TIME (HRS) ABSORBANCE CONCENTRATION (MG/ML)"
496 PRINT "--------  -----------  -----------  ----
497 PRINT
500 FOR I = 1 TO N9
510 PRINT TAB ( 3) I TAB ( 13)M(I) TAB ( 24)A(I) TAB( 39)C(I)
520 NEXT I
525 PRINT : PRINT
530 PR£ 0
540 PRINT : PRINT : PRINT
550 PRINT "CALCULATION OF CORRELATION COEFFICIENTS"
552 PRINT  -------------------------------------------- -
554 PRINT "AND HALF LIFE DATA"
560 PRINT "------------------ "
575 PRINT : PRINT : PRINT
530 PRINT "HOW MANY POINTS DO YOU WANT TO USE TO CALCULATE 
CORRELATION COEFFICIENTS AND ";
590 PRINT "HALF-LIFE DATA ?"
595 PRINT
600 PRINT "-IF YOU DO NOT WISH TO CALCULATE FURTHER REGRESSION LINES 
TYPE - 0"
610 INPUT N
615 PRINT : PRINT
620 IF N = 0 THEN 648
630 GOSUB 999
640 GOTO 575
648 GOTO. 130
690 END
999 FOR I = 1 TO N
1000 X(I) = T(I) :Y(I) = C(I) : GOSUB 1340 
1010 NEXT I
1020 FOR I = 1 TO N: GOSUB 1400 
1030 NEXT I
1040 R1 = SQR (R / (R + G)) :V = SQR (V / (N - 2))
1050 GOSUB 2000 
1060 PR£ 1
1070 PRINT "HALF LIFE IS ";T2;
1080 PRINT " WITH CORRELATION COEFFICIENT ";R1;
1090 PRINT " FOR ";N;" OBSERVATIONS"
1150 PRINT "APPARENT VOLUME OF DISTRIBUTION,V.D. ";DC;
1160 PRINT " LITRES, - V.D.PER KG ";CB
1200 PRINT "TOTAL BODY CLEARANCE, ML/MIN ";CK;
1210 PRINT " CLEARANCE PER KG ";CL
1250 PRINT "ESTIMATED VALUE OF K ";K;
1270 PRINT " CONCENTRATION AT TIME 0 ";CO;" MG"
1285 PRINT "WHOLE BLOOD CLEARANCE ";WBC;" MLS/MIN
1286 PRINT "------------------------------------------ "
1287 PR£ 0
1290 I = 0:R = 0:S1 = 0:S4 = 0:S5 = 0:V = 0:G = 0
1295 PRINT : PRINT
1300 RETURN
1340 Y(I) = LOG (Y(I))
1350 SI = SI + Y(I)
1360 S3 = S3 + X(I)
1370 S5 = S5 + X(I)2 
1380 S4 = S4 + X(I) * Y(I)
1390 RETURN 
1400 S2 = N 
1410 M = SI / S2
1420 K = (SI * S3 - S4 * S2) / (S5 * S2 - S32)
1430 CO = EXP ((SI + S3 * K) / S2)
1440 T2 = LOG (2) / K
1441 T2 = (LOG (2) / K) * 60
1450 G = G + (Y(I) - LOG (CO) + K * X(I))2
1460 R = R + (M - LOG (CO) + K * X(I))2
1470 V = V + (X(I) - (LOG (CO) - Y(I)) / K)2
1480 RETURN
2000 T2 = INT (103 * T2) / 103
2010 R1 = INT (103 * Rl) / 103
2020 DC = D / CO
2030 DC = INT (102 * CB) / 103
2040 CB = (D / CO) / BW
2050 CB = INT (102 * CB) / 102
2060 CK = ((D / CO) * K) * 1000 / 60
2070 CK = INT (103 * CK) / 103
2080 CL = ((D / CO) * K / BW) * 1000 / 60
2090 CL = INT (103 * CL) / 103
3000 WBC = (100 * (((D / CO) * K) * 1000 / 60)) / (100 - PC)
3010 WBC = INT (102 * WBC) / 102
3020 K = INT (103 * K) / 103
3030 CO = INT (103 * CO) / 103 
3040 RETURN
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2 REM PROGRAM UPDATED APRIL 1985
5 REM MEPTAZINOL KINETICS. ENTER FIRST 4 POINTS FROM INITIAL PART
OF CURVE AND THREE POINTS FROM LAST PART OF CURVE. THIS PROGRAM 
ASSUMES TWO COMPARTMENT MODEL 
10 REM DATA INPUT 
20 INPUT "DOSE ( IN MGS )";0 
1010 FOR I = 1 TO 7
1020 PRINT " (":I")":nFOR BLOOD SAMPLE ":I:"INPUT TIME. DRUG CGNC "
1030 INPUT T (I).1(1)
1032 PR£ 1
1033 PRINT T(I).I(I)
1034 PR£ 0
1035 A(I) = 1(1) :B(I) = C(I)
1040 NEXT I
6000 FOR S = 1 TO 7:Y(S) = LOG (I(S)) : NEXT S 
6010 J4 = T(5) + T(6) + T(7)
6020 K4 = Y(5) + Y(6) + Y(7)
6030 L4 = (T(5)2) + (Y(6)2) + (Y(7)2)
6040 M4 = (Y(5)2) + (Y(6)2) + (Y(7)2)
6050 R4 = (T(5) * Y(5)) + (T(6) * Y(6)) + (T(7) * Y(7))
6060 B4 = (3 * R4 - K4 * J4) / (3 * L4 - (J42))
6065 T2 = 0.693 / B4
6070 A4 = (K4 - B4 * J4) / 3
6080 A4 = EXP (A4)
6085 ARB = A4 / B4
6087 CL = D / ARB
6090 P4 = B4 * (R4 - J4 * K4 / 3)
6100 Q4 = M41 - (K42) / 3 
6110 R4 = SQR (P4 / Q4)
6120 REM NOW PERFORM AN EXP STR IF
6130 K5 = 0:J5 = 0:L5 = 0:M5 = 0:R5 = 0
6140 FOR P = 1  TO 4
6150 S(F) = 1(F) - - (A4 * EXP (T(P)
6160 S(P) = LOC (S(P))
6170 J5 = J5 + T(P)
6180 K5 = K5 + S(P)
6190 L5 = L5 + (T(P)2)
6200 M5 = M5 + (S(P)2)
6210 R5 = R5 + (T(P) * S(P))
6215 NEXT P
6220 B5 = (4 * R5 - K5 * J5) / (4
6230 A5 = (K5 - B5 * J5) / 4
6240 A5 = EXP (A5)
6245 Tl = 0.693 / B5
6250 P5 = B5 * (R5 - J5 * K5 / 4)
6260 Q5 = M5 - (K52) / 4 
6270 R5 = SQR (P5 / Q5)
6280 VP = D / (A5 + A4)
6270 K = ((A5 + A4) / ((A5 / B5) + (A4 / B4)))
6275 KE = K * 60
6297 K21 = ((B5 + B4) * 60) * (B4 * 60)) / KE
6299 K12 = (((B5 + B4) * 60) - K2 1) - KE
6302 VDSS = ((K12 + K21) / K21) * VP 
6304 VD1 = CL / (B4 * 60)
6306 VD2 = C / A4 
6310 REM PRINT OUT 
6320 PR£ 1 
6330 PRINT ""
6332 PRINT "DOSE=n:D"MGS"
6350 PRINT "L1=":B5 * 60"HR-ln
6355 PRINT "ALPHA Tl/2=" :T1 "HOURS"
6360 PRINT "Al=" :A5"NG/ML"
6370 PRINT "L2=":B4 * 60"HR-1"
6375 PRINT "BETA Tl/2=":T2"HR-1"
6377 PRINT "AREA BETA=" :ARB"NG/ML/HR"
6378 PRINT "CLEARANCE BETA=":CL * 1000"LITRES/HOUR" 
6380 PRINT "A2=" :A4"NG/ML"
6390 PRINT "R1 = ":R5 
6400 PRINT "R2 = ":R5 
6400 PRINT "R2 = ":R4 
6410 PRINT "VD1= ":VDl * 1000"LITRES"
6420 PR£ 0 
6430 END
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10 REM ********************************
20 REM * APRICOT PHARMACOKINETICS******
30 REM *DR. G. BIRNIE******************
40 REM ********************************
100 PRINT "WESTERN INFIRMARY, GLASGOW"
110 PRINT "PHARMACOKINETICS : INTRAVENOUS INJECTION"
120 PRINT "ADJUSTMENT OF PLOT TO 1,2 OR 3 EXPONENTIAL CURVES BY RESIDUALS 
METHOD"
130 PRINT:PRINT:PRINT"Enter title ..."
140 PRINT:PRINT:INPUT B$:GOSUB 2730:LPRINT B$:CLOSE£l 
150 PRINT:PRINT: INPUT"Enter number of points : ";N
160 PRINT: PRINT: HPOS=l4: PRINT"ENTER POINTS IN INCREASING ORDER ! 111" 
170 DIM X (N) , Y (N), Y2 (N), Y3 (N), Z (N) , Z2 (N) , Z3 (N)
180 FOR 1=1 TO N:PRINT
190 HPOS=4:PRINT"Point " ";I?",:INPUT"t=";X(I)
200 HPOS=4:PRINT, :INPUT"C=";Y(I)
210 NEXT I
220 PRINT:PRINT:PRINT"Point No", "t (h) ", "C ((UG/ML)" :FOR 1=1 TO 
N:PRINT I,X(I),Y(I):NEXT I 
230 PRINT: INPUT"Error (0,N) ? ";JL$
240 IF JL$="N" THEN 300
250 INPUT"Error on point number : ";I
260 INPUT "Error on T or C (,C) ? ";FC$
270 IF FC$="T" THEN PRINT CHR$(7) :INPUT"Enter real value of t for 
this point : ";X(I)
280 IF FC$="C" THEN PRINT CHR$(7) :INPUT"Enter real value of C for 
this point : ";Y(I)
290 GOTO 220
300 FOR 1=1 TO N:Z (I) =Y(I) :NEXT I
310 PRINT:PRINT:GOSUB 2730:PRINT"t(h) ","C(ug/ml) ":FOR 1=1 TO 
N:PRINT X(I) ,Y(I) :NEXT I:PRINT:PRINT 
320 GOSUB 2760 
330 GOSUB 3320 
340 X=X
380 FOR 1=1 TO N:Y(I)=Z(I) :NEXT I
390 LPRINT"t (h) ", "C (ug/ml) ":FOR 1=1 TO N:LPRINT X(I) ,Y(I) :NEXT I 
400 PRINT:PRINT "ATTENTION !!!":PRINT
410 PRINT "I WANT THREE EXPERIMENTAL POINTS FOR EACH REGRESSION."
: PRINT
420 INPUT"Computing : 1,2 or 3 exp (0 to stop) ? ";A
430 IF A=0 THEN END
440 ON A GOSUB 450,870,1640
450 REM 1 EXP
460 PRINT: INPUT"Dose (ug) ? ";D1 
470 M=1:P=N:Z=N:GOSUB 2470 
480 T2=LOG(2)/ABS(B)
490 VD=D1/A 
500 CL=ABS(B)*VD 
510 SC=A/ABS(B)
520 PRINT:PRINT"Equation : C=A*EXP-(B*t) "
530 PRINT"A = ";A;" ug.ml-1"
540 PRINT"B = ";ABS(B);" h-1"
550 PRINT" R~ 2 = ";R2
560 PRINT"Biological half-time (tl/2) = ";T2;" h"
570 PRINT"Apparent volume of distribution (Vd) = ";VD;" ml"
580 PRINT'Plasma clearance (CLP) = ";CL;" ml.h-1"
590 PRINT"Area under curve (AUC) =";SC;" ug.h.ml-1"
600 GOSUB 2730
610 LPRINT:LPRINT"Dose = ";D1;" ug"
620 LPRINT:LPRINT"Equation :C=A*EXP-(B*t)"
630 LPRINT"A = ";A;" ug.ml-1"
640 LPRINT"B = ";ABS(B);" h-1"
650 LPRINT"R"2 = ";R2
660 LPRINT"Biological half-time (tl/2) = ";T2;" h"
670 LPRINT"Apparent volume of distribution (Vd) = ";VD;" ml"
680 LPRINT"Plasma clearance (CLP) = ";CL;" ml.h-1"
690 LPRINT"Area under curve (AUC) = ";SC;" ug.h.ml-1"
710 FOR 1=1 TO N:Z2(I)=A*EXP(B*X(I)):NEXT I 
720 FOR 1=1 TO N:Z3(I)=((Z2(I)-Z(I))*100)/Z(I):NEXT I 
730 GOSUB 2730: PRINT: PRINT"t (h)","Cobs (ug/ml)","Ccal (ug/ml)","Relative 
error (%)":FOR 1 = 1 TO N: PRINT X(I) ,Z (I) ,Z2 (I) ,Z3 (I) :NEXT 
I .-PRINT: PRINT 
740 PRINT
750 LPRINT"t(h)","Cobs(ug/ml)","Ccal (ug/ml)"/'Relative error (%)": FOR 
1=1 TO N:LPRINT X(I),Z(I),Z2(I),Z3(I):NEXT I:PRINT 
760 PRINT:INPUT"Do you want computed predicted values (O for yes,
N for another adjustment ) ? ";A$
770 IF A$="N" THEN 340
780 GOSUB 2730:PRINT:PRINT'Computed predicted Values:":PRINT:
PRINT"t(h)","Ccal(ug/ml)":CL0SE 1 
790 PRINT:INPUT"I compute C for wished r (0 for begin, N for 
another adjustment" ;A$
800 IF A$="N" THEN 340 
810 PRINT:HPOS=4:INPUT"t=";X 
820 Y=A*EXP (B*X)
830 PRINT:HPOS=4:PRINT"C=";Y 
840 GOSUB 2730:PRINT X,Y 
850 GOTO 790 
860 RETURN 
870 REM 2 EXP
880 PRINT:INPUT"Dose (ug( ? ";D 
890 PRINT:INPUT"Break time (h) = ";H:PRINT 
900 PRINT:PRINT:Z=0 
910 FOR 1=1 TO N
920 IF X (I)>=H THEN PRINT X(I),Y(I):Z=Z+1 
930 NEXT I
940 PRINT Z;" values with time higher or equal to ";H:PRINT:M=N-Z+1:P=N
950 GOSUB 2470
960 FOR I=M TO P:Y(I)=EXP(Y(I)):NEXT I 
970 PRINT:A2=A:B2=B:RA=R2 
980 FOR 1=1 TO N 
990 Y2(I)=A*EXP(B*X(I))
1000 NEXT I
1010 PRINT:PRINT:Z=0
1020 FOR 1=1 TO N
1030 IF X(I)<=H THEN PRINT X(I),Y(I):Z=Z+1 
1040 NEXT I
1050 PRINT Z;" values with time lower or equal to 1 ;H:PRINT 
1060 M=1:P=Z:PRINT:PRINT"Resulting differences for these values 
:":FOR I=M TO P:Y(I)=Y(I)-Y2(I) :PRINT X(I),Y(I) :NEXT I:GOSUB 
2470
1070 A1=A:B1=B:RB=R2 
1080 T2=LOG(2)/ABS(B2)
1090 K2= ((A1*ABS (B2)) + (A2*ABS (Bl))) / (A1+A2)
1100 KE=(ABS(B1)*ABS(B2))/K2 
1110 K1=ABS(Bl)+ABS(B2)-K2-KE 
1120 SC= (Al/ABS (Bl)) + (A2/ABS (B2))
1130 CL=D/SC
1140 VD=D/ (ABS (Al) +ABS (A2))
1150 ZZ=D/A2
1160 PRINT :PRINT"Equation : C=Al*EXP-(Bl*t)+A2*EXP-(B2*t)"
1170 PRINT"A1 = ";A1;" UG.ML-1"
1180 PRINT"B1 = ";ABS(B1);"h-l"
1190 PRINT"R/'2(1) = ";RB
1200 PRINT" A2 = " ;A2;" ug.ml-1"
1210 PRINT"B2 = ";ABS(B2);" h=l"
1220 PRINT"R/'2(2)= " ;RA
1230 PRINT"Biological half-time (tl/2) =;T2;" H"
1240 PRINT"Apparent volume of distribution (Vd) = ";ZZ;" ml"
1250 PRINT"Volume of central compartment (Vc) = ";VD;" ml"
1260 PRINT"Plasma clearance (CLP) = ";CL;" ml.h-1"
1270 PRINT"Area under curve (AUC) = ";SC;" ug.h.ml-1"
1280 PRINT"Rate constant for transfer between compartment 2 and 
1(k21) = ";K2;" h-1"
1290 PRINT"Elimination rate constant (kel) =;KE;" H-1"
1300 PRINT"Rate constant for transfer between compartment 1 and 
2(kl2) = ";K1;" h-1"
1310 GOSUB 2730
1320 LPRINT:LPRINT"Dose = ";D;" ug"
1330 LPRINT"Break time = ";H;" h"
1340 LPRINT: LPRINT"Equation : C=A1*EXP-(Bl*t)+A2*EXP-(B2*t)"
1350 LPRINT"A1 = ";A1?" ug.ml-1"
1360 LPRINT"B1 = ";ABS(B1);" h-1"
1370 LPRINT"R~2(1)= ";RB
1380 LPRINT"A2 = ";A2;" ug.ml-1"
1390 LPRINT" B2 = ";ABS(B2);" H-1"
1400 LPRINT"R~2(2) = ";RA
1410 LPRINT"Biological half-time (tl/2) = ";T2;" h"
1420 LPRINT"Apparent voume of distribution (Vd) = ";ZZ;" ml"
1430 LPRINT"Volume of central compartment (Vc) = ";VD;" ml"
1440 LPRINT"Plasma clearance (CLP) = ";CL;" ml.h-1"
1450 LPRINT"Area under curve (AUC) = ";SC;" ug.h.ml-1"
1460 LPRINT "Rate constant for transfer between compartment 2 and
1 (k21) = ";K2;" h-1"
1470 LPRINT"Elimination rate constant (kel) = ";KE;" h-1"
1480 LPRINT"Rate constant for transfer between compartment 1 and
2 (kl2) =";K1;" h-1"
1490 X=X
1500 FOR 1=1 TO N:Z2(I)=A1*EXP(B1*X(I))+A2*EXP(B2*X(I)):NEXT I
1510 FOR 1=1 TO N:Z3(I) = ( (Z2(I) —Z (I) )*100)/Z(I) :NEXT I
1520 GOSUB 2730: PRINT: PRINT" t (h) ", "Cobs (ug/ml)", "Ccal (ug/ml)",
"Relative error(%)":FOR 1=1 TO N:PRINT X(I),Z(I),Z2(I),Z3(I):
NEXT I: PRINT: PRINT 
1530 LPRINT:LPRINT"t(h)", "Cobs (ug/ml)","Ccal (ug/ml)", "Relative
Error (%)":FOR 1=1 TO N:LPRINT X(I) ,Z(I) ,Z2(I) ,Z3(I) :NEXT I:LPRINT
1540 PRINT:INPUT"Do you want computed predicted values (O for yes,
N for another adjustment ) ? ";A$
1550 IF A$="N" THEN 340
1560 GOSUB 2730:PRINT:PRINT"Computed predicted Values:":PRINT:
PRINT"t (h)","Ccal(ug/ml)"
1570 PRINT: INPUT"I conpute C for wised t (0 for begin, N for another 
adjustment) ";A$
1580 IF A$="N" THEN 340
1590 PRINT:HPOS=4:INPUT"t=";X
1600 Y=A1*EXP(B1*X)+A2*EXP(B2*X)
1610 PRINT :HPOS=4:PRINT"C=";Y 
1620 GOSUB 2730:PRINT X,Y 
1630 GOTO 1570 
1640 REM 3 EXP
1650 PRINT:INPUT"Dose (ug) ? ";D 
1660 PRINT"BT2<BT1"
1670 PRINT: INPUT"Break time 2 (h) = ";H2 
1680 PRINT:INPUT"Break time 1 (h) = ";H1 
1690 PRINT:PRINT:Z1=0 
1700 FOR 1=1 TO N
1710 IF X (I)>=H1 THEN PRINT X(I),Y(I):Z1=Z1+1 
1720 NEXT I
1730 PRINT Zl?" values with time higher or equal to ";H1:PRINT: 
M=N-Z1+1:P=N:Z=Z1 
1740 GOSUB 2470
1750 FOR I=M TO P:Y(I) =EXP(Y(I)) :NEXT I 
1760 PRINT: A3=A: B3=B:RA=R2 
1770 FOR 1=1 TO N 
1780 Y3(I)=A*EXP(B*X(I))
1790 NEXT I
1800 PRINT:Z3=0:FOR 1=1 TO N:IF X(I)<=H2 THEN PRINT 
X(I),Y(I):Z3=Z3+1:NEXT I 
1810 PRINT Z3;" values with time lower or equal to ";H2 
1820 PRINT:Z2=0 
1830 FOR 1=1 TO N
1840 IF X(I)<=H1 AND X(I)>=H2 THEN PRINT X(I),Y(I):Z2=Z2+1 
1850 NEXT I
1860 PRINT Z2;" values with time between ";H2;" and ";H1 
1870 M=Z3+1:P=Z2+Z3:PRINT:PRINT"Resulting differences for these values 
:" :FOR I=M TO P:Y(I) =Y(I)-Y3 (I) :PRINT X(I) ,Y(I) :NEXT 
I:Z=Z2:GOSUB 2470 
1880 PRINT: A2=A: B2=B: RB=R2 
1890 FOR 1=1 TO N:Y2(I) =A*EXP(B*X(I))
1900 NEXT I
1910 PRINT Z3=0:FOR 1=1 TO N:IF X(I)<=H2 THEN PRINT 
X(I),Y(I):Z3=Z3+1:NEXT I 
1920 PRINT Z3;" values with time lower or equal to ";H2 
1930 M=1:P=Z3:PRINT:PRINT"Resulting differences for these values 
:":FOR I=M TO P:Y(I)=Y(I)-Y3(I)-Y2(I) :PRINT X(I) ,Y(I) :NEXT 
I:Z=Z3:GOSUB 2470 
1940 PRINT
1950 A1=A:B1=B:RC=R2 
1960 T2=LOG(2)/ABS(B3)
1970 VD=D/ (ABS (Al) +ABS (A2) +ABS (A3))
1980 SC= (ABS (Al)/ABS(Bl)) + (ABS (A2)/ABS (B2)) + (ABS (A3)/ABS (B3))
1990 CL=D/SC
2000 PRINT:PRINT"Equation :
C=A1*EXP- (Bl*t) +A2*EXP- (B2*t) +A3*EXP- (B3*t) "
2010 PRINT"A1 = " ;A1;" ug.ml-1"
2020 PRINT "Bl = ";ABS(B1);" h-1"
2030 PRINT"R~2(1) = ";RC
2040 PRINT"A2 = ";A2;" ug.ml-1"
2050 PRINT"B2 = ";ABS(B2) ;" h-1"
2060 PRINT"R~2(2) = " ;RB 
2070 PRINT"A3 = ";A3;" ug.ml-1"
2080 PRINT"B3 = ";ABS(B3);n h-1"
2090 PRINT"R"2(3)= ";RA
2100 PRINT"Biological half-time (tl/2) = ";T2;" h"
2110 PRINT"Volume of central compartment (Vc) = ";VD;" ml"
2120 PRINT"Plasma clearance (CLP) = ";CL;" ml.h-1"
2130 PRINT"Area under curve (AUC = ";SC;" ug.h.ml-1"
2140 GOSUB 2730
2150 LPRINT"Dose = ";D;" ug"
2160 LPRINT"Break time 2 = ";H2;" h"
2170 LPRINT"Break time 1 = ";H1;" h"
2180 LPRINT: LPRINT"EQUATION :
C=A1*EXP- (Bl*t) +A2*EXP- (B2*t) +A3*EXP- (B3*t) "
2190 LPRINT "Al = ";A1;" ug.ml-1"
2200 LPRINT"Bl = ";ABS(B1);,! h-1"
2210 LPRINT"R~2(1) = ";RC
2220 LPRINT"A2 = ";A2;" ug.ml-1"
2230 LPRINT"B2 = ";ABS(B2);" h-1"
2240 LPRINT"R~2(2) = " ;RB
2250 LPRINT"A3 = ";A3;" ug.ml-1"
2260 LPRINT"B3 = ";ABS(B3);" h-1"
2270 LPRINT"R~2(3) = " ;RA
2280 LPRINT"Biological half-time (tl/2) = ";T2;" h"
2290 LPRINT"Volume of central compartment (Vc) = ";VD;" ml"
2300 LPRINT"Plasma clearance (CLP) = ";CL;" ml.h-1"
2310 LPRINT"Area under curve (AUC) =";SC;" UG.H.ML-1"
2320 X=X
2330 FOR 1=1 TO N:
Z2(I)=A1*EXP(B1*X(I))+A2*EXP(B2*X(I))+A3*EXP(B3*X(I)) :
NEXT I
2340 FOR 1=1 TO N:Z3 (I) = ( (Z2 (I) -Z (I)) *100)/Z (I) :NEXT I 
2350 GOSUB 2730:PRINT:PRINT"t (h) ","Cobs(ug/ml) ”f "Ccal (ug/ml) ", 
"Relative error (%)":FOR 1=1 TO N-.PRINT 
X(I),Z(I),Z2(I),Z3(I):NEXT I:PRINT:PRINT 
2360 LPRINT:LPRINT"t (h) ", "Cobs (ug/ml) ", "Ccal (ug/ml) ", "Relative error 
FOR 1=1 TO N:LPRINT X(I) ,Z(I) ,Z2(I) ,Z3(I) :NEXT I 
2370 PRINT:INPUT"Do you want computed predicted values (0 for yes, 
N for another adjustment) ? ";A$
2380 IF A$="N" THEN 340
2390 GOSUB 2730:PRINT"Computed predicted
values:":PRINT:PRINT"t (h) ", "Ccal (microg/ml) " :CLOSE£l 
2400 PRINT: INPUT"! compute C for wished t (0 for begin, N for another
adjustment) " ;A$
2410 IF A$="N" IHEN 340
2420 PRINT:HPOS=4:INPUT"t=n;X
2430 Y=A1*EXP (B1*X) +A2*EXP (B2*X) +A3*EXP (B3*X)
2440 PRINT:HPOS=4:PRINT"C=" ;Y
2450 GOSUB 2730:PRINT X,Y:CLOSE£l
2460 GOTO 2400
2470 REM COMPUTING METHOD
2480 FOR I=M TO P
2490 Y(I)=LOG(ABS(Y(I)))
2500 NEXT I
2510 XM=0:YM=0:XY=0:X2=0 
2520 SY=0:BX=0:BY=0 
2530 FOR I=M TO P 
2540 SY=SY+Y(I)
2550 BX=BX+(X(I)*Y(I))
2560 BY=BY+(Y(I)~2)
2570 XM=XM+X(I)
2580 YM=YM+Y(I)
2590 NEXT I 
2600 XM=XM/Z 
2610 YM=YM/Z 
2620 FOR I=M TO P 
2630 X2=X2+(X(I)-XM)~2 
2640 XY=XY+(X(I)-XM)*Y(I)
2650 NEXT I 
2660 B=XY/X2 
2670 A=YM-B*XM 
2680 A=EXP(A)
2690 Zl=(LOG(A)*SY) + (B*BX)-((SY~2)/Z)
2700 Z2=3Y-((SY~2)/Z)
2710 R2=Z1/Z2 
2720 RETURN 
2730 X=X 
2750 RETURN
2760 REM TRACING CURVE 
2770 XMAX=X(N)
2780 YMAX=0
2790 YMIN=10000
2800 FOR T= 1 TO N
2810 IF Y (T) >YMAX THEN YMAX=Y (T)
2820 IF Y (T) <YMIN THEN YMIN=Y (T)
2830 NEXT T
2840 ECHX=INT(XMAX/2)
2850 IF XMAX/2XINT(XMAX/2) THEN ECHX=ECHX+1 
2860 ECHY=INT(YMAX/.01)
2870 IF YTiAX/.01XINT(YMAX/.01)THEN ECHY=ECHY+1 
2920 C=0
2930 FOR T=150 TO 550 STEP 100 
2960 C=C+.4 
2990 NEXT T 
3000 C=0
3010 FOR T=50 TO 170 STEP 30 
3040 C=C+,002 
3070 NEXT T
3170 FOR C=1 TO N
3180 V=50+(500/ECHX/2*X(C))
3190 W=20+(150/ECHY/.01*Y(C))
3240 NEXT C 
3250 REM PLOTTING 
3310 RETURN
3320 REM TRACING SEMI-LOG CURVE 
3360 C=0
3530 IF YMAX>100 THEN :C=3:INC=5: GOTO 3560 
3540 IF YMAX>10 THEN C=2:INC=.5:GOTO 3560 
3550 C=1:INC=.05 
3560 V=50:W=20 
3580 AA=0
3590 FOR B2=l TO 3 
3600 AA=INC
3610 W=LOG(5)*.434295*50+((B2-1)*50)+20 
3660 AA=AA+INC
3670 W=LOG(10)*.434295*50+((B2-1)*50)+20
3720 INC=INC*10
3730 NEXT B2
3740 FOR B2=l TO N
3750 ON C GOSUB 3950,3990,4030
3760 IF ZZ=0 OR ZZ<1 THEN W= 20:GOTO 3780
3770 W=LOG(ZZ)*.434295*50+((NBMM-1)*50)+20
3780 V=50+(500/ECHX/2*X(B2))
3830 NEXT B2 
3850 REM PLOTTING 
3890 FOR 1=1 TO 2000:NEXT I 
3940 RETURN
3950 IF Y(B2)<.1 THEN ZZ=Y(B2)*100:NBM=1:GOIO 3980 
3960. IF Y(B2)<1 THEN ZZ=Y(B2)*10:NBM=2:GOTO 3980 
3970 NBMM=3:ZZ=Y(B2)
3980 RETURN
3990 IF Y(B2)<1 THEN ZZ=Y(B2)*10:NBMM=1:GOTO 4020 
4000 IF Y(B2)<10 THEN ZZ=Y(B2):NBMM=2:GOTO 4020 
4010 NBMM=3:ZZ=Y(B2)*.1 
4020 RETURN
4030 IF Y(B2)<10 THEN ZZ=Y(B2):NBMM=1:GOTO 4060 
4040 IF Y(B2)<100 THEN ZZ=Y(B2)*.l:NBMM=2:GOTO 4060 
4050 NBMM=3:ZZ=Y(B2)*.01 
4060 RETURN
PHARMACOKINETIC PROGRAMS
Four pharmacokinetic programs have been developed to determine 
the pharmacokinetic parameters for the various drugs studied in this 
thesis.
Program 1 is for a one compartment analysis and was used for the 
antipyrine data.
Program 2 is for a one compartment analysis and is modified for 
indocyanine green.
Program 3 is for a two compartment analysis and was used for the 
Midazolam and Meptazinol data.
Program 4 is a program which has been developed to allow 1,2 or 3 
compartment analysis of pharmacokinetic data.
PHARMACOKINETIC PROGRAM 1
90 G$ = CHR$ (7)
100 PR£ 1
106 PRINT 1 -------------------------------------------------------------- -
110 PRINT "HALF LIFE PROGRAMME"
111 PRINT ii
112 PR£ 0
113 PRINT ii ii • • **
114 DIM X (50), Y (50)
116 HOME .
120 INPUT "TODAY’S DATE ?.......,"; DA$
125 PRINT I I
130 INPUT "WHICH DRUG ?___" ;Z$
135 PRINT IV 1
190 INPUT "WHAT DOSE OF DRUG ?..,..";N$
191 PRINT 11 II
195 INPUT "SUBJECT'S NAME ?.....- •1 ;N$
200 PRINT ii ii
210 INPUT "SUBJECT'S BODY WEIGHT ?" ;BW
215 PRINT 11 11
216 HOME
220 PRINT "ENTER DATA IN FORMAT, ELAPSED TIME IN HOURS-,
CONCENTRATION-,"
230 PRINT
250 a ll a +
272 PRINT
275 PR£ 1 e
280 PRINT N$ SPC( 2)DA$ SPC(02)Z$ SPC( 2)D"MGS" SPC( 2) "WEIGHT "BW"
KGS"
9Q0 PRINT ii iiU
291 PR£ 0
293 HOME
295 INPUT "HOW MANY ENTRIES ? " ; XI
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